<!DOCTYPE html>
<html lang="en">
  <head>
    <title>WO2021021634A1 - Nanomaterials containing constrained lipids and uses thereof 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/WO2021021634A1/en">
    <meta name="description" content="
     Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Nanomaterials containing constrained lipids and uses thereof 
       ">
    <meta name="DC.date" content="2020-07-24" scheme="dateSubmitted">
    <meta name="DC.description" content="
     Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent. 
   
   ">
    <meta name="citation_patent_application_number" content="PC:T/US2020/043512">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/37/02/06/36e8ca3bbe3c70/WO2021021634A1.pdf">
    <meta name="citation_patent_publication_number" content="WO:2021021634:A1">
    <meta name="DC.date" content="2021-02-04">
    <meta name="DC.contributor" content="James Everett Dahlman" scheme="inventor">
    <meta name="DC.contributor" content="Cory Dane SAGO" scheme="inventor">
    <meta name="DC.contributor" content="Zubao GAN" scheme="inventor">
    <meta name="DC.contributor" content="Georgia Tech Research Institute" scheme="assignee">
    <meta name="DC.contributor" content="Georgia Tech Research Corp" scheme="assignee">
    <meta name="DC.relation" content="WO:2015095340:A1" scheme="references">
    <meta name="DC.relation" content="WO:2017173054:A1" scheme="references">
    <meta name="citation_reference" content="See also references of EP 4003967A4" scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      
      #gb { top: 15px; left: auto; right: 0; width: auto; min-width: 135px !important; }   
      body { transition: none; }
    </style>
    <script></script>

    <script>
      window.version = 'patent-search.search_20250707_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;
      window.experiments.plogs = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.html">
  </head>
  <body unresolved>
    
    
    <script></script>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.js"></script>
    <search-app>
      
      

      <article class="result" itemscope itemtype="http://schema.org/ScholarlyArticle">
  <h1 itemprop="pageTitle">WO2021021634A1 - Nanomaterials containing constrained lipids and uses thereof 
        - Google Patents</h1>
  <span itemprop="title">Nanomaterials containing constrained lipids and uses thereof 
       </span>

  <meta itemprop="type" content="patent">
  <a href="https://patentimages.storage.googleapis.com/37/02/06/36e8ca3bbe3c70/WO2021021634A1.pdf" itemprop="pdfLink">Download PDF</a>
  <h2>Info</h2>

  <dl>
    <dt>Publication number</dt>
    <dd itemprop="publicationNumber">WO2021021634A1</dd>
    <meta itemprop="numberWithoutCodes" content="2021021634">
    <meta itemprop="kindCode" content="A1">
    <meta itemprop="publicationDescription" content="International application published with international search report">
    <span>WO2021021634A1</span>
    <span>PCT/US2020/043512</span>
    <span>US2020043512W</span>
    <span>WO2021021634A1</span>
    <span>WO 2021021634 A1</span>
    <span>WO2021021634 A1</span>
    <span>WO 2021021634A1</span>
    <span>  </span>
    <span> </span>
    <span> </span>
    <span>US 2020043512 W</span>
    <span>US2020043512 W</span>
    <span>US 2020043512W</span>
    <span>WO 2021021634 A1</span>
    <span>WO2021021634 A1</span>
    <span>WO 2021021634A1</span>

    <dt>Authority</dt>
    <dd itemprop="countryCode">WO</dd>
    <dd itemprop="countryName">WIPO (PCT)</dd>

    <dt>Prior art keywords</dt>
    <dd itemprop="priorArtKeywords" repeat>lipid</dd>
    <dd itemprop="priorArtKeywords" repeat>nanoparticle composition</dd>
    <dd itemprop="priorArtKeywords" repeat>subject</dd>
    <dd itemprop="priorArtKeywords" repeat>ionizable</dd>
    <dd itemprop="priorArtKeywords" repeat>nucleic acid</dd>

    <dt>Prior art date</dt>
    <dd><time itemprop="priorArtDate" datetime="2019-07-29">2019-07-29</time></dd>

    <dt>Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)</dt>
    <dd itemprop="legalStatusIfi" itemscope>
      <span itemprop="status">Ceased</span>
    </dd>
  </dl>

  <dt>Application number</dt>
  <dd itemprop="applicationNumber">PCT/US2020/043512</dd>

  <dt>Other languages</dt>
  <dd itemprop="otherLanguages" itemscope repeat>
    <a href="/patent/WO2021021634A1/fr">
      <span itemprop="name">French</span> (<span itemprop="code">fr</span>)
    </a>
  </dd>

  

  <dt>Inventor</dt>
  <dd itemprop="inventor" repeat>James Everett Dahlman</dd>
  <dd itemprop="inventor" repeat>Cory Dane SAGO</dd>
  <dd itemprop="inventor" repeat>Zubao GAN</dd>

  <dt>Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)</dt>
  <dd itemprop="assigneeCurrent" repeat>
    Georgia Tech Research Institute
  </dd>
  <dd itemprop="assigneeCurrent" repeat>
    Georgia Tech Research Corp
  </dd>

  <dt>Original Assignee</dt>
  <dd itemprop="assigneeOriginal" repeat>Georgia Tech Research Institute</dd>
  <dd itemprop="assigneeOriginal" repeat>Georgia Tech Research Corp</dd>

  <dt>Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)</dt>
  <dd><time itemprop="priorityDate" datetime="2019-07-29">2019-07-29</time></dd>

  <dt>Filing date</dt>
  <dd><time itemprop="filingDate" datetime="2020-07-24">2020-07-24</time></dd>

  <dt>Publication date</dt>
  <dd><time itemprop="publicationDate" datetime="2021-02-04">2021-02-04</time></dd>

  
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Application filed by Georgia Tech Research Institute, Georgia Tech Research Corp</span>
    <span itemprop="type">filed</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    <span itemprop="assigneeSearch">Georgia Tech Research Institute</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Priority to CA3145913A</span>
    <span itemprop="type">priority</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/CA3145913A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Priority to KR1020227006660A</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/KR20220040484A/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Priority to US17/630,861</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US20220273566A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Priority to CN202080068505.5A</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/CN114502542A/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Priority to AU2020323897A</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/AU2020323897A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Priority to EP20846355.4A</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/EP4003967A4/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-07-24">2020-07-24</time>
    <span itemprop="title">Priority to JP2022506087A</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/JP7600208B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2021-02-04">2021-02-04</time>
    <span itemprop="title">Publication of WO2021021634A1</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/WO2021021634A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2022-01-29">2022-01-29</time>
    <span itemprop="title">Anticipated expiration</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date">Status</time>
    <span itemprop="title">Ceased</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    <span itemprop="current" content="true" bool>Current</span>
    
    
    
  </dd>

  <h2>Links</h2>
  <ul>
    

    <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="espacenetLink">
        <a href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&amp;NR=2021021634A1&amp;KC=A1&amp;FT=D" itemprop="url" target="_blank"><span itemprop="text">Espacenet</span></a>
      </li>
      

    

    <li itemprop="links" itemscope repeat>
      <meta itemprop="id" content="globalDossierLink">
      <a href="https://globaldossier.uspto.gov/result/application/WIPO/PCTUS2020043512/1" itemprop="url" target="_blank"><span itemprop="text">Global Dossier</span></a>
    </li>

    

      

      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="patentscopeLink">
        <a href="https://patentscope.wipo.int/search/en/WO2021021634" itemprop="url" target="_blank"><span itemprop="text">PatentScope</span></a>
      </li>

      
      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="stackexchangeLink">
        <a href="https://patents.stackexchange.com/questions/tagged/WO2021021634A1" itemprop="url"><span itemprop="text">Discuss</span></a>
      </li>
  </ul>

  <ul itemprop="concept" itemscope>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">0</span>
      <span itemprop="name">CCCCCC=CCC=CCCCCCCCC(NCC(CC)C[U]C(*)=O)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC=CCC=CCCCCCCCC(NCC(CC)C[U]C(*)=O)=O</span>
      <span itemprop="inchi_key"></span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">3</span>
    </li>
  </ul>

  

  <section>
    <h2>Classifications</h2>
    <ul>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D235/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D235/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D235/04</span>&mdash;<span itemprop="Description">Benzimidazoles; Hydrogenated benzimidazoles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D235/06</span>&mdash;<span itemprop="Description">Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D235/08</span>&mdash;<span itemprop="Description">Radicals containing only hydrogen and carbon atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/00</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/02</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/04</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/16</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/10</span>&mdash;<span itemprop="Description">Dispersions; Emulsions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/127</span>&mdash;<span itemprop="Description">Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1271</span>&mdash;<span itemprop="Description">Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/70</span>&mdash;<span itemprop="Description">Carbohydrates; Sugars; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7088</span>&mdash;<span itemprop="Description">Compounds having three or more nucleosides or nucleotides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/713</span>&mdash;<span itemprop="Description">Double-stranded nucleic acids or oligonucleotides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/06</span>&mdash;<span itemprop="Description">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/08</span>&mdash;<span itemprop="Description">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/14</span>&mdash;<span itemprop="Description">Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/06</span>&mdash;<span itemprop="Description">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/16</span>&mdash;<span itemprop="Description">Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/18</span>&mdash;<span itemprop="Description">Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/30</span>&mdash;<span itemprop="Description">Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/34</span>&mdash;<span itemprop="Description">Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0008</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0025</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0033</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0008</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0025</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0041</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0012</span>&mdash;<span itemprop="Description">Galenical forms characterised by the site of application</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0019</span>&mdash;<span itemprop="Description">Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/48</span>&mdash;<span itemprop="Description">Preparations in capsules, e.g. of gelatin, of chocolate</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/50</span>&mdash;<span itemprop="Description">Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/51</span>&mdash;<span itemprop="Description">Nanocapsules; Nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5107</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5123</span>&mdash;<span itemprop="Description">Organic compounds, e.g. fats, sugars</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/48</span>&mdash;<span itemprop="Description">Preparations in capsules, e.g. of gelatin, of chocolate</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/50</span>&mdash;<span itemprop="Description">Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/51</span>&mdash;<span itemprop="Description">Nanocapsules; Nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5107</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/513</span>&mdash;<span itemprop="Description">Organic macromolecular compounds; Dendrimers</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5146</span>&mdash;<span itemprop="Description">Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/00</span>&mdash;<span itemprop="Description">Drugs for immunological or allergic disorders</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/02</span>&mdash;<span itemprop="Description">Immunomodulators</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B</span>&mdash;<span itemprop="Description">PERFORMING OPERATIONS; TRANSPORTING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B82</span>&mdash;<span itemprop="Description">NANOTECHNOLOGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B82Y</span>&mdash;<span itemprop="Description">SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">B82Y5/00</span>&mdash;<span itemprop="Description">Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/00</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/42</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/00</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C215/68</span>&mdash;<span itemprop="Description">Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/00</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/02</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/04</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/06</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/08</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/10</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/00</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/02</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/04</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C217/42</span>&mdash;<span itemprop="Description">Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having etherified hydroxy groups and at least two amino groups bound to the carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/00</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C219/34</span>&mdash;<span itemprop="Description">Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups and esterified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/00</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/02</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/04</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/06</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/08</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/00</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/02</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/04</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/22</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C237/00</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C237/02</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C237/04</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C237/10</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/00</span>&mdash;<span itemprop="Description">Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/06</span>&mdash;<span itemprop="Description">Esters of carbamic acids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/08</span>&mdash;<span itemprop="Description">Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/10</span>&mdash;<span itemprop="Description">Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/22</span>&mdash;<span itemprop="Description">Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/00</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/23</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/24</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/25</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/08</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D231/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D231/54</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D231/56</span>&mdash;<span itemprop="Description">Benzopyrazoles; Hydrogenated benzopyrazoles</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D239/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D239/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D239/24</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D239/28</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D239/32</span>&mdash;<span itemprop="Description">One oxygen, sulfur or nitrogen atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D239/42</span>&mdash;<span itemprop="Description">One nitrogen atom</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/10</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/14</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/24</span>&mdash;<span itemprop="Description">Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/36</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/38</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/40</span>&mdash;<span itemprop="Description">Benzopyrazines</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/36</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/38</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/40</span>&mdash;<span itemprop="Description">Benzopyrazines</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D241/42</span>&mdash;<span itemprop="Description">Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/08</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/084</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D295/088</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D475/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing pteridine ring systems</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D475/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D513/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00-C07D507/00</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D513/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00-C07D507/00 in which the condensed system contains two hetero rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D513/04</span>&mdash;<span itemprop="Description">Ortho-condensed systems</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F</span>&mdash;<span itemprop="Description">ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F5/00</span>&mdash;<span itemprop="Description">Compounds containing elements of Groups 3 or 13 of the Periodic Table</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F5/02</span>&mdash;<span itemprop="Description">Boron compounds</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F5/025</span>&mdash;<span itemprop="Description">Boronic and borinic acid compounds</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/00</span>&mdash;<span itemprop="Description">Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/09</span>&mdash;<span itemprop="Description">Recombinant DNA-technology</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/11</span>&mdash;<span itemprop="Description">DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/111</span>&mdash;<span itemprop="Description">General methods applicable to biologically active non-coding nucleic acids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/00</span>&mdash;<span itemprop="Description">Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/09</span>&mdash;<span itemprop="Description">Recombinant DNA-technology</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/87</span>&mdash;<span itemprop="Description">Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/88</span>&mdash;<span itemprop="Description">Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y</span>&mdash;<span itemprop="Description">ENZYMES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y304/00</span>&mdash;<span itemprop="Description">Hydrolases acting on peptide bonds, i.e. peptidases (3.4)</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y304/24</span>&mdash;<span itemprop="Description">Metalloendopeptidases (3.4.24)</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y304/24003</span>&mdash;<span itemprop="Description">Microbial collagenase (3.4.24.3)</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y</span>&mdash;<span itemprop="Description">ENZYMES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y304/00</span>&mdash;<span itemprop="Description">Hydrolases acting on peptide bonds, i.e. peptidases (3.4)</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y304/24</span>&mdash;<span itemprop="Description">Metalloendopeptidases (3.4.24)</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12Y304/24007</span>&mdash;<span itemprop="Description">Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2603/00</span>&mdash;<span itemprop="Description">Systems containing at least three condensed rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2603/56</span>&mdash;<span itemprop="Description">Ring systems containing bridged rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2603/58</span>&mdash;<span itemprop="Description">Ring systems containing bridged rings containing three rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2603/70</span>&mdash;<span itemprop="Description">Ring systems containing bridged rings containing three rings containing only six-membered rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2603/74</span>&mdash;<span itemprop="Description">Adamantanes</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/00</span>&mdash;<span itemprop="Description">Structure or type of the nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/10</span>&mdash;<span itemprop="Description">Type of nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/14</span>&mdash;<span itemprop="Description">Type of nucleic acid interfering nucleic acids [NA]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/00</span>&mdash;<span itemprop="Description">Structure or type of the nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/10</span>&mdash;<span itemprop="Description">Type of nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/20</span>&mdash;<span itemprop="Description">Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
    </ul>
  </section>

  

  

  <section>
    <h2>Definitions</h2>
    <ul>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">T lymphocytes</span>
        <span itemprop="definition">regulate immune responses making them important drug targets for developing new medicines.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">antibody therapies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4), programmed cell death protein 1 (PD1), or PD1 ligand 1 (PDL1)) signaling</span>
        <span itemprop="definition">have driven potent anti-tumor responses (Khalil, D.N., et al., Nat Rev Clin Oncol, 13:273-290 (2016); Sharma, P. &amp; Allison, J. P., Science, 348:5661 (2015)).</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CTL1 ligand 1</span>
        <span itemprop="definition">PD1 ligand 1</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">antibody therapies</span>
        <span itemprop="definition">can only inhibit the activity ofdruggable proteins, which are thought to constitute   15% of the total protein coding genome (Dixon, S. and Stockwell, B., Curr Opin Chem Biol, 13(5-6):549-555 (2009)).</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Antibody therapies</span>
        <span itemprop="definition">are limited to druggable proteins because the antibody must be able to bind to the protein to exert its therapeutic effect.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">can be used to inhibit the translation of any gene including genes that encode an undruggable protein.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Several undruggable protein targets</span>
        <span itemprop="definition">have been identified in T cell activity.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">can be useful to treat a large number of diseases caused byundruggable proteins including diseases involving T cells.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">clinically relevant siRNA delivery to cells other than hepatocytes</span>
        <span itemprop="definition">Adams, D., et al., N Engl J Med, 379:11-21 (2018)</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">has remained challenging</span>
        <span itemprop="definition">Lienzar, C., et al., J Control Release, 203:1-15 (2015)).</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">was delivered to T cells using a single chain antibody linked to a positively charged peptide; this led to target gene silencing at 5 mg / kg, a high dosage (Kumar, P., et al., Cell, 134:577-586 (2008)).</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nanoparticles</span>
        <span itemprop="definition">were coated with anti-CD4 antibodies, leading to 20% in vivo target gene silencing at 1 mg / kg doses (Ramishetti, S., et al., ACS Nano, 9:6706-6716 (2015)).</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs</span>
        <span itemprop="definition">lipid nanoparticles</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CD4 antibodies</span>
        <span itemprop="definition">CD4 antibodies</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">All these therapies</span>
        <span itemprop="definition">share two important commonalities. First, they require more than 1 mg / kg siRNA to achieve 50% gene silencing, which is above the current siRNA dose approved for human use (Adams, D., et al., N Engl J Med, 379:11-21 (2018)). Second, they achieve T cell delivery using peptide-, protein-, or aptamer-based targeting ligands.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanomedicines</span>
        <span itemprop="definition">are often trafficked to cell using targeting ligands (Cheng, S., et al., Science, 338:903-910 (2012)).</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the only FDA approved RNA nanoparticle therapy</span>
        <span itemprop="definition">utilizes a simple mixture of lipids that are naturally trafficked to hepatic cells (Adams, D., et al., N Engl J Med, 379:11-21 (2016)). Natural trafficking has not been shown to promote nanoparticle delivery to immune cells. Because the current options for nanoparticle delivery to T cells require high doses of nucleic acid to achieve gene silencing and rely on targeting ligands for cell delivery, there is a need for improved nanoparticle compositions for delivery to T cells.</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions for delivering nucleic acids to specific cells or tissue microenvironments</span>
        <span itemprop="definition">are provided.</span>
        <meta itemprop="num_attr" content="0010">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compositions</span>
        <span itemprop="definition">are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent.</span>
        <meta itemprop="num_attr" content="0010">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid nanoparticle having a conformationally constrained ionizable lipid, a phospholipid, a polyethylene glycol-lipid; a cholesterol, and optionally a nucleic acid.</span>
        <meta itemprop="num_attr" content="0011">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the constrained ionizable lipid</span>
        <span itemprop="definition">has a structure according to Formula I:</span>
        <meta itemprop="num_attr" content="0011">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the constrained ionizable lipid</span>
        <span itemprop="definition">contains an adamantane tail.</span>
        <meta itemprop="num_attr" content="0019">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the constrained ionizable lipid</span>
        <span itemprop="definition">is 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate.</span>
        <meta itemprop="num_attr" content="0019">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phosphlipid</span>
        <span itemprop="definition">is 1-2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1-2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE).</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG-lipid</span>
        <span itemprop="definition">is C14PEG2000 or C18PEG2000.</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticles</span>
        <span itemprop="definition">contain a sterol.</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sterol</span>
        <span itemprop="definition">is cholesterol.</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">can be RNA, DNA, single-stranded RNA, single-stranded DNA, double-stranded RNA, double stranded DNA, triple-stranded DNA, siRNA, shRNA, sgRNA, mRNA, miRNA, antisense DNA, or a combination thereof.</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid</span>
        <span itemprop="definition">encodes an RNA-guided DNA endonuclease, including but not limited to Cas9, CasX, CasY, Cas13, or Cpf1.</span>
        <meta itemprop="num_attr" content="0021">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">contain about 30 mol % to about 70 mol % conformationally constrained ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 25 mol % to about 45 mol % cholesterol, and about 0.1 mol % to about 5 mol % PEG-lipid.</span>
        <meta itemprop="num_attr" content="0022">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained ionizable lipid</span>
        <span itemprop="definition">can be present at 35, 45, 50, or 65 mole percent.</span>
        <meta itemprop="num_attr" content="0022">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle</span>
        <span itemprop="definition">has a hydrodynamic diameter from about 30 nm to about 170 nm. In another embodiment, the lipid nanoparticles have an average diameter of 50 nm to 100 nm.</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">can be formulated as a pharmaceutical composition optionally containing a pharmaceutically acceptable excipient or pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0024">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides lipid nanoparticles in which C 14 PEG 2000 is present at 2.0 to 3.0 mole percent, DSPC is present at 15 to 17 mole percent, cholesterol is present at 45 to 47 mole percent, and the constrained lipid is present at 33 to 36 mole percent.</span>
        <meta itemprop="num_attr" content="0025">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Still another embodiment</span>
        <span itemprop="definition">provides a method of delivering a therapeutic or prophylactic agent to a subject in need thereof, by administering to the subject one or more of the disclosed lipid nanoparticle compositions loaded with a therapeutic nucleic acid, for example a nucleic acid encoding a therapeutic protein, or an inhibitory or enzymatic nucleic acid.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">can further include administering a second therapeutic agent.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticles</span>
        <span itemprop="definition">preferentially deliver cargo to immune cells.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the immune cells</span>
        <span itemprop="definition">can be T cells, such as CD8&#43; T cells, CD4&#43; T cells, or T regulatory cells.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the immune cells</span>
        <span itemprop="definition">can also be macrophages or dendritic cells.</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides a method for reducing splenic or hepatic clearance of a nanoparticle composition by formulating the nanoparticles with an effective amount of conformationally constrained ionizable lipid to reduce or inhibit splenic or hepatic clearance of the nanoparticles.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides a method of delivering a nucleic acid to an immune cell in a subject in need thereof by administering to the subject a lipid nanoparticle consisting of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, a cholesterol, and the nucleic acid, wherein the lipid nanoparticle composition delivers the nucleic acid to the immune cell in the subject, optionally in the absence of a targeting ligand.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the T cell</span>
        <span itemprop="definition">is a CD8&#43; T cell.</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Yet another embodiment</span>
        <span itemprop="definition">provides a method for reducing gene expression in an immune cell in a subject in need thereof by administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and an inhibitory nucleic acid, wherein the lipid nanoparticle composition delivers the inhibitory nucleic acid to the immune cell in the subject.</span>
        <meta itemprop="num_attr" content="0028">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides a method for editing a gene in an immune cell in a subject in need thereof by administering to the subject a lipid nanoparticle composition comprising a first and second population of lipid nanoparticles, wherein the first population of lipid nanoparticles consist of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for a the gene, and wherein the second population of lipid nanoparticles consist of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA</span>
        <meta itemprop="num_attr" content="0029">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 1A</span>
        <span itemprop="definition">is the structure of an ionizable lipid scaffold to which tail variants (structure shown in Figure 1B) and head group variants (structures shown in Figure 1C) were added.</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 1D</span>
        <span itemprop="definition">is a schematic showing 4 molar ratios of ionizable lipid, cholesterol, lipid-PEG, and either DSPC or DOPE used to formulate 104 distinct LNPs.</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 1E</span>
        <span itemprop="definition">is a dot plot showing hydrodynamic diameter (nm) of all formulated LNPs, measured individually.</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 1F</span>
        <span itemprop="definition">is a dot plot showing polydispersity index of all formulated LNPs, measured individually.</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figures 1G-1I</span>
        <span itemprop="definition">are bar graphs showing hydrodynamic diameter of LNPs plotted as a function of ionizable lipid type (Figure 1G), molar percent of ionizable lipid (Figure 1H), and phospholipid type ( Figure 1I).</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2A</span>
        <span itemprop="definition">is a schematic showing the nanoparticles formulated to carry a distinct DNA barcode and siGFP.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2B</span>
        <span itemprop="definition">is a schematic showing an experimental workflow including steps of pooling 100 stable LNPs together, administering them to mice expressing GFP, isolating GFP Low cells after 3 days, and sequencing the DNA barcodes within that population.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2C</span>
        <span itemprop="definition">is a bar graph showing the percent GFP Low cells in 9 cell types.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2D</span>
        <span itemprop="definition">is a bar graph showing the percent GFP MFI in 9 cell types.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2E</span>
        <span itemprop="definition">is a dot plot showing normalized DNA delivery in lung endothelial cells, splenic B and T cells, as well as liver immune cells.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2F</span>
        <span itemprop="definition">is a schematic showing the enrichment of DSPC-containing LNPs in splenic T cells.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2G</span>
        <span itemprop="definition">is a dot plot showing normalized DNA delivery of LNPs plotted as a function of phospholipid. 2- way T test, **P  0.01.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2H</span>
        <span itemprop="definition">is a paired analysis of normalized DNA delivery of LNPs containing DSPC or DOPE. Paired 2-way T test, *P  0.05.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2I</span>
        <span itemprop="definition">is a bar graph showing enrichment for each of the 13 ionizable lipids.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 2J</span>
        <span itemprop="definition">is a bar graph showing normalized DNA delivery of LNPs formulated with head group 11 and tail L, S, or A. One-way ANOVA, *P  0.05, **P  0.01.</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3A</span>
        <span itemprop="definition">shows the structure of ionizable lipid 11-A.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3B</span>
        <span itemprop="definition">shows the molar composition of top performing cLNP.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3C</span>
        <span itemprop="definition">is a flow cytometry histogram showing GFP expression in splenic CD3 &#43; T cells 72 hours after treatment of cLNP carrying siLuc at a dose of 1.5 mg / kg or siGFP at doses of 0.5 mg / kg and 1.5 mg / kg.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3D</span>
        <span itemprop="definition">is a bar graph showing normalized GFP MFI in splenic CD3&#43; T cells 72 hours after treatment of cLNP carrying either siLuc or siGFP at various doses.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3E</span>
        <span itemprop="definition">is a bar graph showing normalized GFP MFI in splenic CD8&#43; and CD4&#43; T cells 72 hours after treatment of cLNP carrying siGFP at a dose of 2.0 mg / kg.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3F</span>
        <span itemprop="definition">is a bar graph showing normalized GFP MFI in splenic CD3&#43; T cells as well as CD8&#43; and CD4&#43; T cells after treatment of cLNPs carrying sgRNA at a dose of 2.0 mg / kg.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 3G</span>
        <span itemprop="definition">is a bar graph showing percent GFP Low CD8&#43; T cells after treatment of cLNPs carrying sgRNA at a dose of 2.0 mg / kg.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 4A</span>
        <span itemprop="definition">shows a graph relating the molecular weight of the headgroup of the ionizable lipid to the enrichment in T-cells.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 4B</span>
        <span itemprop="definition">shows a graph relating the LogP of the headgroup of the ionizable lipid to the enrichment in T-cells.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 4C</span>
        <span itemprop="definition">shows a graph relating the LogP of the polar surface area of the headgroup on the ionizable lipid to the enrichment in T-cells.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 4D</span>
        <span itemprop="definition">shows a paired analysis of LNPs containing DSPC and ionizable lipids differing only by one tail.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 4E</span>
        <span itemprop="definition">shows a comparison of normalized DNA Delivery and LNP diameter.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 5A-F</span>
        <span itemprop="definition">are the normalized GFP protein MFI in PBS-treated mice as well as those dosed with LNP containing constrained lipid delivering siLuciferase, and siGFP (at 1.5 mg / kg and 0.5 mg / kg) to hepatocytes, liver immune cells, liver Kupffer cells, Liver Endothelial cells, Splenic monocytes, and Splenic B Cells.</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Figure 5G</span>
        <span itemprop="definition">is the sequence and chemical modification on sgGFP. DETAILED DESCRIPTION I. Definitions</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each center</span>
        <span itemprop="definition">may independently be of R-configuration or S-configuration or a mixture thereof.</span>
        <meta itemprop="num_attr" content="0038">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds provided herein</span>
        <span itemprop="definition">may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched, or a stereoisomeric mixture.</span>
        <meta itemprop="num_attr" content="0038">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each double bond</span>
        <span itemprop="definition">may independently be E or Z a mixture thereof.</span>
        <meta itemprop="num_attr" content="0038">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anRNA</span>
        <span itemprop="definition">refers to a ribonucleic acid that may be naturally or non-naturally occurring.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an RNA</span>
        <span itemprop="definition">may include modified and/or non-naturally occurring components such as one or more nucleobases, nucleosides, nucleotides, or linkers.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An RNA</span>
        <span itemprop="definition">may include a cap structure, a chain terminating nucleoside, a stem loop, a polyA sequence, and/or a polyadenylation signal.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An RNA</span>
        <span itemprop="definition">may have a nucleotide sequence encoding a polypeptide of interest.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an RNA</span>
        <span itemprop="definition">may be a messenger RNA (mRNA).</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNAs</span>
        <span itemprop="definition">may be selected from the nonlimiting group consisting of small interfering RNA (siRNA), microRNA (miRNA), Dicer- substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, single-guide RNA (sgRNA), cas9 mRNA, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polypeptide</span>
        <span itemprop="definition">may be used interchangeably to refer a string of at least three amino acids linked together by peptide bonds.</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Peptide</span>
        <span itemprop="definition">may refer to an individual peptide or a collection of peptides.</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Peptides</span>
        <span itemprop="definition">can contain natural amino acids, non-natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain), and/or amino acid analogs.</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more of the amino acids in a peptide</span>
        <span itemprop="definition">may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. Modifications may include cyclization of the peptide, the incorporation of D-amino acids, etc.</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">atherapeutically effective amount</span>
        <span itemprop="definition">refers to that amount of a therapeutic agent sufficient to mediate a clinically relevant elimination, reduction or amelioration of such symptoms. An effect is clinically relevant if its magnitude is sufficient to impact the health or prognosis of a recipient subject.</span>
        <meta itemprop="num_attr" content="0043">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutically effective amount</span>
        <span itemprop="definition">may refer to the amount of therapeutic agent sufficient to delay or minimize the onset of disease, e.g., delay or minimize the spread of cancer.</span>
        <meta itemprop="num_attr" content="0043">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutically effective amount</span>
        <span itemprop="definition">may also refer to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease.</span>
        <meta itemprop="num_attr" content="0043">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the termprophylactic agent</span>
        <span itemprop="definition">refers to an agent that can be used in the prevention of a disorder or disease prior to the detection of any symptoms of such disorder or disease.</span>
        <meta itemprop="num_attr" content="0044">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Aprophylactically effective amount</span>
        <span itemprop="definition">is the amount of prophylactic agent sufficient to mediate such protection.</span>
        <meta itemprop="num_attr" content="0044">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a prophylactically effective amount</span>
        <span itemprop="definition">may also refer to the amount of the prophylactic agent that provides a prophylactic benefit in the prevention of disease.</span>
        <meta itemprop="num_attr" content="0044">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the termsindividual,host,subject, andpatient</span>
        <span itemprop="definition">are used interchangeably herein, and refer to a mammal, including, but not limited to, humans, rodents, such as mice and rats, and other laboratory animals.</span>
        <meta itemprop="num_attr" content="0045">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the termpharmaceutically acceptable carrier</span>
        <span itemprop="definition">encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.</span>
        <meta itemprop="num_attr" content="0046">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the termconformationally constrained lipid</span>
        <span itemprop="definition">refers to a lipid whose molecular structure is predominantly in one architecture, such as an adamantane, whose shape resembles anarmchair.</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the termPEG-lipid</span>
        <span itemprop="definition">refers to a lipid modified with polyethylene glycol. Exemplary PEG-lipids, include but are not limited to C 14 PEG 350 , C 14 PEG 1000 , C 14 PEG 2000 , C14PEG3000, and C18PEG2000.</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oligonucleotide</span>
        <span itemprop="definition">refers to short DNA, RNA, or DNA/RNA molecules or oligomers containing a relatively small number of nucleotides.</span>
        <meta itemprop="num_attr" content="0048">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R1</span>
        <span itemprop="definition">is:</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is:</span>
        <meta itemprop="num_attr" content="0053">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3 and R 4</span>
        <span itemprop="definition">are each independently or ;</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R8</span>
        <span itemprop="definition">isH or ;</span>
        <meta itemprop="num_attr" content="0058">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 5 , R 6 , R 7 , and R 9</span>
        <span itemprop="definition">are each independently: -C 8 H 17 , -C 10 H 21 , -C 12 H 25 , -C 13 H 27 , -C 14 H 29 , C 16 H 33 , or adamantanyl,</span>
        <meta itemprop="num_attr" content="0059">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">are each independently 0, 1, 2, 3, or 4;</span>
        <meta itemprop="num_attr" content="0060">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">A</span>
        <span itemprop="definition">is ,</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 10 and R 11</span>
        <span itemprop="definition">are each independentlyH or ;</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R12</span>
        <span itemprop="definition">is -C10H21.</span>
        <meta itemprop="num_attr" content="0063">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a compound in which R2 is or .</span>
        <meta itemprop="num_attr" content="0063">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle composition</span>
        <span itemprop="definition">comprising: a conformationally constrained ionizable lipid; a phospholipid; a polyethylene glycol-lipid; a cholesterol; and optionally a nucleic acid.</span>
        <meta itemprop="num_attr" content="0064">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a lipid nanoparticle composition in which the amount of conformationally constrained ionizable lipid present is in the range of about 35 to about 65 mole percent, based on total moles.</span>
        <meta itemprop="num_attr" content="0064">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a lipid nanoparticle composition in which the conformationally constrained ionizable lipid has a structure according to</span>
        <meta itemprop="num_attr" content="0065">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a lipid nanoparticle composition in which the conformationally constrained ionizable lipid has a structure according to</span>
        <meta itemprop="num_attr" content="0067">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a lipid nanoparticle composition in which the phospholipid is 1-2-distearoyl-sn-glycero-3-phosphocholine (DSPC). Some embodiments relate to a lipid nanoparticle composition in which the polyethylene glycol-lipid is C14PEG2000 or C18PEG2000. [0050] Some embodiments relate to a lipid nanoparticle composition in which the composition comprises about 30 mol % to about 70 mol % conformationally constrained ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 25 mol % to about 45 mol % cholesterol, and about 0.1 mol % to about 5 mol % polyethylene glycol-lipid.</span>
        <meta itemprop="num_attr" content="0069">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle composition</span>
        <span itemprop="definition">in which the nucleic acid comprises RNA, DNA, single-stranded RNA, single-stranded DNA, double-stranded RNA, double stranded DNA, triple-stranded DNA, siRNA, shRNA, sgRNA, mRNA, miRNA, antisense DNA, or a combination thereof.</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle composition</span>
        <span itemprop="definition">is one in which the nucleic acid encodes a protein.</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle composition</span>
        <span itemprop="definition">is one in which the nucleic acid encodes an RNA-guided DNA endonuclease.</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle composition</span>
        <span itemprop="definition">is one in which the RNA- guided DNA endonuclease is Cas9, CasX, CasY, Cas13, or Cpf1.</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle composition</span>
        <span itemprop="definition">is one in which the lipid nanoparticle has a hydrodynamic diameter in the range of from about 30 nm to about 170 nm.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle composition</span>
        <span itemprop="definition">comprises: a conformationally constrained ionizable lipid comprising an adamantane tail; 1-2-distearoyl-sn- glycero-3-phosphocholine (DSPC); C 14 PEG 2000 ; cholesterol; and siRNA.</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained ionizable lipid</span>
        <span itemprop="definition">is 3-[(1- Adamantanyl)acetoxy]-2-  [3-(diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12- octadecadienoate.</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C14PEG2000</span>
        <span itemprop="definition">is present at about 2.0 to about 3.0 mole percent</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPC</span>
        <span itemprop="definition">is present at about 15 to about 17 mole percent</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at about 45 to about 47 mole percent</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained ionizable lipid</span>
        <span itemprop="definition">is present at about 33 to about 36 mole percent</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">is present at 5 to 20 mass ratio of total lipid to siRNA.</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 14 PEG 2000</span>
        <span itemprop="definition">is present at about 2.5 mole percent</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPC</span>
        <span itemprop="definition">is present at about 16 mole percent</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cholesterol</span>
        <span itemprop="definition">is present at about 46.5 mole percent</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained ionizable lipid</span>
        <span itemprop="definition">is present at about 35 mole percent.</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a pharmaceutical composition</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">comprising a lipid nanoparticle composition as described herein and a pharmaceutically acceptable excipient.</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a method of delivering a nucleic acid to a subject in need thereof, comprising, administering to the subject a lipid nanoparticle composition or a pharmaceutical composition as described herein. Some embodiments further comprise administering a second therapeutic agent to the subject.</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a method of delivering a nucleic acid to an immune cell in a subject in need thereof, comprising: administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate; DSPC; a polyethylene glycol-lipid; a cholesterol; and a nucleic acid, in which the lipid nanoparticle composition delivers the nucleic acid to the immune cell in the subject.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle composition</span>
        <span itemprop="definition">does not contain a targeting ligand that targets the lipid nanoparticle composition to the immune cell.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the immune cell</span>
        <span itemprop="definition">is a T cell.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the T cell</span>
        <span itemprop="definition">is a CD8&#43; T cell.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the T cell</span>
        <span itemprop="definition">is a T regulatory cell.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the T cell</span>
        <span itemprop="definition">is CD4&#43;.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the immune cell</span>
        <span itemprop="definition">is a macrophage, dendritic cell, or liver immune cell.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a method for reducing splenic or hepatic clearance of a nanoparticle composition comprising formulating the nanoparticle composition with an amount of a conformationally constrained ionizable lipid that is effective to reduce or inhibit splenic or hepatic clearance of the nanoparticle composition when administered to a subject.</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained ionizable lipid</span>
        <span itemprop="definition">comprises a structure as described herein.</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a method for increasing delivery of a nanoparticle composition to non-hepatocyte cells in a subject comprising formulating the nanoparticle composition to comprise an amount of a conformationally constrained ionizable lipid that is effective to increase delivery of the nanoparticle composition to non-hepatocyte cells when administered to the subject.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained ionizable lipid</span>
        <span itemprop="definition">comprises a structure as described herein.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle composition</span>
        <span itemprop="definition">is a lipid nanoparticle pharmaceutical composition.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle pharmaceutical composition</span>
        <span itemprop="definition">comprises a phospholipid, a polyethylene glycol-lipid, a cholesterol, and optionally a first nucleic acid.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the non-hepatocyte cells</span>
        <span itemprop="definition">are at least one of splenic B cells, splenic T cells, lung endothelial cells, and liver immune cells.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle composition</span>
        <span itemprop="definition">further comprises a second nucleic acid that is delivered to the subject in an amount in the range of about 0.5 mg/kg to about 2.0 mg/kg. In some embodiments, the amount of the second nucleic acid delivered to the subject is less than about 1.0 mg/kg.</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a method for reducing gene expression in an immune cell in a subject in need thereof, comprising: administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate; DSPC; a polyethylene glycol-lipid; cholesterol; and an inhibitory nucleic acid, in which the lipid nanoparticle composition delivers the inhibitory nucleic acid to the immune cell in the subject.</span>
        <meta itemprop="num_attr" content="0079">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitory nucleic acid</span>
        <span itemprop="definition">is siRNA.</span>
        <meta itemprop="num_attr" content="0079">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of the inhibitory nucleic acid administered to the subject</span>
        <span itemprop="definition">is less than about 1.0 mg/kg. In some embodiments, the amount of inhibitory nucleic acid administered to the subject is about 0.5 mg/kg.</span>
        <meta itemprop="num_attr" content="0079">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some embodiments</span>
        <span itemprop="definition">relate to a method for editing a gene in an immune cell in a subject in need thereof, comprising: administering to the subject a lipid nanoparticle composition comprising a first and second population of lipid nanoparticles, in which the first population of lipid nanoparticles consists of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for the gene, and in which the second population of lipid nanoparticles consists of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the RNA guided DNA endonuclease</span>
        <span itemprop="definition">is selected from the group consisting of Cas9, CasX, CasY, Cas13, and Cpf1.</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of one or both of the sgRNA and mRNA administered to the subject</span>
        <span itemprop="definition">is less than about 1.0 mg/kg. In some embodiments, the amount of one or both of the sgRNA and mRNA administered to the subject is about 0.5 mg/kg.</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticles having constrained lipids</span>
        <span itemprop="definition">can more effectively deliver nucleic acids to specific tissues in the body.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticles</span>
        <span itemprop="definition">can be formulated by mixing nucleic acids with conformationally constrained ionizable lipids, PEG-lipids, phospholipids, cholesterol, and optionally a nucleic acid.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An exemplary lipid nanoparticle formulation</span>
        <span itemprop="definition">includes the conformationally constrained ionizable lipid 3-[(1-Adamantanyl)acetoxy]-2-  [3-(diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)- 9,12-octadecadienoate, a PEG-lipid, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), and cholesterol.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">do not contain a targeting ligand.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">preferentially target T cells over hepatocytes in the absence of a targeting ligand.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid nanoparticle sizes</span>
        <span itemprop="definition">vary.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">can have a hydroscopic diameter from between about 30 to about 170 nm.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">can have a diameter that is about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, or 170 nm.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticles</span>
        <span itemprop="definition">have a diameter from between 50 nm to 100 nm.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">include an ionizable lipid.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ionizable lipid</span>
        <span itemprop="definition">typically includes an amine-containing on the head group.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ionizable lipid</span>
        <span itemprop="definition">is a conformationally constrained ionizable lipid.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained lipid</span>
        <span itemprop="definition">is present at 35, 45, 50, or 65 mole percent.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained lipid</span>
        <span itemprop="definition">is present at about 33 mol % to about 36 mol%.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conformationally constrained lipid</span>
        <span itemprop="definition">is present at 35 mol %.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides a LNP containing a lipid having a structure according to Formula I:</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is a lipid tail selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">A, and R2</span>
        <span itemprop="definition">is a head group selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0089">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides an ionizable lipid having a structure according to Formula II:</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to Formula I, wherein R 1 is tail L, and R 2 is compound (1) or an LNP containing said ionizable lipid.</span>
        <meta itemprop="num_attr" content="0096">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Still another embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to Formula I, wherein R 1 is tail L, and R 2 is compound (2) or an LNP containing said ionizable lipid.</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0107">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0113">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0129">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0135">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0138">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0143">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0149">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0154">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0157">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0160">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0163">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0166">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0175">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0178">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0181">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0186">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0189">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0192">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0201">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0207">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0210">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0213">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0216">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0219">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0222">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0225">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0237">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0240">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0242">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides an ionizable lipid according to the following structure:</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">include one or more sterols.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sterol</span>
        <span itemprop="definition">is cholesterol, or a variant or derivative thereof.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol</span>
        <span itemprop="definition">is modified, for example oxidized. Unmodified cholesterol can be acted upon by enzymes to form variants that are side-chain or ring oxidized. The cholesterol can be oxidized on the beta-ring structure or on the hydrocarbon tail structure.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary cholesterols that are considered for use in the disclosed lipid nanoparticles</span>
        <span itemprop="definition">include but are not limited to 25- hydroxycholesterol (25-OH), 20  -hydroxycholesterol (20  -OH), 27-hydroxycholesterol, 6-keto- 5  -hydroxycholesterol, 7-ketocholesterol, 7  -hydroxycholesterol, 7  -25- dihydroxycholesterol, beta-sitosterol, stigmasterol or combinations thereof.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">side-chain oxidized cholesterol</span>
        <span itemprop="definition">can enhance cargo delivery relative to other cholesterol variants.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cholesterol</span>
        <span itemprop="definition">is an unmodified cholesterol.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed nanoparticle compositions</span>
        <span itemprop="definition">also include one or more PEG or PEG-modified lipids.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG or PEG-modified lipids</span>
        <span itemprop="definition">Such species may be alternately referred to as PEGylated lipids or PEG-lipids.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEGylated lipids</span>
        <span itemprop="definition">PEG-lipids.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Inclusion of a PEGylating lipid</span>
        <span itemprop="definition">can be used to enhance lipid nanoparticle colloidal stability in vitro and circulation time in vivo.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEGylation</span>
        <span itemprop="definition">is reversible in that the PEG moiety is gradually released in blood circulation.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary PEG-lipids</span>
        <span itemprop="definition">include but are not limited to PEG conjugated to saturated or unsaturated alkyl chains having a length of C6-C20.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a PEG lipid</span>
        <span itemprop="definition">may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPE, PEG- DSG or a PEG-DSPE lipid.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG lipid</span>
        <span itemprop="definition">is DMPE-PEG2000 or DSPE-PEG2000.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid component of the nanoparticle</span>
        <span itemprop="definition">may include one or more phospholipids, such as one or more (poly)unsaturated lipids.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipids</span>
        <span itemprop="definition">may assemble into one or more lipid bilayers.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipids</span>
        <span itemprop="definition">may include a phospholipid moiety and one or more fatty acid moieties.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid moiety</span>
        <span itemprop="definition">includes but is not limited to phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidic acid, 2-lysophosphatidyl choline, and sphingomyelin.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the fatty acid moiety</span>
        <span itemprop="definition">includes but is not limited to lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nonnatural species including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes</span>
        <span itemprop="definition">are also contemplated.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid</span>
        <span itemprop="definition">may be functionalized with or cross-linked to one or more alkynes (e.g., an alkenyl group in which one or more double bonds is replaced with a triple bond).</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynes</span>
        <span itemprop="definition">e.g., an alkenyl group in which one or more double bonds is replaced with a triple bond.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an alkyne group</span>
        <span itemprop="definition">may undergo a copper-catalyzed cycloaddition upon exposure to an azide.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such reactions</span>
        <span itemprop="definition">may be useful in functionalizing a lipid bilayer of a nanoparticle composition to facilitate membrane permeation or cellular recognition or in conjugating a nanoparticle composition to a useful component such as a targeting or imaging moiety (e.g., a dye).</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary phospholipids</span>
        <span itemprop="definition">include but are not limited to 1,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero- phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl- sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), l- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-0-octadecenyl-sn-glycero-3-phosphocholine</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticle compositions</span>
        <span itemprop="definition">include a therapeutic or prophylactic agent to a subject.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the therapeutic or prophylactic agent</span>
        <span itemprop="definition">is encapsulated by the lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">are loaded with one or more nucleic acids.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">include but are not limited to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) RNA, DNA, single-stranded RNA, single-stranded DNA, double-stranded RNA, double stranded DNA, triple-stranded DNA, siRNA, shRNA, sgRNA, mRNA, miRNA, and antisense DNA.</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CRISPR</span>
        <span itemprop="definition">Clustered Regularly Interspaced Short Palindromic Repeats</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the guide RNA</span>
        <span itemprop="definition">directs the Cas nuclease to the specific target DNA sequence. Cas then creates a double-strand break in the DNA at that site.</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">can be used to carry the components required for CRISPR-based gene editing.</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid cargo</span>
        <span itemprop="definition">is a guide-RNA.</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a second lipid nanoparticle</span>
        <span itemprop="definition">can contain nucleic acid cargo that encodes an RNA-guided endonuclease.</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the two lipid nanoparticles</span>
        <span itemprop="definition">can be administered together.</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary RNA-guided endonucleases</span>
        <span itemprop="definition">include but are not limited to Cas9, CasX, CasY, Cas13, or Cpf1.</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cargo</span>
        <span itemprop="definition">is siRNA.</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Short Interfering RNA</span>
        <span itemprop="definition">is a double-stranded RNA that can induce sequence-specific post-transcriptional gene silencing, thereby decreasing or even inhibiting gene expression.</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an siRNA</span>
        <span itemprop="definition">triggers the specific degradation of homologous RNA molecules, such as mRNAs, within the region of sequence identity between both the siRNA and the target RNA.</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">WO 02/44321</span>
        <span itemprop="definition">discloses siRNAs capable of sequence-specific degradation of target mRNAs when base-paired with 3 overhanging ends, herein incorporated by reference for the method of making these siRNAs.</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Sequence specific gene silencing</span>
        <span itemprop="definition">can be achieved in mammalian cells using synthetic, short double-stranded RNAs that mimic the siRNAs produced by the enzyme dicer (Elbashir, et al. (2001) Nature, 411:494498) (Ui-Tei, et al. (2000) FEBS Lett 479:79-82.</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">contains less than 1.0 mg/kg inhibitory nucleic acid.</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle</span>
        <span itemprop="definition">can contain 1.0, 0.9, 0.8, 0.7, 0.6, or 0.5 mg/kg inhibitory nucleic acid.</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">contains 0.5 mg/kg inhibitory nucleic acid. This is an advantage over current technology in which nanoparticles require high doses of nucleic acid (&gt; 1 mg/kg) to achieve gene silencing, doses of which are not approve for human delivery.</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed technology</span>
        <span itemprop="definition">can achieve gene silencing using 0.5 mg/kg inhibitory nucleic acid in a lipid nanoparticle that does not include targeting ligands.</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids</span>
        <span itemprop="definition">including but not limited to oligonucleotides, are modified or include one more modified nucleotides to increase stability, half- life, and nuclease sensitivity.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the native phosphodiester oligodeoxyribonucleotide, native phosphodiester oligoribonucleotide, ribonucleotide polymers, and deoxyribonucleotide polymers</span>
        <span itemprop="definition">can include one more different modifications.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary modifications</span>
        <span itemprop="definition">include but are not limited to phosphorothioate (PS) bonds, 2-O Methyl (2OMe), 2 Fluor bases, inverted dT and ddT, phosphorylation of the 3end of oligonucleotides, locked nucleic acids, and including a phosphoramidite C3 Spacer.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phosphorothioate bond</span>
        <span itemprop="definition">substitutes a sulfur atom for a non-bridging oxygen in the phosphate backbone of an oligonucleotide.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PS modification</span>
        <span itemprop="definition">renders the internucleotide linkage more resistant to nuclease degradation.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids</span>
        <span itemprop="definition">include one or more PS bonds, for example at least 3 PS bonds at the 5   and 3   oligonucleotide ends to inhibit exonuclease degradation.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some nucleic acid</span>
        <span itemprop="definition">include PS bonds throughout the entire oligonucleotide to help reduce attack by endonucleases as well.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA, 2OMe</span>
        <span itemprop="definition">A naturally occurring post-transcriptional modification of RNA, 2OMe is found in tRNA and other small RNAs.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids or oligonucleotides</span>
        <span itemprop="definition">are directly synthesized to contain 2OMe. This modification increases the Tm of RNA:RNA duplexes, but results in only small changes in RNA:DNA stability. It prevents attack by single- stranded endonucleases, but not exonuclease digestion. In some embodiment, these nucleic acids or oligonucleotides are also end blocked. DNA oligonucleotides that include this modification are typically 5- to 10-fold less susceptible to DNases than unmodified DNA. The 2  OMe modification is commonly used in antisense oligonucleotides as a means to increase stability and binding affinity to target transcripts.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">2-fluoro bases</span>
        <span itemprop="definition">have a fluorine-modified ribose which increases binding affinity (Tm) and also confers some relative nuclease resistance compared to native RNA.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids or oligonucleotides</span>
        <span itemprop="definition">include 2 fluoro bases in conjunction with PS-modified bonds.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Inverted dT</span>
        <span itemprop="definition">can be incorporated at the 3   end of an oligonucleotide, leading to a 3-3 linkage that will inhibit degradation by 3 exonucleases and extension by DNA polymerases.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">placing an inverted, 2  ,3   dideoxy-dT base (5 Inverted ddT) at the 5   end of an oligonucleotide</span>
        <span itemprop="definition">prevents spurious ligations and may protect against some forms of enzymatic degradation.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids or oligonucleotides</span>
        <span itemprop="definition">that include a phosphoramidite C3 Spacer.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phosphoramidite C3 Spacer</span>
        <span itemprop="definition">can be incorporated internally, or at either end of an oligo to introduce a long hydrophilic spacer arm for the attachment of fluorophores or other pendent groups.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the C3 spacer</span>
        <span itemprop="definition">also can be used to inhibit degradation by 3 exonucleases.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids or oligonucleotides</span>
        <span itemprop="definition">include locked nucleic acids.</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Locked nucleic acids</span>
        <span itemprop="definition">include modified RNA nucleotides in which the 2-O and 4- C atoms of the ribose are joined through a methylene bridge. This additional bridge limits the flexibility normally associated with the ring, essentially locking the structure into a rigid conformation.</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNAs</span>
        <span itemprop="definition">can be inserted into both RNA and DNA oligonucleotides.</span>
        <meta itemprop="num_attr" content="0288">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Other types of cargo that can be delivered via the disclosed nanoparticles</span>
        <span itemprop="definition">include but are not limited to chemotherapeutic agents, cytotoxic agents, radioactive ions, small molecules, proteins, polynucleotides, and nucleic acids.</span>
        <meta itemprop="num_attr" content="0288">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">chemotherapeutic agents</span>
        <span itemprop="definition">include, but are not limited to amsacrine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxycarbamide, idarubicin, ifosfamide, irinotecan, leucovorin, liposomal doxorubicin, liposomal daunorubicin, lomustine, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitoxantrone, oxaliplatin, pac</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pro-apoptotic agents</span>
        <span itemprop="definition">include, but are not limited to fludarabinetaurosporine, cycloheximide, actinomycin D, lactosylceramide, 15d-PGJ(2) and combinations thereof.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation</span>
        <span itemprop="definition">includes about 30 mol % to about 70 mol % conformationally constrained ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 25 mol % to about 45 mol % cholesterol, and about 0 mol % to about 5 mol % PEG-lipid.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation</span>
        <span itemprop="definition">include about 35 mol % conformationally constrained ionizable lipid, about 16 mol % phospholipid, about 46.5 mol % cholesterol, and about 2.5 mol % PEG-lipid.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation</span>
        <span itemprop="definition">include about 50 mol % conformationally constrained ionizable lipid, about 10 mol % phospholipid, about 38.5 mol % cholesterol, and about 1.5 mol % PEG-lipid.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides a lipid nanoparticle formulation including about 33 mol % to about 36 mol % conformationally constrained ionizable lipid with an adamantane tail, about 15 mol% to about 17 mol % 1-2-distearoyl-sn-glycero-3-phosphocholine, about 2 mol % to about 3 mol % C 14 PEG 2000, and about 45 mol % to about 47 mol % cholesterol, based on the total moles of these four ingredients.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides a lipid nanoparticle formulation including 35 mol % conformationally constrained ionizable lipid with an adamantane tail, 16 mol % 1-2- distearoyl-sn-glycero-3-phosphocholine, and 2.5 mol % C 14 PEG 2000, 46 mol % cholesterol, based on the total moles of these four ingredients.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides a lipid nanoparticle formulation in which the mass ratio of (ionizable lipid, cholesterol, lipid-PEG, and phospholipid):siRNA is between about 2:1 and 20:1.</span>
        <meta itemprop="num_attr" content="0293">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle formulation</span>
        <span itemprop="definition">includes 3-[(1- Adamantanyl)acetoxy]-2-  [3-(diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12- octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and an inhibitory nucleic acid.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One embodiment</span>
        <span itemprop="definition">provides a lipid nanoparticles composition containing 3-[(1- Adamantanyl)acetoxy]-2-  [3-(diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12- octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for a gene.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides a lipid nanoparticle including 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA encoding an RNA guided DNA endonuclease.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions including the disclosed lipid nanoparticles</span>
        <span itemprop="definition">are provided.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle compositions</span>
        <span itemprop="definition">can be formulated in whole or in part as pharmaceutical compositions.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Pharmaceutical compositions</span>
        <span itemprop="definition">may include one or more nanoparticle compositions.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">may include one or more nanoparticle compositions including one or more different therapeutic and/or prophylactics including but not limited to one or more nucleic acids of different types or encode different agents.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical compositions</span>
        <span itemprop="definition">include one or more pharmaceutically acceptable excipients or accessory ingredients including but not limited to a pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions containing the nanoparticles</span>
        <span itemprop="definition">can be formulated for administration by parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), transdermal (either passively or using iontophoresis or electroporation), or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration or using bioerodible inserts and can be formulated in dosage forms appropriate for each route of administration.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle compositions disclosed herein</span>
        <span itemprop="definition">are administered to a subject in a therapeutically effective amount.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the termeffective amount ortherapeutically effective amount</span>
        <span itemprop="definition">means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of the disorder being treated or to otherwise provide a desired pharmacologic and/or physiologic effect. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed nanoparticles</span>
        <span itemprop="definition">As further studies are conducted, information will emerge regarding appropriate dosage levels for treatment of various conditions in various patients, and the ordinary skilled worker, considering the therapeutic context, age, and general health of the recipient, will be able to ascertain proper dosing.</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the selected dosage</span>
        <span itemprop="definition">depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired.</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dosage levels of 0.001 mg to 5 mg of nucleic acid per kg of body weight daily</span>
        <span itemprop="definition">are administered to mammals. More specifically, a preferential dose for the disclosed nanoparticles is 0.01 mg / kg to 0.25 mg/kg.</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a preferential dose of the disclosed nanoparticles</span>
        <span itemprop="definition">is 0.05 mg / kg to 0.5 mg / kg of the four components / kg of body weight.</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle composition</span>
        <span itemprop="definition">is administered locally, for example by injection directly into a site to be treated.</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the injection</span>
        <span itemprop="definition">causes an increased localized concentration of the lipid nanoparticle composition which is greater than that which can be achieved by systemic administration.</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle compositions</span>
        <span itemprop="definition">can be combined with a matrix as described above to assist in creating an increased localized concentration of the polypeptide compositions by reducing the passive diffusion of the polypeptides out of the site to be treated.</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle compositions disclosed herein</span>
        <span itemprop="definition">are administered in an aqueous solution, by parenteral injection.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">may also be in the form of a suspension or emulsion.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pharmaceutical compositions</span>
        <span itemprop="definition">are provided including effective amounts of a lipid nanoparticle, and optionally include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">optionally include one or more for the following: diluents, sterile water, buffered saline of various buffer content (e.g., Tris- HCl, acetate, phosphate), pH and ionic strength; and additives such as detergents and solubilizing agents (e.g., TWEEN 20 (polysorbate-20), TWEEN 80 (polysorbate-80)), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), and preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol).</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diluents</span>
        <span itemprop="definition">sterile water, buffered saline of various buffer content (e.g., Tris- HCl, acetate, phosphate), pH and ionic strength</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">additives</span>
        <span itemprop="definition">such as detergents and solubilizing agents (e.g., TWEEN 20 (polysorbate-20), TW</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-aqueous solvents or vehicles</span>
        <span itemprop="definition">examples include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulations</span>
        <span itemprop="definition">may be lyophilized and redissolved/resuspended immediately before use.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles disclosed herein</span>
        <span itemprop="definition">can also be administered in controlled release formulations.</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Controlled release polymeric devices</span>
        <span itemprop="definition">can be made for long term release systemically following implantation of a polymeric device (rod, cylinder, film, disk) or injection (microparticles).</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the matrix</span>
        <span itemprop="definition">can be in the form of microparticles such as microspheres, where the agent is dispersed within a solid polymeric matrix or microcapsules, where the core is of a different material than the polymeric shell, and the peptide is dispersed or suspended in the core, which may be liquid or solid in nature.</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">microparticles, microspheres, and microcapsules</span>
        <span itemprop="definition">are used interchangeably.</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polymer</span>
        <span itemprop="definition">may be cast as a thin slab or film, ranging from nanometers to four centimeters, a powder produced by grinding or other standard techniques, or even a gel such as a hydrogel.</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Either non-biodegradable or biodegradable matrices</span>
        <span itemprop="definition">can be used for delivery of lipid nanoparticles, although in some embodiments biodegradable matrices are preferred. These may be natural or synthetic polymers, although synthetic polymers are preferred in some embodiments due to the better characterization of degradation and release profiles. The polymer is selected based on the period over which release is desired. In some cases, linear release may be most useful, although in others a pulse release orbulk release may provide more effective results.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polymer</span>
        <span itemprop="definition">may be in the form of a hydrogel (typically in absorbing up to about 90% by weight of water), and can optionally be crosslinked with multivalent ions or polymers.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the matrices</span>
        <span itemprop="definition">can be formed by solvent evaporation, spray drying, solvent extraction and other methods known to those skilled in the art.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Bioerodible microspheres</span>
        <span itemprop="definition">can be prepared using any of the methods developed for making microspheres for drug delivery, for example, as described by Mathiowitz and Langer, J. Controlled Release, 5:13-22 (1987); Mathiowitz, et al., Reactive Polymers, 6:275-283 (1987); and Mathiowitz, et al., J. Appl. Polymer Sci., 35:755-774 (1988).</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the devices</span>
        <span itemprop="definition">can be formulated for local release to treat the area of implantation or injection which will typically deliver a dosage that is much less than the dosage for treatment of an entire body or systemic delivery. These can be implanted or injected subcutaneously, into the muscle, fat, or swallowed. III. Methods of Manufacturing Lipid Nanoparticles</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticles</span>
        <span itemprop="definition">are manufactured using microfluidics.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">microfluidics</span>
        <span itemprop="definition">For exemplary methods of using microfluidics to form lipid nanoparticles, see Leung, A.K.K, et al., J Phys Chem, 116:18440-18450 (2012), Chen, D., et al., J Am Chem Soc, 134:6947-6951 (2012), and Belliveau, N.M., et al., Molecular Therapy-Nucleic Acids, 1: e37 (2012). Briefly, the cargo, such as an oligonucleotide or siRNA, is prepared in one buffer.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the other lipid nanoparticle components</span>
        <span itemprop="definition">(ionizable lipid, PEG-lipid, cholesterol, and DSPC) are prepared in another buffer.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a syringe pump</span>
        <span itemprop="definition">introduces the two solutions into a microfluidic device. The two solutions come into contact within the microfluidic device to form lipid nanoparticles encapsulating the cargo.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the screening methods</span>
        <span itemprop="definition">characterizes vehicle delivery formulations to identify formulations with a desired tropism and that deliver functional cargo to the cytoplasm of specific cells.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the screening method</span>
        <span itemprop="definition">uses a reporter that has a functionality that can be detected when delivered to the cell. Detecting the function of the reporter in the cell indicates that the formulation of the delivery vehicle will deliver functional cargo to the cell.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a chemical composition identifier</span>
        <span itemprop="definition">is included in each different delivery vehicle formulation to keep track of the chemical composition specific for each different delivery vehicle formulation.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the chemical composition identifier</span>
        <span itemprop="definition">is a nucleic acid barcode.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sequence of the nucleic acid bar code</span>
        <span itemprop="definition">is paired to the chemical components used to formulate the delivery vehicle in which it is loaded so that when the nucleic acid bar code is sequenced, the chemical composition of the delivery vehicle that delivered the barcode is identified.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Representative reporters</span>
        <span itemprop="definition">include, but are not limited to siRNA, mRNA, nuclease protein, nuclease mRNA, small molecules, epigenetic modifiers, and phenotypic modifiers. IV. Methods of Use</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">deliver therapeutic or prophylactic agents to specific cells or organs in a subject in need thereof in the absence of a targeting ligand.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">are useful to treat or prevent diseases in a subject in need thereof.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed nanoparticles</span>
        <span itemprop="definition">are delivered directly to the subject.</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">are contacted with cells ex vivo, and the treated cells are administered to the subject.</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cells</span>
        <span itemprop="definition">can be autologous cells, for example immune cells including but not limited to T cells or cells that differentiate into T cells.</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticles</span>
        <span itemprop="definition">may be used as vehicles for adoptive cell transfer.</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosed lipid nanoparticle composition</span>
        <span itemprop="definition">targets a particular type or class of cells (e.g., cells of a particular organ or system thereof).</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition including a therapeutic and/or prophylactic of interest</span>
        <span itemprop="definition">may be specifically delivered to immune cells in the subject.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary immune cells</span>
        <span itemprop="definition">include but are not limited to CD8&#43;, CD4&#43;, or CD8&#43;CD4&#43; cells.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">can be formulated to be delivered in the absence of a targeting ligand to a mammalian liver immune cells, spleen T cells, or lung endothelial cells. Specific delivery to a particular class or type of cells indicates that a higher proportion of lipid nanoparticles are delivered to target type or class of cells. In some embodiments, specific delivery may result in a greater than 2 fold, 5 fold, 10 fold, 15 fold, or 20 fold increase in the amount of therapeutic and/or prophylactic per 1 g of tissue of the targeted destination.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticles</span>
        <span itemprop="definition">can be used for reducing gene expression in a target cell in a subject in need thereof.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subject</span>
        <span itemprop="definition">is administered a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and an inhibitory nucleic acid.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid nanoparticle</span>
        <span itemprop="definition">can deliver the inhibitory nucleic acid to the target cell in the subject without a targeting ligand.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inhibitory nucleic acid</span>
        <span itemprop="definition">can be siRNA.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another embodiment</span>
        <span itemprop="definition">provides methods of using the disclosed lipid nanoparticles for editing a gene in a cell in a subject in need thereof.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the subject</span>
        <span itemprop="definition">is administered two populations of lipid nanoparticles.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the first population</span>
        <span itemprop="definition">includes lipid nanoparticles having a formulation including Adamantanyl)acetoxy]-2-  [3- (diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for the gene that is being targeted.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the second population of lipid nanoparticles</span>
        <span itemprop="definition">includes lipid nanoparticles having a formulation including Adamantanyl)acetoxy]-2-  [3-(diethylamino)propoxycarbonyloxy]methyl  propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA encoding an RNA-guided DNA endonuclease.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the RNA-guided DNA endonuclease</span>
        <span itemprop="definition">can be Cas9, CasX, CasY, Cas13, or Cpf1.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell that is targeted for gene regulation</span>
        <span itemprop="definition">is an immune cell.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the immune cell</span>
        <span itemprop="definition">can be a T cell, such as CD8&#43; T cell, CD4&#43; T cell, or T regulatory cell.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Other exemplary immune cells for gene editing</span>
        <span itemprop="definition">include but are not limited to macrophages, dendritic cells, or liver immune cells.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">genes that can be targeted</span>
        <span itemprop="definition">include but are not limited to T cell receptors, B cell receptors, CTLA4, PD1, FOXO1, FOXO3, AKTs, CCR5, CXCR4, LAG3, TIM3, Killer immunoglobulin-like receptors, GITR, BTLA, LFA-4, T4, LFA-1, Bp35, CD27L receptor, TNFRSF8, TNFRSF5, CD47, CD52, ICAM-1, LFA-3, L-selectin, Ki-24, MB1, B7, B70, M- CSFR, TNFR-II, IL-7R, OX-40, CD137, CD137L, CD30L, CD40L, FasL, TRAIL, CD257, LIGHT, TRAIL-R1, TRAILR2, TRAIL-R4, TWEAK-R, TNFR, BCMA, B7DC, BTLA, B7-H1, B7-H2, B7-H3, ICOS, VEGFR2, NKG2</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary tumor-associated antigens</span>
        <span itemprop="definition">that can be recognized by T cells and are contemplated for targeting, include but are not limited to MAGE1, MAGE3, MAGE6, BAGE, GAGE, NYESO-1, MART1/Melan A, MC1R, GP100, tyrosinase, TRP-1, TRP-2, PSA, CEA, Cyp-B, Her2/Neu, hTERT, MUC1, PRAME, WT1, RAS, CDK-4, MUM-1, KRAS, MSLN and   - catenin.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Subjects to be Treated</span>
        <span itemprop="definition">include but are not limited to MAGE1, MAGE3, MAGE6, BAGE, GAGE, NYESO-1, MART1/Melan A, MC1R, GP100, tyrosinase, TRP-1, TRP-2, PSA, CEA, Cyp-B, Her2/Neu, hTERT, MUC1, PRAME, WT1, RAS, CDK-4, MUM-1, KRAS, MSLN and</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the subjects treated</span>
        <span itemprop="definition">are mammals experiencing cancer, autoimmune disease, infections disease, organ transplant, organ failure, or a combination thereof.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods described herein</span>
        <span itemprop="definition">may cause T cells to present specific antigens for the treatment of cancer or autoimmune disease.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods described herein</span>
        <span itemprop="definition">may be used for T cell priming.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods described herein</span>
        <span itemprop="definition">may be used to deliver DNA or mRNA that cause T cells to present MHC-peptide complexes.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the methods described herein</span>
        <span itemprop="definition">may be used to deliver one or more of DNA, siRNA, or mRNA to a T cell to avoid anergy.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">reaction mixture</span>
        <span itemprop="definition">was stirred at room temperature overnight and linoleic acid 1 was consumed completely as monitored by TLC. Then the reaction mixture was directly concentrated under reduced pressure. Purification of the crude residue via silica gel flash column chromatography (gradient eluent: 1-30% of EtOAc/hexane) afforded compound 2 (2.3 g, 44% yield) and compound 3 (1.7 g, 30% yield) as colorless oil.</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids</span>
        <span itemprop="definition">were prepared by methods similar to the steps described in this example.</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Example 2</span>
        <span itemprop="definition">Lipid nanoparticles containing a conformationally constrained lipid can form stable LNPs. Materials and Methods:</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle Formulation</span>
        <span itemprop="definition">Nanoparticles were formulated using a microfluidic device as previously described. Briefly, nucleic acids (siRNA and DNA barcodes) were diluted in citrate buffer while lipid-amine compounds, alkyl tailed PEG, cholesterol, and DSPC were diluted in ethanol. PEG, cholesterol, and DSPC was purchased from Avanti Lipids. Citrate and ethanol phases were combined in a microfluidic device by syringe pumps.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">siRNA and DNA barcodes</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP hydrodynamic diameter</span>
        <span itemprop="definition">was measured using a plate reader formatted dynamic light scattering machine (Wyatt). LNPs were diluted in sterile 1X PBS to a concentration of   0.06 mg/mL and analyzed. LNPs were only included if they formed monodisperse populations with diameter between 20 and 200nm. Particles that met these criteria were dialyzed with 1X phosphate buffered saline (PBS, Invitrogen), and were sterile filtered with a 0.22   m filter. Results:</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">tail A</span>
        <span itemprop="definition">contained adamantane, a constrained lipid with a defined armchair structure.</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">11 amine-containing head groups</span>
        <span itemprop="definition">were added via esterification, resulting in head groups linked by ester or carbonate linkages, respectively. Head groups were chose based on previous reports that small molecules with similar structures have biological activity.</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the chemical structure of all 13 lipids</span>
        <span itemprop="definition">was confirmed using high resolution mass spectroscopy or 1H-NMR. For clarity, each ionizable lipid was named with the nomenclature, head group number tail letter (e.g.1-L, 11-A).</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each lipid</span>
        <span itemprop="definition">was formulated with 2 phospholipids and 4 molar ratios, for a total of 104 LNPs (Fig.1D).</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">100 of the LNPs</span>
        <span itemprop="definition">formed small, monodisperse populations, as evidenced both by hydrodynamic diameter and polydispersity index.</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the diameter for individual LNPs</span>
        <span itemprop="definition">varied between 30 and 170 nm, with an average of 76 nm (Fig. 1E) and an average PDI of 0.15 (Fig.1F).</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrodynamic diameter</span>
        <span itemprop="definition">was analyzed as a function of ionizable lipid (Fig.1G), molar ratio of the four constituents (Fig.1H), and the type of phospholipid (DSPC / DOPE) added to the formulation (Fig.1I). In all cases, the average diameter varied between 50 and 100 nm. These data show that non-traditional lipids formed LNPs with hydrodynamic diameters similar to lipoproteins and natural viruses.</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Example 3</span>
        <span itemprop="definition">A high throughput siRNA screen for in vivo activity reveals LNPs with constrained lipids have biological activity in T cells. Materials and Methods:</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DNA Barcoding</span>
        <span itemprop="definition">Each chemically distinct LNP was formulated to carry its own unique DNA barcode and siRNA.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP1</span>
        <span itemprop="definition">carried DNA barcode 1 and siICAM2</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the chemically distinct LNP2</span>
        <span itemprop="definition">carried DNA barcode 2 and siGFP.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Single stranded DNA sequences</span>
        <span itemprop="definition">were purchased from Integrated DNA Technologies (IDT). To ensure equal amplification of each sequence, we included universal forward and reverse primer regions.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each barcode</span>
        <span itemprop="definition">was distinguished using a unique 8 nucleotide sequence. An 8 nucleotide sequence can generate 65,536 distinct barcodes. 156 distinct sequences designed to prevent sequence bleaching on the Illumina MiniSeq sequencing machine were used.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the digestive enzyme for heart</span>
        <span itemprop="definition">included Collagenase IX.</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cell suspension</span>
        <span itemprop="definition">was filtered through 70mm mesh and red blood cells were lysed. Cells were stained to identify populations and sorted using the BD FacsFusion in the Georgia Institute of Technology Cellular Analysis Core for in vivo experiments.</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the antibody clones used</span>
        <span itemprop="definition">were: anti-CD31 (390, BioLegend), anti-CD45.2 (104, BioLegend), anti-CD19 (6D5, Biolegend), anti-CD3 (17A2, Biolegend), anti-CD8a (53-6.7, Biolegend), and anti-CD4 (GK1.5, Biolegend).</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PCR Amplification for Illumina Sequencing</span>
        <span itemprop="definition">All samples were amplified and prepared for sequencing using nested PCR.2   L of primers were added to 5   L of Kapa HiFi 2X master mix, and 3   L template DNA/water. The second PCR, added Nextera XT chemistry, indices and i5/i7 adapter regions. Dual-indexed samples were run on a 2% agarose gel to ensure that PCR reaction occurred before being pooled and gel purified.</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TNS Assay</span>
        <span itemprop="definition">The pKa of 7C1 and BM1 was measured as previously described (Dahlman, J.E., et al., Nat Nano, 9:648-655 (2014)). Briefly, a stock solution of 10mM HEPES (Sigma), 10mM MES (Sigma), 10mM sodium acetate (Sigma), and 140nM sodium chloride (Sigma) was prepared and pH adjusted with hydrogen chloride and sodium hydroxide to a range of pH between 4 and 10.</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA interference</span>
        <span itemprop="definition">siRNAs were chemically modified at the 2 position to increase stability and negate immunostimulation. 72 hours after injection, tissues were isolated and protein expression was determined via flow cytometry. GFP mean fluorescent intensity in PBS-treated mice was normalized to 100 percent.</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA delivery of siRNA to target cells</span>
        <span itemprop="definition">in this case, T lymphocytes</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">target cells</span>
        <span itemprop="definition">in this case, T lymphocytes</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siGFP chemically modified to reduce immunostimulation and enhance on-target silencing via preferential antisense RISC loading</span>
        <span itemprop="definition">(Fig. S2A) was used. Studying 1 LNP per group, and using 5 mice / group, this screen would require &gt;500 mice and significant time / flow cytometry resources. Therefore a DNA barcode-based screen was developed to evaluate how over 100 LNPs functionally delivered siGFP, in any combination of target cells, in a single mouse (Fig. 2A). LNP-1, with chemical structure 1, was formulated to carry siGFP and DNA barcode 1.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNP-N</span>
        <span itemprop="definition">LNP-N, with chemical structure N, was separately formulated to carry siGFP and DNA barcode N. Naked barcodes were also included as an experimental control (Paunovska, K., et al., Nano Lett, 18:2148-2157 (2016)), since DNA does not readily cross the cell bilayer.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNPs</span>
        <span itemprop="definition">were pooled together, and intravenously injected into mice that constitutively express GFP under a CAG promoter (Fig. 2B). The GFP acted as the functional delivery readout. It was hypothesized that LNPs which functionally delivered siGFP into the cytoplasm would have lower GFP protein expression.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GFP Low cells</span>
        <span itemprop="definition">were isolated using fluorescence activated cell sorting (FACS), and deep sequenced to quantify the efficiency with which all N LNPs delivered barcodes into the cells.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FACS</span>
        <span itemprop="definition">fluorescence activated cell sorting</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Normalized delivery</span>
        <span itemprop="definition">i.e., the number of barcodes for each individual barcode, normalized by the total number of barcode counts within that sample, was used. Normalized delivery can be used to analyze barcoded LNP datasets and is analogous to counts per million in RNAseq experiments (Lokugamage, M.P., et al., Current Opinion in Biomedical Engineering, 7:1-8 (2018)). Since GFP is expressed in all cell types, this assay can (i) compare GFP knockdown in any combination of on- / off-target cells and (ii) quickly identify LNPs that co-localized in GFPLow cells, all in a single animal.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GFP silencing</span>
        <span itemprop="definition">was quantified in 9 cell types. Compared to PBS treated mice, there was an increased number of GFP Low splenic B cells and splenic T cells (Fig. 2C). The average GFP protein silencing, quantified by mean fluorescent intensity, was highest in splenic T cells, followed by liver immune cells, splenic B cells, and lung endothelial cells (Fig.2D). Surprisingly, no evidence of silencing was found in hepatocytes, a cell type that is preferentially targeted12-15 by most LNPs (Fig.2C,D).</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the GFP Low lung splenic T cells</span>
        <span itemprop="definition">were sequenced, and as a further check, lung endothelial cells, splenic B cells, and liver immune cells were also sequenced.</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the normalized delivery of both negative controls</span>
        <span itemprop="definition">was lower than barcodes delivered by LNPs, as expected (Fig.2E).</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a large-scale in vivo structure function analysis using the DNA sequencing data</span>
        <span itemprop="definition">was then performed to evaluate whether any nanoparticle material properties promoted delivery to splenic T cells.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the enrichment for different nanoparticle properties</span>
        <span itemprop="definition">was calculated. Enrichment is the odds a nanoparticle with a particular property would show up by chance in particles that (i) performed in the top 10%, and separately, (ii) particles that performed in the bottom 10% was calculated.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticles formulated with DSPC</span>
        <span itemprop="definition">were enriched in effective particles, whereas nanoparticles formulated with DOPE were enriched in particles that performed poorly (Fig. 2F). To confirm these results, the normalized delivery for all LNPs formulated with DSPC and DOPE, respectively, was compared.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DSPC-containing LNPs</span>
        <span itemprop="definition">outperformed DOPE-containing LNPs (Fig. 2G).</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the normalized delivery ofpaired LNPs</span>
        <span itemprop="definition">was calculated, i.e., LNPs that had the same molar ratios and ionizable lipids (but different phospholipids).</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the specific DSPC LNPs that significantly outperformed their paired DOPE containing LNP</span>
        <span itemprop="definition">were identified (Fig. 2H). Based on these data, it was concluded that the phospholipid contained within the LNP affected splenic T cell delivery. Having observed the impact of phospholipid, future chemical analysis was limited to DSPC containing formulations.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cLNPs</span>
        <span itemprop="definition">deliver small RNAs that change gene expression in CD8 &#43; T cells.</span>
        <meta itemprop="num_attr" content="0341">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the value of the siGFP / DNA barcode assay</span>
        <span itemprop="definition">is related to its ability to make predictions.</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle</span>
        <span itemprop="definition">was selected for further investigation ( Figures. 3A-3B).</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">this cLNP</span>
        <span itemprop="definition">contained a constrained lipid as well as DSPC.</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the LNP</span>
        <span itemprop="definition">was formulated with a control siRNA targeting Luciferase (siLuc) or siGFP, and intravenously injected into mice at doses between 0.5 mg / kg and 2.0 mg / kg (Fig. 3C,D).</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siLuc</span>
        <span itemprop="definition">Luciferase</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siGFP</span>
        <span itemprop="definition">intravenously injected into mice at doses between 0.5 mg / kg and 2.0 mg / kg</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Fig.3C,D</span>
        <span itemprop="definition">GFP protein expression was measured in subsets of T cells, namely CD4&#43; and CD8&#43;, observing more potent protein silencing in CD8&#43; T cells (Fig.3E). Additionally, GFP silencing was quantified in 6 off-target cell types in the liver and the spleen. No significant silencing was observed at doses of 0.5 mg / kg and 1.5 mg / kg (Fig. S4A-F), suggesting that these cLNPs preferentially silence genes in splenic CD8&#43; T cells.</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mice</span>
        <span itemprop="definition">(Platt, R.J., et al., Cell, 159:440-445 (2014)) constitutively expressing Cas9 and GFP at a dose of 2.0 mg / kg.</span>
        <meta itemprop="num_attr" content="0344">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GFP expression</span>
        <span itemprop="definition">was measured in CD3&#43; T cells as well as in CD4&#43; and CD8&#43; T cells. Similar to the observed CD8&#43; tropism with siRNA, more potent protein silencing was observed in CD8&#43; than in CD4&#43; T cells (Fig. 3F). Additionally, this decrease in GFP expression was coupled with an increase in % GFP Low CD8&#43; T cells (Fig. 3G).</span>
        <meta itemprop="num_attr" content="0344">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticles targeting non-hepatocytes</span>
        <span itemprop="definition">are notoriously difficult to design (Lorenzer, C., et al., J Control Release, 203:1-15 (2015)), in large part because there is no high throughput method to study nanoparticle siRNA delivery in vivo.</span>
        <meta itemprop="num_attr" content="0345">
      </li>
    </ul>
  </section>

  <section>
    <h2>Landscapes</h2>
    <ul>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Life Sciences &amp; Earth Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmacology &amp; Pharmacy</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Veterinary Medicine</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Public Health</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Animal Behavior &amp; Ethology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Bioinformatics &amp; Cheminformatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Epidemiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Genetics &amp; Genomics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biomedical Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Molecular Biology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biochemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nanotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical Kinetics &amp; Catalysis</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Physics &amp; Mathematics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Immunology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Zoology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Wood Science &amp; Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Optics &amp; Photonics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Oil, Petroleum &amp; Natural Gas</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Inorganic Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Proteomics, Peptides &amp; Aminoacids</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biophysics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nuclear Medicine, Radiotherapy &amp; Molecular Imaging</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Dispersion Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Plant Pathology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Microbiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Crystallography &amp; Structural Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medical Informatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Dermatology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmaceuticals Containing Other Organic And Inorganic Compounds</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Preparation</span>
        (<span itemprop="type">AREA</span>)
      </li>
    </ul>
  </section>


  <section itemprop="abstract" itemscope>
    <h2>Abstract</h2>
    
    <div itemprop="content" html><abstract mxw-id="PA432081950" lang="EN" load-source="patent-office">
    <div num="0000" class="abstract">Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent.</div>
  </abstract>
  </div>
  </section>

  <section itemprop="description" itemscope>
    <h2>Description</h2>
    
    <div itemprop="content" html><div mxw-id="PDES285399173" lang="EN" load-source="WIPO-OCR" class="description">
    
    <div id="p0001" num="0001" class="description-paragraph"> NANOMATERIALS CONTAINING CONSTRAINED LIPIDS AND USES THEREOF INCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS </div>
    <div id="p0002" num="0002" class="description-paragraph"> [0001] This application claims the benefit of U.S. Provisional Application No. 62/879,731 filed July 29, 2019 entitled,NANOMATERIALS CONTAINING CONSTRAINED LIPIDS AND USES THEREOF, which is incorporated by reference in its entirety. FIELD </div>
    <div id="p0003" num="0003" class="description-paragraph"> [0002] The subject matter described herein is generally related to drug delivery systems and methods of their use. REFERENCE TO SEQUENCE LISTING </div>
    <div id="p0004" num="0004" class="description-paragraph"> [0003] The present application is being filed along with an Electronic Sequence Listing. The Electronic Sequence Listing is provided as a file entitled GUIDE005WO.txt, created and last modified on July 4, 2020, which is 6,977 bytes in size. The information in the electronic format of the Electronic Sequence Listing is incorporated herein by reference in its entirety. BACKGROUND </div>
    <div id="p0005" num="0005" class="description-paragraph"> [0004] T lymphocytes regulate immune responses making them important drug targets for developing new medicines. For example, antibody therapies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4), programmed cell death protein 1 (PD1), or PD1 ligand 1 (PDL1)) signaling have driven potent anti-tumor responses (Khalil, D.N., et al., Nat Rev Clin Oncol, 13:273-290 (2016); Sharma, P. &amp; Allison, J. P., Science, 348:5661 (2015)). However, a large number of patients do not respond to these agents, and many of those who do respond eventually relapse (Jenkins, T, et al., BJC, 118:9-16 (2018)). Additionally, antibody therapies can only inhibit the activity ofdruggable proteins, which are thought to constitute ~15% of the total protein coding genome (Dixon, S. and Stockwell, B., Curr Opin Chem Biol, 13(5-6):549-555 (2009)). </div>
    <div id="p0006" num="0006" class="description-paragraph"> [0005] Some proteins that play important roles in disease pathology areundruggable. The term undruggable was coined to describe proteins that could not be targeted pharmacologically (Cang, C.V., et al., Nature Reviews Cancer, 17:502-508 (2017)). Today, there 

 are many cancer targets that are considered undruggable (Cang, C.V., et al., Nature Reviews Cancer, 17:502-508 (2017)). Examples of undruggable proteins include intracellular proteins and proteins that lack domains that are readily bound by small molecule drugs. </div>
    <div id="p0007" num="0007" class="description-paragraph"> [0006] Antibody therapies are limited to druggable proteins because the antibody must be able to bind to the protein to exert its therapeutic effect. siRNA can be used to inhibit the translation of any gene including genes that encode an undruggable protein. Several undruggable protein targets have been identified in T cell activity. Thus, siRNA can be useful to treat a large number of diseases caused byundruggable proteins including diseases involving T cells. Unfortunately, clinically relevant siRNA delivery to cells other than hepatocytes (Adams, D., et al., N Engl J Med, 379:11-21 (2018)) has remained challenging (Lorenzar, C., et al., J Control Release, 203:1-15 (2015)). Although several advances have been made in T cell siRNA delivery, several obstacles remain. For example, siRNA was delivered to T cells using a single chain antibody linked to a positively charged peptide; this led to target gene silencing at 5 mg / kg, a high dosage (Kumar, P., et al., Cell, 134:577-586 (2008)). In a second example, nanoparticles were coated with anti-CD4 antibodies, leading to 20% in vivo target gene silencing at 1 mg / kg doses (Ramishetti, S., et al., ACS Nano, 9:6706-6716 (2015)). More recently, lipid nanoparticles (LNPs) that target hepatocytes were re-targeted to T cells by coating them with CD4 antibodies, leading to 50% in vivo T cell gene silencing at 6 mg / kg doses (Kedmi, R., et al., Nat Nanotechnol, 13:214-219 (2018)). All these therapies share two important commonalities. First, they require more than 1 mg / kg siRNA to achieve 50% gene silencing, which is above the current siRNA dose approved for human use (Adams, D., et al., N Engl J Med, 379:11-21 (2018)). Second, they achieve T cell delivery using peptide-, protein-, or aptamer-based targeting ligands. </div>
    <div id="p0008" num="0008" class="description-paragraph"> [0007] Nanomedicines are often trafficked to cell using targeting ligands (Cheng, S., et al., Science, 338:903-910 (2012)). However, the only FDA approved RNA nanoparticle therapy utilizes a simple mixture of lipids that are naturally trafficked to hepatic cells (Adams, D., et al., N Engl J Med, 379:11-21 (2018)). Natural trafficking has not been shown to promote nanoparticle delivery to immune cells. Because the current options for nanoparticle delivery to T cells require high doses of nucleic acid to achieve gene silencing and rely on targeting ligands for cell delivery, there is a need for improved nanoparticle compositions for delivery to T cells. </div>
    <div id="p0009" num="0009" class="description-paragraph"> [0008] It is therefore an object of the invention to provide delivery vehicles that can deliver nucleic acids to immune cells and methods of their use. 

 [0009] It is another object of the invention to provide methods of modulating immune cell function. SUMMARY </div>
    <div id="p0010" num="0010" class="description-paragraph"> [0010] Compositions for delivering nucleic acids to specific cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been discovered that the chemical composition of lipid nanoparticles significantly influences the natural trafficking of the lipid nanoparticles. More specifically, it has been discovered that conformationally constrained ionizable lipids can modify the tropism and clearance profile of lipid nanoparticles without the need of a targeting ligand. It has also been discovered that tropism of the disclosed lipid nanoparticles is size-independent. </div>
    <div id="p0011" num="0011" class="description-paragraph"> [0011] One embodiment provides an ionizable lipid nanoparticle having a conformationally constrained ionizable lipid, a phospholipid, a polyethylene glycol-lipid; a cholesterol, and optionally a nucleic acid. In one embodiment, the constrained ionizable lipid has a structure according to Formula I: </div>
    <div id="p0012" num="0012" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d2/b7/d7/f4e7d31f45e29d/imgf000005_0001.png"><img id="imgf000005_0001" he="36" wi="110" file="imgf000005_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="440" height="144" alt="Figure imgf000005_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d2/b7/d7/f4e7d31f45e29d/imgf000005_0001.png"/></a></div>
    </div>
    <div id="p0013" num="0013" class="description-paragraph">wherein: </div>
    <div id="p0014" num="0014" class="description-paragraph">R<sub>1</sub> is </div>
    <div id="p0015" num="0015" class="description-paragraph">, or</div>
    <div id="p0016" num="0016" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d4/a5/6b/df06bd37dd475f/imgf000005_0002.png"><img id="imgf000005_0002" he="51" wi="121" file="imgf000005_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="484" height="204" alt="Figure imgf000005_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d4/a5/6b/df06bd37dd475f/imgf000005_0002.png"/></a></div> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3b/7e/52/fd8571f906ab9e/imgf000006_0001.png"><img id="imgf000006_0001" he="44" wi="31" file="imgf000006_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="124" height="176" alt="Figure imgf000006_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3b/7e/52/fd8571f906ab9e/imgf000006_0001.png"/></a></div>
 ; and </div>
    <div id="p0017" num="0017" class="description-paragraph">R2 is </div>
    <div id="p0018" num="0018" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/62/c8/9ab34b691ad3aa/imgf000006_0002.png"><img id="imgf000006_0002" he="116" wi="143" file="imgf000006_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="572" height="464" alt="Figure imgf000006_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/62/c8/9ab34b691ad3aa/imgf000006_0002.png"/></a></div>
 . </div>
    <div id="p0019" num="0019" class="description-paragraph"> [0012] In another embodiment the constrained ionizable lipid contains an adamantane tail. In some embodiments the constrained ionizable lipid is 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate. </div>
    <div id="p0020" num="0020" class="description-paragraph">In some embodiments, the phosphlipid is 1-2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1-2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE). In some embodiments, the PEG-lipid is C14PEG2000 or C18PEG2000. In some embodiments, lipid nanoparticles contain a sterol. In some embodiments, the sterol is cholesterol. The nucleic acid can be RNA, DNA, single-stranded RNA, 

 single-stranded DNA, double-stranded RNA, double stranded DNA, triple-stranded DNA, siRNA, shRNA, sgRNA, mRNA, miRNA, antisense DNA, or a combination thereof. </div>
    <div id="p0021" num="0021" class="description-paragraph"> [0013] In some embodiments, the nucleic acid encodes an RNA-guided DNA endonuclease, including but not limited to Cas9, CasX, CasY, Cas13, or Cpf1. </div>
    <div id="p0022" num="0022" class="description-paragraph"> [0014] In one embodiment the lipid nanoparticles contain about 30 mol % to about 70 mol % conformationally constrained ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 25 mol % to about 45 mol % cholesterol, and about 0.1 mol % to about 5 mol % PEG-lipid. In other emobodiments, the conformationally constrained ionizable lipid can be present at 35, 45, 50, or 65 mole percent. </div>
    <div id="p0023" num="0023" class="description-paragraph"> [0015] In some embodiments, the nanoparticle has a hydrodynamic diameter from about 30 nm to about 170 nm. In another embodiment, the lipid nanoparticles have an average diameter of 50 nm to 100 nm. </div>
    <div id="p0024" num="0024" class="description-paragraph"> [0016] The disclosed lipid nanoparticles can be formulated as a pharmaceutical composition optionally containing a pharmaceutically acceptable excipient or pharmaceutically acceptable carrier. </div>
    <div id="p0025" num="0025" class="description-paragraph"> [0017] One embodiment provides lipid nanoparticles in which C<sub>14</sub>PEG<sub>2000</sub> is present at 2.0 to 3.0 mole percent, DSPC is present at 15 to 17 mole percent, cholesterol is present at 45 to 47 mole percent, and the constrained lipid is present at 33 to 36 mole percent. </div>
    <div id="p0026" num="0026" class="description-paragraph"> [0018] Still another embodiment provides a method of delivering a therapeutic or prophylactic agent to a subject in need thereof, by administering to the subject one or more of the disclosed lipid nanoparticle compositions loaded with a therapeutic nucleic acid, for example a nucleic acid encoding a therapeutic protein, or an inhibitory or enzymatic nucleic acid. The method can further include administering a second therapeutic agent. In one embodiment, the nanoparticles preferentially deliver cargo to immune cells. The immune cells can be T cells, such as CD8+ T cells, CD4+ T cells, or T regulatory cells. The immune cells can also be macrophages or dendritic cells. </div>
    <div id="p0027" num="0027" class="description-paragraph"> [0019] One embodiment provides a method for reducing splenic or hepatic clearance of a nanoparticle composition by formulating the nanoparticles with an effective amount of conformationally constrained ionizable lipid to reduce or inhibit splenic or hepatic clearance of the nanoparticles. 

 [0020] Another embodiment provides a method of delivering a nucleic acid to an immune cell in a subject in need thereof by administering to the subject a lipid nanoparticle consisting of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, a cholesterol, and the nucleic acid, wherein the lipid nanoparticle composition delivers the nucleic acid to the immune cell in the subject, optionally in the absence of a targeting ligand. In one embodiment the T cell is a CD8+ T cell. </div>
    <div id="p0028" num="0028" class="description-paragraph"> [0021] Yet another embodiment provides a method for reducing gene expression in an immune cell in a subject in need thereof by administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and an inhibitory nucleic acid, wherein the lipid nanoparticle composition delivers the inhibitory nucleic acid to the immune cell in the subject. </div>
    <div id="p0029" num="0029" class="description-paragraph"> [0022] Another embodiment provides a method for editing a gene in an immune cell in a subject in need thereof by administering to the subject a lipid nanoparticle composition comprising a first and second population of lipid nanoparticles, wherein the first population of lipid nanoparticles consist of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for a the gene, and wherein the second population of lipid nanoparticles consist of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA encoding an RNA guided DNA endonuclease. BRIEF DESCRIPTION OF THE DRAWINGS </div>
    <div id="p0030" num="0030" class="description-paragraph"> [0023] Figure 1A is the structure of an ionizable lipid scaffold to which tail variants (structure shown in Figure 1B) and head group variants (structures shown in Figure 1C) were added. Figure 1D is a schematic showing 4 molar ratios of ionizable lipid, cholesterol, lipid-PEG, and either DSPC or DOPE used to formulate 104 distinct LNPs. Figure 1E is a dot plot showing hydrodynamic diameter (nm) of all formulated LNPs, measured individually. Figure 1F is a dot plot showing polydispersity index of all formulated LNPs, measured individually. Figures 1G-1I 

 are bar graphs showing hydrodynamic diameter of LNPs plotted as a function of ionizable lipid type (Figure 1G), molar percent of ionizable lipid (Figure 1H), and phospholipid type (Figure 1I). </div>
    <div id="p0031" num="0031" class="description-paragraph"> [0024] Figure 2A is a schematic showing the nanoparticles formulated to carry a distinct DNA barcode and siGFP. Figure 2B is a schematic showing an experimental workflow including steps of pooling 100 stable LNPs together, administering them to mice expressing GFP, isolating GFP<sup>Low</sup> cells after 3 days, and sequencing the DNA barcodes within that population. Figure 2C is a bar graph showing the percent GFP<sup>Low</sup> cells in 9 cell types. Figure 2D is a bar graph showing the percent GFP MFI in 9 cell types. Figure 2E is a dot plot showing normalized DNA delivery in lung endothelial cells, splenic B and T cells, as well as liver immune cells. Figure 2F is a schematic showing the enrichment of DSPC-containing LNPs in splenic T cells. Figure 2G is a dot plot showing normalized DNA delivery of LNPs plotted as a function of phospholipid. 2- way T test, **P&lt;0.01. Figure 2H is a paired analysis of normalized DNA delivery of LNPs containing DSPC or DOPE. Paired 2-way T test, *P&lt;0.05. Figure 2I is a bar graph showing enrichment for each of the 13 ionizable lipids. Figure 2J is a bar graph showing normalized DNA delivery of LNPs formulated with head group 11 and tail L, S, or A. One-way ANOVA, *P&lt;0.05, **P&lt;0.01. </div>
    <div id="p0032" num="0032" class="description-paragraph"> [0025] Figure 3A shows the structure of ionizable lipid 11-A. Figure 3B shows the molar composition of top performing cLNP. Figure 3C is a flow cytometry histogram showing GFP expression in splenic CD3<sup>+</sup> T cells 72 hours after treatment of cLNP carrying siLuc at a dose of 1.5 mg / kg or siGFP at doses of 0.5 mg / kg and 1.5 mg / kg. Figure 3D is a bar graph showing normalized GFP MFI in splenic CD3+ T cells 72 hours after treatment of cLNP carrying either siLuc or siGFP at various doses. Figure 3E is a bar graph showing normalized GFP MFI in splenic CD8+ and CD4+ T cells 72 hours after treatment of cLNP carrying siGFP at a dose of 2.0 mg / kg. Figure 3F is a bar graph showing normalized GFP MFI in splenic CD3+ T cells as well as CD8+ and CD4+ T cells after treatment of cLNPs carrying sgRNA at a dose of 2.0 mg / kg. Figure 3G is a bar graph showing percent GFP<sup>Low</sup> CD8+ T cells after treatment of cLNPs carrying sgRNA at a dose of 2.0 mg / kg. </div>
    <div id="p0033" num="0033" class="description-paragraph"> [0026] Figure 4A shows a graph relating the molecular weight of the headgroup of the ionizable lipid to the enrichment in T-cells. Figure 4B shows a graph relating the LogP of the headgroup of the ionizable lipid to the enrichment in T-cells. Figure 4C shows a graph relating the LogP of the polar surface area of the headgroup on the ionizable lipid to the enrichment in T-cells. 

 Figure 4D shows a paired analysis of LNPs containing DSPC and ionizable lipids differing only by one tail. Figure 4E shows a comparison of normalized DNA Delivery and LNP diameter. </div>
    <div id="p0034" num="0034" class="description-paragraph"> [0027] Figure 5A-F are the normalized GFP protein MFI in PBS-treated mice as well as those dosed with LNP containing constrained lipid delivering siLuciferase, and siGFP (at 1.5 mg / kg and 0.5 mg / kg) to hepatocytes, liver immune cells, liver Kupffer cells, Liver Endothelial cells, Splenic monocytes, and Splenic B Cells. Figure 5G is the sequence and chemical modification on sgGFP. DETAILED DESCRIPTION I. Definitions </div>
    <div id="p0035" num="0035" class="description-paragraph"> [0028] It should be appreciated that this disclosure is not limited to the compositions and methods described herein as well as the experimental conditions described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing certain embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims. </div>
    <div id="p0036" num="0036" class="description-paragraph"> [0029] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any compositions, methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All publications mentioned are incorporated herein by reference in their entirety. </div>
    <div id="p0037" num="0037" class="description-paragraph"> [0030] The use of the termsa,an,the, and similar referents in the context of describing the presently claimed invention (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. </div>
    <div id="p0038" num="0038" class="description-paragraph"> [0031] It is understood that, in any compound described herein having one or more chiral centers, if an absolute stereochemistry is not expressly indicated, then each center may independently be of R-configuration or S-configuration or a mixture thereof. Thus, the compounds provided herein may be enantiomerically pure, enantiomerically enriched, racemic mixture, diastereomerically pure, diastereomerically enriched, or a stereoisomeric mixture. In addition it is understood that, in any compound described herein having one or more double bond(s) generating 

 geometrical isomers that can be defined as E or Z, each double bond may independently be E or Z a mixture thereof. </div>
    <div id="p0039" num="0039" class="description-paragraph"> [0032] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. </div>
    <div id="p0040" num="0040" class="description-paragraph"> [0033] Use of the termabout is intended to describe values either above or below the stated value in a range of approx. +/- 10%; in other embodiments the values may range in value either above or below the stated value in a range of approx. +/- 5%; in other embodiments the values may range in value either above or below the stated value in a range of approx. +/- 2%; in other embodiments the values may range in value either above or below the stated value in a range of approx. +/- 1%. The preceding ranges are intended to be made clear by context, and no further limitation is implied. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g.,such as) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non- claimed element as essential to the practice of the invention. </div>
    <div id="p0041" num="0041" class="description-paragraph"> [0034] As used herein, anRNA refers to a ribonucleic acid that may be naturally or non-naturally occurring. For example, an RNA may include modified and/or non-naturally occurring components such as one or more nucleobases, nucleosides, nucleotides, or linkers. An RNA may include a cap structure, a chain terminating nucleoside, a stem loop, a polyA sequence, and/or a polyadenylation signal. An RNA may have a nucleotide sequence encoding a polypeptide of interest. For example, an RNA may be a messenger RNA (mRNA). Translation of an mRNA encoding a particular polypeptide, for example, in vivo translation of an mRNA inside a mammalian cell, may produce the encoded polypeptide. RNAs may be selected from the nonlimiting group consisting of small interfering RNA (siRNA), microRNA (miRNA), Dicer- substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, single-guide RNA (sgRNA), cas9 mRNA, and mixtures thereof. </div>
    <div id="p0042" num="0042" class="description-paragraph"> [0035] The terms polypeptide, peptide, and protein, may be used interchangeably to refer a string of at least three amino acids linked together by peptide bonds. 

 Peptide may refer to an individual peptide or a collection of peptides. Peptides can contain natural amino acids, non-natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain), and/or amino acid analogs. Also, one or more of the amino acids in a peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. Modifications may include cyclization of the peptide, the incorporation of D-amino acids, etc. </div>
    <div id="p0043" num="0043" class="description-paragraph"> [0036] As used herein, the termstreat,treating,treatment andtherapeutic use refer to the elimination, reduction or amelioration of one or more symptoms of a disease or disorder. As used herein, atherapeutically effective amount refers to that amount of a therapeutic agent sufficient to mediate a clinically relevant elimination, reduction or amelioration of such symptoms. An effect is clinically relevant if its magnitude is sufficient to impact the health or prognosis of a recipient subject. A therapeutically effective amount may refer to the amount of therapeutic agent sufficient to delay or minimize the onset of disease, e.g., delay or minimize the spread of cancer. A therapeutically effective amount may also refer to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease. </div>
    <div id="p0044" num="0044" class="description-paragraph"> [0037] As used herein, the termprophylactic agent refers to an agent that can be used in the prevention of a disorder or disease prior to the detection of any symptoms of such disorder or disease. Aprophylactically effective amount is the amount of prophylactic agent sufficient to mediate such protection. A prophylactically effective amount may also refer to the amount of the prophylactic agent that provides a prophylactic benefit in the prevention of disease. </div>
    <div id="p0045" num="0045" class="description-paragraph"> [0038] As used herein, the termsindividual,host,subject, andpatient are used interchangeably herein, and refer to a mammal, including, but not limited to, humans, rodents, such as mice and rats, and other laboratory animals. </div>
    <div id="p0046" num="0046" class="description-paragraph"> [0039] As used herein, the termpharmaceutically acceptable carrier encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. </div>
    <div id="p0047" num="0047" class="description-paragraph"> [0040] As used herein, the termconformationally constrained lipid refers to a lipid whose molecular structure is predominantly in one architecture, such as an adamantane, whose shape resembles anarmchair. 

 [0041] The termPEG-lipid refers to a lipid modified with polyethylene glycol. Exemplary PEG-lipids, include but are not limited to C<sub>14</sub>PEG<sub>350</sub>, C<sub>14</sub>PEG<sub>1000</sub>, C<sub>14</sub>PEG<sub>2000</sub>, C14PEG3000, and C18PEG2000. </div>
    <div id="p0048" num="0048" class="description-paragraph"> [0042] The termoligonucleotide refers to short DNA, RNA, or DNA/RNA molecules or oligomers containing a relatively small number of nucleotides. </div>
    <div id="p0049" num="0049" class="description-paragraph"> [0043] Some embodiments described herein related to a compound of Formula (I): </div>
    <div id="p0050" num="0050" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3a/7c/cf/281920c012ac23/imgf000013_0001.png"><img id="imgf000013_0001" he="30" wi="112" file="imgf000013_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="448" height="120" alt="Figure imgf000013_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3a/7c/cf/281920c012ac23/imgf000013_0001.png"/></a></div>
    </div>
    <div id="p0051" num="0051" class="description-paragraph">in which R1 is: </div>
    <div id="p0052" num="0052" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/d2/bc/fe54534d322384/imgf000013_0002.png"><img id="imgf000013_0002" he="50" wi="150" file="imgf000013_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="600" height="200" alt="Figure imgf000013_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/d2/bc/fe54534d322384/imgf000013_0002.png"/></a></div>
    </div>
    <div id="p0053" num="0053" class="description-paragraph">R<sub>2</sub> is: </div>
    <div id="p0054" num="0054" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6c/d9/9d/736fec58368b5f/imgf000013_0003.png"><img id="imgf000013_0003" he="88" wi="165" file="imgf000013_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="660" height="352" alt="Figure imgf000013_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6c/d9/9d/736fec58368b5f/imgf000013_0003.png"/></a></div>
 in which X is or ; and</div>
    <div id="p0055" num="0055" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/c9/c7/6b6c9024420c28/imgf000014_0001.png"><img id="imgf000014_0001" he="27" wi="32" file="imgf000014_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="128" height="108" alt="Figure imgf000014_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/c9/c7/6b6c9024420c28/imgf000014_0001.png"/></a></div> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/fc/aa/9acbae093766dd/imgf000014_0002.png"><img id="imgf000014_0002" he="34" wi="30" file="imgf000014_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="120" height="136" alt="Figure imgf000014_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/fc/aa/9acbae093766dd/imgf000014_0002.png"/></a></div>
 R<sub>3</sub> and R<sub>4</sub> are each independently
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f2/d8/35/b73de8abc0732e/imgf000014_0003.png"><img id="imgf000014_0003" he="16" wi="84" file="imgf000014_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="336" height="64" alt="Figure imgf000014_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f2/d8/35/b73de8abc0732e/imgf000014_0003.png"/></a></div>
 or 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/32/60/5b/8a27b0af9b1a2b/imgf000014_0004.png"><img id="imgf000014_0004" he="21" wi="59" file="imgf000014_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="236" height="84" alt="Figure imgf000014_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/32/60/5b/8a27b0af9b1a2b/imgf000014_0004.png"/></a></div>
 ; </div>
    <div id="p0056" num="0056" class="description-paragraph"> [0044] Some embodiments relate to a compound of Formula (III): </div>
    <div id="p0057" num="0057" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/06/92/8e/e628d0f802b2ef/imgf000014_0005.png"><img id="imgf000014_0005" he="27" wi="87" file="imgf000014_0005.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="348" height="108" alt="Figure imgf000014_0005" class="patent-full-image" src="https://patentimages.storage.googleapis.com/06/92/8e/e628d0f802b2ef/imgf000014_0005.png"/></a></div>
    </div>
    <div id="p0058" num="0058" class="description-paragraph">in which: R8 isH or
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/80/6c/3bcecb832b1928/imgf000014_0006.png"><img id="imgf000014_0006" he="20" wi="22" file="imgf000014_0006.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="88" height="80" alt="Figure imgf000014_0006" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/80/6c/3bcecb832b1928/imgf000014_0006.png"/></a></div>
 ; </div>
    <div id="p0059" num="0059" class="description-paragraph">R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>9</sub> are each independently: -C<sub>8</sub>H<sub>17</sub>, -C<sub>10</sub>H<sub>21</sub>, -C<sub>12</sub>H<sub>25</sub>, -C<sub>13</sub>H<sub>27</sub>, -C<sub>14</sub>H<sub>29</sub>, C<sub>16</sub>H<sub>33</sub>, or adamantanyl, </div>
    <div id="p0060" num="0060" class="description-paragraph">m and n are each independently 0, 1, 2, 3, or 4; </div>
    <div id="p0061" num="0061" class="description-paragraph">A is , 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/15/c6/0a47038a654f40/imgf000014_0007.png"><img id="imgf000014_0007" he="28" wi="138" file="imgf000014_0007.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="552" height="112" alt="Figure imgf000014_0007" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/15/c6/0a47038a654f40/imgf000014_0007.png"/></a></div>
 </div>
    <div id="p0062" num="0062" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/af/80/d3/aea84eb362d2c9/imgf000014_0008.png"><img id="imgf000014_0008" he="25" wi="159" file="imgf000014_0008.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="636" height="100" alt="Figure imgf000014_0008" class="patent-full-image" src="https://patentimages.storage.googleapis.com/af/80/d3/aea84eb362d2c9/imgf000014_0008.png"/></a></div>
 ; R<sub>10</sub> and R<sub>11</sub> are each independentlyH or
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f2/36/6c/05da6f96441f7c/imgf000014_0009.png"><img id="imgf000014_0009" he="15" wi="22" file="imgf000014_0009.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="88" height="60" alt="Figure imgf000014_0009" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f2/36/6c/05da6f96441f7c/imgf000014_0009.png"/></a></div>
 ; and </div>
    <div id="p0063" num="0063" class="description-paragraph">R12 is -C10H21. 

 [0045] Some embodiments relate to a compound in which R2 is
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/50/d5/38/d6ce761741cbc6/imgf000015_0003.png"><img id="imgf000015_0003" he="15" wi="36" file="imgf000015_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="144" height="60" alt="Figure imgf000015_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/50/d5/38/d6ce761741cbc6/imgf000015_0003.png"/></a></div>
 or 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/e0/2e/fd4b75395b2fec/imgf000015_0004.png"><img id="imgf000015_0004" he="16" wi="36" file="imgf000015_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="144" height="64" alt="Figure imgf000015_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/e0/2e/fd4b75395b2fec/imgf000015_0004.png"/></a></div>
 . </div>
    <div id="p0064" num="0064" class="description-paragraph"> [0046] Some embodiments relate to a lipid nanoparticle composition comprising: a conformationally constrained ionizable lipid; a phospholipid; a polyethylene glycol-lipid; a cholesterol; and optionally a nucleic acid. Some embodiments relate to a lipid nanoparticle in which the conformationally constrained ionizable lipid comprises a structure according to a structure described herein. Some embodiments relate to a lipid nanoparticle composition in which the amount of conformationally constrained ionizable lipid present is in the range of about 35 to about 65 mole percent, based on total moles. </div>
    <div id="p0065" num="0065" class="description-paragraph"> [0047] Some embodiments relate to a lipid nanoparticle composition in which the conformationally constrained ionizable lipid has a structure according to </div>
    <div id="p0066" num="0066" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/57/3f/58/e0d68ecf0001d9/imgf000015_0001.png"><img id="imgf000015_0001" he="40" wi="127" file="imgf000015_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="508" height="160" alt="Figure imgf000015_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/57/3f/58/e0d68ecf0001d9/imgf000015_0001.png"/></a></div>
 . </div>
    <div id="p0067" num="0067" class="description-paragraph"> [0048] Some embodiments relate to a lipid nanoparticle composition in which the conformationally constrained ionizable lipid has a structure according to </div>
    <div id="p0068" num="0068" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3a/0a/5b/ffb895a549bbaf/imgf000015_0002.png"><img id="imgf000015_0002" he="40" wi="127" file="imgf000015_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="508" height="160" alt="Figure imgf000015_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3a/0a/5b/ffb895a549bbaf/imgf000015_0002.png"/></a></div>
 . </div>
    <div id="p0069" num="0069" class="description-paragraph"> [0049] Some embodiments relate to a lipid nanoparticle composition in which the phospholipid is 1-2-distearoyl-sn-glycero-3-phosphocholine (DSPC). Some embodiments relate to a lipid nanoparticle composition in which the polyethylene glycol-lipid is C14PEG2000 or C18PEG2000. 

 [0050] Some embodiments relate to a lipid nanoparticle composition in which the composition comprises about 30 mol % to about 70 mol % conformationally constrained ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 25 mol % to about 45 mol % cholesterol, and about 0.1 mol % to about 5 mol % polyethylene glycol-lipid. </div>
    <div id="p0070" num="0070" class="description-paragraph"> [0051] Some embodiments relate to a lipid nanoparticle composition in which the nucleic acid comprises RNA, DNA, single-stranded RNA, single-stranded DNA, double-stranded RNA, double stranded DNA, triple-stranded DNA, siRNA, shRNA, sgRNA, mRNA, miRNA, antisense DNA, or a combination thereof. In some embodiments, the lipid nanoparticle composition is one in which the nucleic acid encodes a protein. In some embodiments, the lipid nanoparticle composition is one in which the nucleic acid encodes an RNA-guided DNA endonuclease. In some embodiments, the lipid nanoparticle composition is one in which the RNA- guided DNA endonuclease is Cas9, CasX, CasY, Cas13, or Cpf1. </div>
    <div id="p0071" num="0071" class="description-paragraph"> [0052] In some embodiments, the nanoparticle composition is one in which the lipid nanoparticle has a hydrodynamic diameter in the range of from about 30 nm to about 170 nm. </div>
    <div id="p0072" num="0072" class="description-paragraph"> [0053] In some embodiments, the lipid nanoparticle composition comprises: a conformationally constrained ionizable lipid comprising an adamantane tail; 1-2-distearoyl-sn- glycero-3-phosphocholine (DSPC); C<sub>14</sub>PEG<sub>2000</sub>; cholesterol; and siRNA. In some embodiments of the lipid nanoparticle, the conformationally constrained ionizable lipid is 3-[(1- Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12- octadecadienoate. </div>
    <div id="p0073" num="0073" class="description-paragraph"> [0054] In some embodiments of the lipid nanoparticle, C14PEG2000 is present at about 2.0 to about 3.0 mole percent, DSPC is present at about 15 to about 17 mole percent, cholesterol is present at about 45 to about 47 mole percent, the conformationally constrained ionizable lipid is present at about 33 to about 36 mole percent, and the siRNA is present at 5 to 20 mass ratio of total lipid to siRNA. In some embodiments, C<sub>14</sub>PEG<sub>2000</sub> is present at about 2.5 mole percent, DSPC is present at about 16 mole percent, cholesterol is present at about 46.5 mole percent, and the conformationally constrained ionizable lipid is present at about 35 mole percent. </div>
    <div id="p0074" num="0074" class="description-paragraph"> [0055] Some embodiments relate to a pharmaceutical composition comprising a lipid nanoparticle composition as described herein and a pharmaceutically acceptable excipient. </div>
    <div id="p0075" num="0075" class="description-paragraph"> [0056] Some embodiments relate to a method of delivering a nucleic acid to a subject in need thereof, comprising, administering to the subject a lipid nanoparticle composition or a 

 pharmaceutical composition as described herein. Some embodiments further comprise administering a second therapeutic agent to the subject. </div>
    <div id="p0076" num="0076" class="description-paragraph"> [0057] Some embodiments relate to a method of delivering a nucleic acid to an immune cell in a subject in need thereof, comprising: administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate; DSPC; a polyethylene glycol-lipid; a cholesterol; and a nucleic acid, in which the lipid nanoparticle composition delivers the nucleic acid to the immune cell in the subject. In some embodiments, the lipid nanoparticle composition does not contain a targeting ligand that targets the lipid nanoparticle composition to the immune cell. In some embodiments, the immune cell is a T cell. In some embodiments, the T cell is a CD8+ T cell. In some embodiments, the T cell is a T regulatory cell. In some embodiments, the T cell is CD4+. In some embodiments, the immune cell is a macrophage, dendritic cell, or liver immune cell. </div>
    <div id="p0077" num="0077" class="description-paragraph"> [0058] Some embodiments relate to a method for reducing splenic or hepatic clearance of a nanoparticle composition comprising formulating the nanoparticle composition with an amount of a conformationally constrained ionizable lipid that is effective to reduce or inhibit splenic or hepatic clearance of the nanoparticle composition when administered to a subject. In some embodiments, the conformationally constrained ionizable lipid comprises a structure as described herein. </div>
    <div id="p0078" num="0078" class="description-paragraph"> [0059] Some embodiments relate to a method for increasing delivery of a nanoparticle composition to non-hepatocyte cells in a subject comprising formulating the nanoparticle composition to comprise an amount of a conformationally constrained ionizable lipid that is effective to increase delivery of the nanoparticle composition to non-hepatocyte cells when administered to the subject. In some embodiments, the conformationally constrained ionizable lipid comprises a structure as described herein. In some embodiments, the nanoparticle composition is a lipid nanoparticle pharmaceutical composition. In some embodiments, the lipid nanoparticle pharmaceutical composition comprises a phospholipid, a polyethylene glycol-lipid, a cholesterol, and optionally a first nucleic acid. In some embodiments, the non-hepatocyte cells are at least one of splenic B cells, splenic T cells, lung endothelial cells, and liver immune cells. In some embodiments, the nanoparticle composition further comprises a second nucleic acid that is delivered to the subject in an amount in the range of about 0.5 mg/kg to about 2.0 mg/kg. In some 

 embodiments, the amount of the second nucleic acid delivered to the subject is less than about 1.0 mg/kg. </div>
    <div id="p0079" num="0079" class="description-paragraph"> [0060] Some embodiments relate to a method for reducing gene expression in an immune cell in a subject in need thereof, comprising: administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate; DSPC; a polyethylene glycol-lipid; cholesterol; and an inhibitory nucleic acid, in which the lipid nanoparticle composition delivers the inhibitory nucleic acid to the immune cell in the subject. In some embodiments, the inhibitory nucleic acid is siRNA. In some embodiments, the amount of the inhibitory nucleic acid administered to the subject is less than about 1.0 mg/kg. In some embodiments, the amount of inhibitory nucleic acid administered to the subject is about 0.5 mg/kg. </div>
    <div id="p0080" num="0080" class="description-paragraph"> [0061] Some embodiments relate to a method for editing a gene in an immune cell in a subject in need thereof, comprising: administering to the subject a lipid nanoparticle composition comprising a first and second population of lipid nanoparticles, in which the first population of lipid nanoparticles consists of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for the gene, and in which the second population of lipid nanoparticles consists of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA encoding an RNA guided DNA endonuclease. In some embodiments, the RNA guided DNA endonuclease is selected from the group consisting of Cas9, CasX, CasY, Cas13, and Cpf1. In some embodiments, the amount of one or both of the sgRNA and mRNA administered to the subject is less than about 1.0 mg/kg. In some embodiments, the amount of one or both of the sgRNA and mRNA administered to the subject is about 0.5 mg/kg. II. Lipid Nanoparticles </div>
    <div id="p0081" num="0081" class="description-paragraph"> [0062] Effective, targeted delivery of biologically active substances such as small molecule drugs, proteins, and nucleic acids is a continuing challenge in the field of medicine. The delivery of nucleic acids specifically is made difficult by the relative instability and low cell permeability of nucleic acids. It has been discovered that lipid nanoparticles having constrained lipids can more effectively deliver nucleic acids to specific tissues in the body. In one embodiment, lipid nanoparticles can be formulated by mixing nucleic acids with conformationally constrained 

 ionizable lipids, PEG-lipids, phospholipids, cholesterol, and optionally a nucleic acid. An exemplary lipid nanoparticle formulation includes the conformationally constrained ionizable lipid 3-[(1-Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)- 9,12-octadecadienoate, a PEG-lipid, 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), and cholesterol. In some embodiments, the lipid nanoparticles do not contain a targeting ligand. In some embodiments, the disclosed lipid nanoparticles preferentially target T cells over hepatocytes in the absence of a targeting ligand. </div>
    <div id="p0082" num="0082" class="description-paragraph"> [0063] Lipid nanoparticle sizes vary. In one embodiment, the lipid nanoparticles can have a hydroscopic diameter from between about 30 to about 170 nm. The lipid nanoparticles can have a diameter that is about 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, or 170 nm. In another embodiment the nanoparticles have a diameter from between 50 nm to 100 nm. A. Ionizable Lipids </div>
    <div id="p0083" num="0083" class="description-paragraph"> [0064] In one embodiment, the disclosed lipid nanoparticles include an ionizable lipid. The ionizable lipid typically includes an amine-containing on the head group. In one embodiment, the ionizable lipid is a conformationally constrained ionizable lipid. In some embodiments, the conformationally constrained lipid is present at 35, 45, 50, or 65 mole percent. In another embodiment, the conformationally constrained lipid is present at about 33 mol % to about 36 mol%. In yet another embodiment, the conformationally constrained lipid is present at 35 mol %. One embodiment provides a LNP containing a lipid having a structure according to Formula I: </div>
    <div id="p0084" num="0084" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5f/1a/9a/92a7da42059ad8/imgf000019_0001.png"><img id="imgf000019_0001" he="26" wi="106" file="imgf000019_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="424" height="104" alt="Figure imgf000019_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5f/1a/9a/92a7da42059ad8/imgf000019_0001.png"/></a></div>
    </div>
    <div id="p0085" num="0085" class="description-paragraph"> Formula I, </div>
    <div id="p0086" num="0086" class="description-paragraph">wherein R<sub>1</sub> is a lipid tail selected from the group consisting of: 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/5f/62/26623ea3fc8a8c/imgf000019_0002.png"><img id="imgf000019_0002" he="18" wi="116" file="imgf000019_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="464" height="72" alt="Figure imgf000019_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/5f/62/26623ea3fc8a8c/imgf000019_0002.png"/></a></div>
 </div>
    <div id="p0087" num="0087" class="description-paragraph"> L, 

</div>
    <div id="p0088" num="0088" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/43/0b/8e/d73abed7443cb0/imgf000020_0001.png"><img id="imgf000020_0001" he="71" wi="82" file="imgf000020_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="328" height="284" alt="Figure imgf000020_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/43/0b/8e/d73abed7443cb0/imgf000020_0001.png"/></a></div>
    </div>
    <div id="p0089" num="0089" class="description-paragraph"> A, and R2 is a head group selected from the group consisting of: </div>
    <div id="p0090" num="0090" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/02/a4/0aa0d2e9935400/imgf000020_0002.png"><img id="imgf000020_0002" he="113" wi="139" file="imgf000020_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="556" height="452" alt="Figure imgf000020_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/02/a4/0aa0d2e9935400/imgf000020_0002.png"/></a></div>
 .</div>
    <div id="p0091" num="0091" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d6/b0/4c/6ea5be7ca9242e/imgf000021_0001.png"><img id="imgf000021_0001" he="29" wi="49" file="imgf000021_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="196" height="116" alt="Figure imgf000021_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d6/b0/4c/6ea5be7ca9242e/imgf000021_0001.png"/></a></div>
    </div>
    <div id="p0092" num="0092" class="description-paragraph"> [0065] Another embodiment provides an ionizable lipid having a structure according to Formula II: </div>
    <div id="p0093" num="0093" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/16/9d/be/be75ba0f137631/imgf000021_0002.png"><img id="imgf000021_0002" he="40" wi="129" file="imgf000021_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="516" height="160" alt="Figure imgf000021_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/16/9d/be/be75ba0f137631/imgf000021_0002.png"/></a></div>
    </div>
    <div id="p0094" num="0094" class="description-paragraph"> Formula II </div>
    <div id="p0095" num="0095" class="description-paragraph">3-[(1-Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)- 9,12-octadecadienoate or an LNP containing the ionizable lipid of Formula II. </div>
    <div id="p0096" num="0096" class="description-paragraph"> [0066] Another embodiment provides an ionizable lipid according to Formula I, wherein R<sub>1</sub> is tail L, and R<sub>2</sub> is compound (1) or an LNP containing said ionizable lipid. </div>
    <div id="p0097" num="0097" class="description-paragraph"> [0067] Still another embodiment provides an ionizable lipid according to Formula I, wherein R<sub>1</sub> is tail L, and R<sub>2</sub> is compound (2) or an LNP containing said ionizable lipid. </div>
    <div id="p0098" num="0098" class="description-paragraph"> [0068] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0099" num="0099" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/62/e5/4b/44a4f6a45fdd41/imgf000021_0003.png"><img id="imgf000021_0003" he="45" wi="98" file="imgf000021_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="392" height="180" alt="Figure imgf000021_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/62/e5/4b/44a4f6a45fdd41/imgf000021_0003.png"/></a></div>
    </div>
    <div id="p0100" num="0100" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0101" num="0101" class="description-paragraph"> [0069] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0102" num="0102" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8a/a1/2c/debfc9f1bfc89b/imgf000022_0001.png"><img id="imgf000022_0001" he="45" wi="101" file="imgf000022_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="404" height="180" alt="Figure imgf000022_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8a/a1/2c/debfc9f1bfc89b/imgf000022_0001.png"/></a></div>
    </div>
    <div id="p0103" num="0103" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0104" num="0104" class="description-paragraph"> [0070] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0105" num="0105" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/5b/82/312b77143d2634/imgf000022_0002.png"><img id="imgf000022_0002" he="45" wi="101" file="imgf000022_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="404" height="180" alt="Figure imgf000022_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/5b/82/312b77143d2634/imgf000022_0002.png"/></a></div>
    </div>
    <div id="p0106" num="0106" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0107" num="0107" class="description-paragraph"> [0071] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0108" num="0108" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/00/85/87/3ee62487a4113a/imgf000022_0003.png"><img id="imgf000022_0003" he="45" wi="101" file="imgf000022_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="404" height="180" alt="Figure imgf000022_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/00/85/87/3ee62487a4113a/imgf000022_0003.png"/></a></div>
    </div>
    <div id="p0109" num="0109" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0110" num="0110" class="description-paragraph"> [0072] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0111" num="0111" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1c/ab/54/2c3edb054b998e/imgf000023_0001.png"><img id="imgf000023_0001" he="45" wi="101" file="imgf000023_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="404" height="180" alt="Figure imgf000023_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1c/ab/54/2c3edb054b998e/imgf000023_0001.png"/></a></div>
    </div>
    <div id="p0112" num="0112" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0113" num="0113" class="description-paragraph"> [0073] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0114" num="0114" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f4/38/a1/61564d22454996/imgf000023_0002.png"><img id="imgf000023_0002" he="61" wi="96" file="imgf000023_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="384" height="244" alt="Figure imgf000023_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f4/38/a1/61564d22454996/imgf000023_0002.png"/></a></div>
    </div>
    <div id="p0115" num="0115" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0116" num="0116" class="description-paragraph"> [0074] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0117" num="0117" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c2/ce/42/82e8208a5aa462/imgf000023_0003.png"><img id="imgf000023_0003" he="30" wi="155" file="imgf000023_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="620" height="120" alt="Figure imgf000023_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c2/ce/42/82e8208a5aa462/imgf000023_0003.png"/></a></div>
    </div>
    <div id="p0118" num="0118" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0119" num="0119" class="description-paragraph"> [0075] One embodiment an ionizable lipid according to the following structure: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/94/78/f94f0d22189b2d/imgf000024_0001.png"><img id="imgf000024_0001" he="30" wi="150" file="imgf000024_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="600" height="120" alt="Figure imgf000024_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/94/78/f94f0d22189b2d/imgf000024_0001.png"/></a></div>
 </div>
    <div id="p0120" num="0120" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0121" num="0121" class="description-paragraph"> [0076] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0122" num="0122" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/77/19/a0/a6f001f6749f2d/imgf000024_0002.png"><img id="imgf000024_0002" he="30" wi="150" file="imgf000024_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="600" height="120" alt="Figure imgf000024_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/77/19/a0/a6f001f6749f2d/imgf000024_0002.png"/></a></div>
    </div>
    <div id="p0123" num="0123" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0124" num="0124" class="description-paragraph"> [0077] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0125" num="0125" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bd/ad/8e/b670b64d1aeb52/imgf000024_0003.png"><img id="imgf000024_0003" he="38" wi="151" file="imgf000024_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="604" height="152" alt="Figure imgf000024_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bd/ad/8e/b670b64d1aeb52/imgf000024_0003.png"/></a></div>
    </div>
    <div id="p0126" num="0126" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0127" num="0127" class="description-paragraph"> [0078] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0128" num="0128" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/51/cb/974f83022b6bc5/imgf000024_0004.png"><img id="imgf000024_0004" he="32" wi="135" file="imgf000024_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="540" height="128" alt="Figure imgf000024_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/51/cb/974f83022b6bc5/imgf000024_0004.png"/></a></div>
    </div>
    <div id="p0129" num="0129" class="description-paragraph">or an LNP containing said ionizable lipid. 

 [0079] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0130" num="0130" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/68/81/89/96e65a4f81ad25/imgf000025_0001.png"><img id="imgf000025_0001" he="30" wi="136" file="imgf000025_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="544" height="120" alt="Figure imgf000025_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/68/81/89/96e65a4f81ad25/imgf000025_0001.png"/></a></div>
    </div>
    <div id="p0131" num="0131" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0132" num="0132" class="description-paragraph"> [0080] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0133" num="0133" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/35/69/0e/b5e6087b81957e/imgf000025_0002.png"><img id="imgf000025_0002" he="30" wi="140" file="imgf000025_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="560" height="120" alt="Figure imgf000025_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/35/69/0e/b5e6087b81957e/imgf000025_0002.png"/></a></div>
    </div>
    <div id="p0134" num="0134" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0135" num="0135" class="description-paragraph"> [0081] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0136" num="0136" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f2/f7/4b/1da914dd102942/imgf000025_0003.png"><img id="imgf000025_0003" he="30" wi="130" file="imgf000025_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="520" height="120" alt="Figure imgf000025_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f2/f7/4b/1da914dd102942/imgf000025_0003.png"/></a></div>
    </div>
    <div id="p0137" num="0137" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0138" num="0138" class="description-paragraph"> [0082] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0139" num="0139" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/16/20/c8/58bf97f2c62ec7/imgf000025_0004.png"><img id="imgf000025_0004" he="38" wi="136" file="imgf000025_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="544" height="152" alt="Figure imgf000025_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/16/20/c8/58bf97f2c62ec7/imgf000025_0004.png"/></a></div>
    </div>
    <div id="p0140" num="0140" class="description-paragraph">or an LNP containing said ionizable lipid. 

 [0083] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0141" num="0141" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/20/da/7d42f09af405a8/imgf000026_0001.png"><img id="imgf000026_0001" he="36" wi="145" file="imgf000026_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="580" height="144" alt="Figure imgf000026_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/20/da/7d42f09af405a8/imgf000026_0001.png"/></a></div>
    </div>
    <div id="p0142" num="0142" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0143" num="0143" class="description-paragraph"> [0084] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0144" num="0144" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/44/5d/08/a53f0e27c2676a/imgf000026_0002.png"><img id="imgf000026_0002" he="30" wi="152" file="imgf000026_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="608" height="120" alt="Figure imgf000026_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/44/5d/08/a53f0e27c2676a/imgf000026_0002.png"/></a></div>
    </div>
    <div id="p0145" num="0145" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0146" num="0146" class="description-paragraph"> [0085] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0147" num="0147" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4c/79/ea/c0e2cafec632d9/imgf000026_0003.png"><img id="imgf000026_0003" he="30" wi="136" file="imgf000026_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="544" height="120" alt="Figure imgf000026_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4c/79/ea/c0e2cafec632d9/imgf000026_0003.png"/></a></div>
    </div>
    <div id="p0148" num="0148" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0149" num="0149" class="description-paragraph"> [0086] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0150" num="0150" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/ab/d0/2ad3cd70a68a1a/imgf000026_0004.png"><img id="imgf000026_0004" he="35" wi="62" file="imgf000026_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="248" height="140" alt="Figure imgf000026_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/ab/d0/2ad3cd70a68a1a/imgf000026_0004.png"/></a></div>
 or an LNP containing said ionizable lipid. </div>
    <div id="p0151" num="0151" class="description-paragraph"> [0087] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0152" num="0152" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c6/16/59/65b3eca1f2e8a2/imgf000027_0002.png"><img id="imgf000027_0002" he="34" wi="62" file="imgf000027_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="248" height="136" alt="Figure imgf000027_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c6/16/59/65b3eca1f2e8a2/imgf000027_0002.png"/></a></div>
    </div>
    <div id="p0153" num="0153" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0154" num="0154" class="description-paragraph"> [0088] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0155" num="0155" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/b7/fa/8b56b14b1fd7c2/imgf000027_0001.png"><img id="imgf000027_0001" he="22" wi="92" file="imgf000027_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="368" height="88" alt="Figure imgf000027_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/b7/fa/8b56b14b1fd7c2/imgf000027_0001.png"/></a></div>
    </div>
    <div id="p0156" num="0156" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0157" num="0157" class="description-paragraph"> [0089] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0158" num="0158" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/72/1e/fc/e36c2c32a2086a/imgf000027_0003.png"><img id="imgf000027_0003" he="37" wi="116" file="imgf000027_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="464" height="148" alt="Figure imgf000027_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/72/1e/fc/e36c2c32a2086a/imgf000027_0003.png"/></a></div>
    </div>
    <div id="p0159" num="0159" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0160" num="0160" class="description-paragraph"> [0090] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0161" num="0161" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3b/6b/a5/723fa1fd067453/imgf000028_0001.png"><img id="imgf000028_0001" he="37" wi="108" file="imgf000028_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="432" height="148" alt="Figure imgf000028_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3b/6b/a5/723fa1fd067453/imgf000028_0001.png"/></a></div>
    </div>
    <div id="p0162" num="0162" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0163" num="0163" class="description-paragraph"> [0091] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0164" num="0164" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b8/df/c0/ba98ec42de7e41/imgf000028_0004.png"><img id="imgf000028_0004" he="27" wi="137" file="imgf000028_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="548" height="108" alt="Figure imgf000028_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b8/df/c0/ba98ec42de7e41/imgf000028_0004.png"/></a></div>
    </div>
    <div id="p0165" num="0165" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0166" num="0166" class="description-paragraph"> [0092] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0167" num="0167" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/14/ce/bd/bbe24d54172863/imgf000028_0002.png"><img id="imgf000028_0002" he="27" wi="43" file="imgf000028_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="172" height="108" alt="Figure imgf000028_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/14/ce/bd/bbe24d54172863/imgf000028_0002.png"/></a></div>
    </div>
    <div id="p0168" num="0168" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0169" num="0169" class="description-paragraph"> [0093] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0170" num="0170" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/41/08/a77dd34a17f45e/imgf000028_0003.png"><img id="imgf000028_0003" he="31" wi="42" file="imgf000028_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="168" height="124" alt="Figure imgf000028_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/41/08/a77dd34a17f45e/imgf000028_0003.png"/></a></div>
    </div>
    <div id="p0171" num="0171" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0172" num="0172" class="description-paragraph"> [0094] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0173" num="0173" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b4/e5/6f/d36ea40e9e53f2/imgf000029_0001.png"><img id="imgf000029_0001" he="36" wi="72" file="imgf000029_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="288" height="144" alt="Figure imgf000029_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b4/e5/6f/d36ea40e9e53f2/imgf000029_0001.png"/></a></div>
    </div>
    <div id="p0174" num="0174" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0175" num="0175" class="description-paragraph"> [0095] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0176" num="0176" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/09/10/2aa2fa28c61365/imgf000029_0002.png"><img id="imgf000029_0002" he="25" wi="57" file="imgf000029_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="228" height="100" alt="Figure imgf000029_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8f/09/10/2aa2fa28c61365/imgf000029_0002.png"/></a></div>
    </div>
    <div id="p0177" num="0177" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0178" num="0178" class="description-paragraph"> [0096] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0179" num="0179" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5f/0b/22/54e700e901f9be/imgf000029_0003.png"><img id="imgf000029_0003" he="23" wi="71" file="imgf000029_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="284" height="92" alt="Figure imgf000029_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5f/0b/22/54e700e901f9be/imgf000029_0003.png"/></a></div>
    </div>
    <div id="p0180" num="0180" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0181" num="0181" class="description-paragraph"> [0097] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0182" num="0182" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/45/e4/54/f8fa812eb32a1f/imgf000029_0004.png"><img id="imgf000029_0004" he="31" wi="47" file="imgf000029_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="188" height="124" alt="Figure imgf000029_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/45/e4/54/f8fa812eb32a1f/imgf000029_0004.png"/></a></div>
    </div>
    <div id="p0183" num="0183" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0184" num="0184" class="description-paragraph"> [0098] One embodiment provides an ionizable lipid according to the following structure: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c6/2a/b7/7a31a69f9971a4/imgf000030_0004.png"><img id="imgf000030_0004" he="21" wi="47" file="imgf000030_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="188" height="84" alt="Figure imgf000030_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c6/2a/b7/7a31a69f9971a4/imgf000030_0004.png"/></a></div>
 </div>
    <div id="p0185" num="0185" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0186" num="0186" class="description-paragraph"> [0099] One embodiment an ionizable lipid according to the following structure: </div>
    <div id="p0187" num="0187" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/42/43/41400b28b955b5/imgf000030_0001.png"><img id="imgf000030_0001" he="30" wi="55" file="imgf000030_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="220" height="120" alt="Figure imgf000030_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/42/43/41400b28b955b5/imgf000030_0001.png"/></a></div>
    </div>
    <div id="p0188" num="0188" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0189" num="0189" class="description-paragraph"> [0100] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0190" num="0190" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/35/94/74/93094bf41e7513/imgf000030_0002.png"><img id="imgf000030_0002" he="42" wi="55" file="imgf000030_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="220" height="168" alt="Figure imgf000030_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/35/94/74/93094bf41e7513/imgf000030_0002.png"/></a></div>
    </div>
    <div id="p0191" num="0191" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0192" num="0192" class="description-paragraph"> [0101] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0193" num="0193" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/78/b5/cf959136803fda/imgf000030_0003.png"><img id="imgf000030_0003" he="22" wi="82" file="imgf000030_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="328" height="88" alt="Figure imgf000030_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/78/b5/cf959136803fda/imgf000030_0003.png"/></a></div>
    </div>
    <div id="p0194" num="0194" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0195" num="0195" class="description-paragraph"> [0102] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0196" num="0196" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e8/87/93/9e4c9ca9674d66/imgf000031_0001.png"><img id="imgf000031_0001" he="54" wi="57" file="imgf000031_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="228" height="216" alt="Figure imgf000031_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e8/87/93/9e4c9ca9674d66/imgf000031_0001.png"/></a></div>
    </div>
    <div id="p0197" num="0197" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0198" num="0198" class="description-paragraph"> [0103] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0199" num="0199" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/9f/18/ae9c299e970216/imgf000031_0002.png"><img id="imgf000031_0002" he="45" wi="56" file="imgf000031_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="224" height="180" alt="Figure imgf000031_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/9f/18/ae9c299e970216/imgf000031_0002.png"/></a></div>
    </div>
    <div id="p0200" num="0200" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0201" num="0201" class="description-paragraph"> [0104] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0202" num="0202" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/05/ce/c7/78f9405d9f0675/imgf000031_0003.png"><img id="imgf000031_0003" he="44" wi="114" file="imgf000031_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="456" height="176" alt="Figure imgf000031_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/05/ce/c7/78f9405d9f0675/imgf000031_0003.png"/></a></div>
    </div>
    <div id="p0203" num="0203" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0204" num="0204" class="description-paragraph"> [0105] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0205" num="0205" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d6/4b/90/8908847596d2b5/imgf000032_0001.png"><img id="imgf000032_0001" he="63" wi="114" file="imgf000032_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="456" height="252" alt="Figure imgf000032_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d6/4b/90/8908847596d2b5/imgf000032_0001.png"/></a></div>
    </div>
    <div id="p0206" num="0206" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0207" num="0207" class="description-paragraph"> [0106] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0208" num="0208" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/07/92/ac292e3ee7aadd/imgf000032_0002.png"><img id="imgf000032_0002" he="34" wi="54" file="imgf000032_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="216" height="136" alt="Figure imgf000032_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/07/92/ac292e3ee7aadd/imgf000032_0002.png"/></a></div>
    </div>
    <div id="p0209" num="0209" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0210" num="0210" class="description-paragraph"> [0107] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0211" num="0211" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1b/28/22/a58f2010f71cdd/imgf000032_0003.png"><img id="imgf000032_0003" he="49" wi="47" file="imgf000032_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="188" height="196" alt="Figure imgf000032_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1b/28/22/a58f2010f71cdd/imgf000032_0003.png"/></a></div>
    </div>
    <div id="p0212" num="0212" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0213" num="0213" class="description-paragraph"> [0108] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0214" num="0214" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/6b/4c/7e7b16e1ddab0d/imgf000033_0001.png"><img id="imgf000033_0001" he="40" wi="62" file="imgf000033_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="248" height="160" alt="Figure imgf000033_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/6b/4c/7e7b16e1ddab0d/imgf000033_0001.png"/></a></div>
    </div>
    <div id="p0215" num="0215" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0216" num="0216" class="description-paragraph"> [0109] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0217" num="0217" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ec/5c/3e/a5e99e18a78e9b/imgf000033_0002.png"><img id="imgf000033_0002" he="42" wi="60" file="imgf000033_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="240" height="168" alt="Figure imgf000033_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ec/5c/3e/a5e99e18a78e9b/imgf000033_0002.png"/></a></div>
    </div>
    <div id="p0218" num="0218" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0219" num="0219" class="description-paragraph"> [0110] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0220" num="0220" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/84/ed/08/4552d81ad94ef5/imgf000033_0003.png"><img id="imgf000033_0003" he="36" wi="62" file="imgf000033_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="248" height="144" alt="Figure imgf000033_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/84/ed/08/4552d81ad94ef5/imgf000033_0003.png"/></a></div>
    </div>
    <div id="p0221" num="0221" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0222" num="0222" class="description-paragraph"> [0111] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0223" num="0223" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/3e/ba/07a13fc710e339/imgf000034_0001.png"><img id="imgf000034_0001" he="42" wi="59" file="imgf000034_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="236" height="168" alt="Figure imgf000034_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/3e/ba/07a13fc710e339/imgf000034_0001.png"/></a></div>
    </div>
    <div id="p0224" num="0224" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0225" num="0225" class="description-paragraph"> [0112] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0226" num="0226" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/45/0f/a2/19d7b97288c1a3/imgf000034_0002.png"><img id="imgf000034_0002" he="47" wi="136" file="imgf000034_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="544" height="188" alt="Figure imgf000034_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/45/0f/a2/19d7b97288c1a3/imgf000034_0002.png"/></a></div>
    </div>
    <div id="p0227" num="0227" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0228" num="0228" class="description-paragraph"> [0113] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0229" num="0229" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/01/20/56/9b35be77f71c75/imgf000034_0003.png"><img id="imgf000034_0003" he="41" wi="162" file="imgf000034_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="648" height="164" alt="Figure imgf000034_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/01/20/56/9b35be77f71c75/imgf000034_0003.png"/></a></div>
    </div>
    <div id="p0230" num="0230" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0231" num="0231" class="description-paragraph"> [0114] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0232" num="0232" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/11/ea/6e/9c6b035941c510/imgf000035_0001.png"><img id="imgf000035_0001" he="47" wi="136" file="imgf000035_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="544" height="188" alt="Figure imgf000035_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/11/ea/6e/9c6b035941c510/imgf000035_0001.png"/></a></div>
    </div>
    <div id="p0233" num="0233" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0234" num="0234" class="description-paragraph"> [0115] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0235" num="0235" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d4/9e/54/f0f54117248ad5/imgf000035_0002.png"><img id="imgf000035_0002" he="41" wi="162" file="imgf000035_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="648" height="164" alt="Figure imgf000035_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d4/9e/54/f0f54117248ad5/imgf000035_0002.png"/></a></div>
    </div>
    <div id="p0236" num="0236" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0237" num="0237" class="description-paragraph"> [0116] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0238" num="0238" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/20/b2/74/9e4511567b2971/imgf000035_0003.png"><img id="imgf000035_0003" he="53" wi="149" file="imgf000035_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="596" height="212" alt="Figure imgf000035_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/20/b2/74/9e4511567b2971/imgf000035_0003.png"/></a></div>
    </div>
    <div id="p0239" num="0239" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0240" num="0240" class="description-paragraph"> [0117] One embodiment provides an ionizable lipid according to the following structure: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a2/86/2c/8a2abffa8698c9/imgf000036_0001.png"><img id="imgf000036_0001" he="31" wi="145" file="imgf000036_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="580" height="124" alt="Figure imgf000036_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a2/86/2c/8a2abffa8698c9/imgf000036_0001.png"/></a></div>
 </div>
    <div id="p0241" num="0241" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0242" num="0242" class="description-paragraph"> [0118] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0243" num="0243" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b6/84/3b/56eabe58bbe50c/imgf000036_0002.png"><img id="imgf000036_0002" he="46" wi="138" file="imgf000036_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="552" height="184" alt="Figure imgf000036_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b6/84/3b/56eabe58bbe50c/imgf000036_0002.png"/></a></div>
    </div>
    <div id="p0244" num="0244" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0245" num="0245" class="description-paragraph"> [0119] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0246" num="0246" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3c/ba/7b/174b1399c1834e/imgf000036_0003.png"><img id="imgf000036_0003" he="77" wi="138" file="imgf000036_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="552" height="308" alt="Figure imgf000036_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3c/ba/7b/174b1399c1834e/imgf000036_0003.png"/></a></div>
    </div>
    <div id="p0247" num="0247" class="description-paragraph">or an LNP containing said ionizable lipid. 

 [0120] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0248" num="0248" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e3/d3/6d/af68a9500999c4/imgf000037_0001.png"><img id="imgf000037_0001" he="43" wi="71" file="imgf000037_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="284" height="172" alt="Figure imgf000037_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e3/d3/6d/af68a9500999c4/imgf000037_0001.png"/></a></div>
    </div>
    <div id="p0249" num="0249" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0250" num="0250" class="description-paragraph"> [0121] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0251" num="0251" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/53/77/c7/f76bcb33fa7dec/imgf000037_0002.png"><img id="imgf000037_0002" he="31" wi="66" file="imgf000037_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="264" height="124" alt="Figure imgf000037_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/53/77/c7/f76bcb33fa7dec/imgf000037_0002.png"/></a></div>
    </div>
    <div id="p0252" num="0252" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0253" num="0253" class="description-paragraph"> [0122] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0254" num="0254" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/b8/36/a1635d722864ec/imgf000037_0003.png"><img id="imgf000037_0003" he="31" wi="66" file="imgf000037_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="264" height="124" alt="Figure imgf000037_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/b8/36/a1635d722864ec/imgf000037_0003.png"/></a></div>
    </div>
    <div id="p0255" num="0255" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0256" num="0256" class="description-paragraph"> [0123] One embodiment provides an ionizable lipid according to the following structure: 

 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/62/d4/2c/12762297ef3bfc/imgf000038_0001.png"><img id="imgf000038_0001" he="31" wi="102" file="imgf000038_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="408" height="124" alt="Figure imgf000038_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/62/d4/2c/12762297ef3bfc/imgf000038_0001.png"/></a></div>
 </div>
    <div id="p0257" num="0257" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0258" num="0258" class="description-paragraph"> [0124] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0259" num="0259" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/11/fb/e5/fc2c8c11b0d4b3/imgf000038_0002.png"><img id="imgf000038_0002" he="35" wi="73" file="imgf000038_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="292" height="140" alt="Figure imgf000038_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/11/fb/e5/fc2c8c11b0d4b3/imgf000038_0002.png"/></a></div>
    </div>
    <div id="p0260" num="0260" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0261" num="0261" class="description-paragraph"> [0125] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0262" num="0262" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/86/1f/6f/0870815220ba98/imgf000038_0003.png"><img id="imgf000038_0003" he="27" wi="52" file="imgf000038_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="208" height="108" alt="Figure imgf000038_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/86/1f/6f/0870815220ba98/imgf000038_0003.png"/></a></div>
    </div>
    <div id="p0263" num="0263" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0264" num="0264" class="description-paragraph"> [0126] One embodiment provides an ionizable lipid according to the following structure: </div>
    <div id="p0265" num="0265" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/86/d0/210f220bb2d091/imgf000038_0004.png"><img id="imgf000038_0004" he="27" wi="53" file="imgf000038_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="212" height="108" alt="Figure imgf000038_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8f/86/d0/210f220bb2d091/imgf000038_0004.png"/></a></div>
    </div>
    <div id="p0266" num="0266" class="description-paragraph">or an LNP containing said ionizable lipid. </div>
    <div id="p0267" num="0267" class="description-paragraph"> [0127] One embodiment provides an ionizable lipid according to the following structure: 

</div>
    <div id="p0268" num="0268" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0b/48/fe/8adc6105a9014c/imgf000039_0001.png"><img id="imgf000039_0001" he="39" wi="63" file="imgf000039_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="252" height="156" alt="Figure imgf000039_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0b/48/fe/8adc6105a9014c/imgf000039_0001.png"/></a></div>
    </div>
    <div id="p0269" num="0269" class="description-paragraph">or an LNP containing said ionizable lipid. B. Sterols </div>
    <div id="p0270" num="0270" class="description-paragraph"> [0128] In some embodiments, the disclosed lipid nanoparticles include one or more sterols. In one embodiment, the sterol is cholesterol, or a variant or derivative thereof. In some embodiments, the cholesterol is modified, for example oxidized. Unmodified cholesterol can be acted upon by enzymes to form variants that are side-chain or ring oxidized. The cholesterol can be oxidized on the beta-ring structure or on the hydrocarbon tail structure. Exemplary cholesterols that are considered for use in the disclosed lipid nanoparticles include but are not limited to 25- hydroxycholesterol (25-OH), 20-hydroxycholesterol (20-OH), 27-hydroxycholesterol, 6-keto- 5-hydroxycholesterol, 7-ketocholesterol, 7-hydroxycholesterol, 7-hydroxycholesterol, 7-25- dihydroxycholesterol, beta-sitosterol, stigmasterol or combinations thereof. In one embodiment, side-chain oxidized cholesterol can enhance cargo delivery relative to other cholesterol variants. In one embodiment, the cholesterol is an unmodified cholesterol. C. PEG-Lipids </div>
    <div id="p0271" num="0271" class="description-paragraph"> [0129] In some embodiments, the disclosed nanoparticle compositions also include one or more PEG or PEG-modified lipids. Such species may be alternately referred to as PEGylated lipids or PEG-lipids. Inclusion of a PEGylating lipid can be used to enhance lipid nanoparticle colloidal stability in vitro and circulation time in vivo. In some embodiments, the PEGylation is reversible in that the PEG moiety is gradually released in blood circulation. Exemplary PEG-lipids include but are not limited to PEG conjugated to saturated or unsaturated alkyl chains having a length of C6-C20. PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides (PEG-CER), PEG-modified dialkylamines, PEG-modified diacylglycerols (PEG-DAG), PEG-modified dialkylglycerols, and mixtures thereof. For example, 

 a PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPE, PEG- DSG or a PEG-DSPE lipid. </div>
    <div id="p0272" num="0272" class="description-paragraph"> [0130] In a one embodiment, the PEG lipid is DMPE-PEG2000 or DSPE-PEG2000. D. Phospholipids </div>
    <div id="p0273" num="0273" class="description-paragraph"> [0131] The phospholipid component of the nanoparticle may include one or more phospholipids, such as one or more (poly)unsaturated lipids. The phospholipids may assemble into one or more lipid bilayers. In some embodiments, the phospholipids may include a phospholipid moiety and one or more fatty acid moieties. </div>
    <div id="p0274" num="0274" class="description-paragraph"> [0132] In some embodiments, the phospholipid moiety includes but is not limited to phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidic acid, 2-lysophosphatidyl choline, and sphingomyelin. In some embodiments, the fatty acid moiety includes but is not limited to lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid. Nonnatural species including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes are also contemplated. For example, a phospholipid may be functionalized with or cross-linked to one or more alkynes (e.g., an alkenyl group in which one or more double bonds is replaced with a triple bond). Under appropriate reaction conditions, an alkyne group may undergo a copper-catalyzed cycloaddition upon exposure to an azide. Such reactions may be useful in functionalizing a lipid bilayer of a nanoparticle composition to facilitate membrane permeation or cellular recognition or in conjugating a nanoparticle composition to a useful component such as a targeting or imaging moiety (e.g., a dye). </div>
    <div id="p0275" num="0275" class="description-paragraph"> [0133] Exemplary phospholipids include but are not limited to 1,2-distearoyl-sn- glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero- phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl- sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), l- palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-0-octadecenyl-sn-glycero-3- phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoy l-sn-glycero-3- phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2- 

 dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2- didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3- phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2- dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3- phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2- didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac- (1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phosphatidy ethanolamine (SOPE), 1-stearoyl-2-oleoyl- phosphatidylcholine (SOPC), sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoyl phosphatidylcholine, lysophosphatidylcholine, lysophosphatidylethanolamine (LPE). In a preferred embodiment, the phospholipid is DSPC. E. Cargo </div>
    <div id="p0276" num="0276" class="description-paragraph"> [0134] In one embodiment, the disclosed lipid nanoparticle compositions include a therapeutic or prophylactic agent to a subject. In some embodiments, the therapeutic or prophylactic agent is encapsulated by the lipid nanoparticle. In one embodiment, the lipid nanoparticles are loaded with one or more nucleic acids. </div>
    <div id="p0277" num="0277" class="description-paragraph"> [0135] Representative nucleic acids include but are not limited to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) RNA, DNA, single-stranded RNA, single-stranded DNA, double-stranded RNA, double stranded DNA, triple-stranded DNA, siRNA, shRNA, sgRNA, mRNA, miRNA, and antisense DNA. </div>
    <div id="p0278" num="0278" class="description-paragraph"> [0136] CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) based gene editing requires two components: a guide-RNA and a CRISPR-associated endonuclease protein (Cas). The guide RNA directs the Cas nuclease to the specific target DNA sequence. Cas then creates a double-strand break in the DNA at that site. In one embodiment, the disclosed lipid nanoparticles can be used to carry the components required for CRISPR-based gene editing. In one lipid nanoparticle, the nucleic acid cargo is a guide-RNA. In such an embodiment, a second lipid nanoparticle can contain nucleic acid cargo that encodes an RNA-guided endonuclease. The 

 two lipid nanoparticles can be administered together. Exemplary RNA-guided endonucleases include but are not limited to Cas9, CasX, CasY, Cas13, or Cpf1. </div>
    <div id="p0279" num="0279" class="description-paragraph"> [0137] In one embodiment, the cargo is siRNA. Short Interfering RNA (siRNA) is a double-stranded RNA that can induce sequence-specific post-transcriptional gene silencing, thereby decreasing or even inhibiting gene expression. In one example, an siRNA triggers the specific degradation of homologous RNA molecules, such as mRNAs, within the region of sequence identity between both the siRNA and the target RNA. For example, WO 02/44321 discloses siRNAs capable of sequence-specific degradation of target mRNAs when base-paired with 3 overhanging ends, herein incorporated by reference for the method of making these siRNAs. Sequence specific gene silencing can be achieved in mammalian cells using synthetic, short double-stranded RNAs that mimic the siRNAs produced by the enzyme dicer (Elbashir, et al. (2001) Nature, 411:494498) (Ui-Tei, et al. (2000) FEBS Lett 479:79-82. </div>
    <div id="p0280" num="0280" class="description-paragraph"> [0138] In one embodiment, the lipid nanoparticle contains less than 1.0 mg/kg inhibitory nucleic acid. The nanoparticle can contain 1.0, 0.9, 0.8, 0.7, 0.6, or 0.5 mg/kg inhibitory nucleic acid. In another embodiment, the lipid nanoparticle contains 0.5 mg/kg inhibitory nucleic acid. This is an advantage over current technology in which nanoparticles require high doses of nucleic acid (&gt; 1 mg/kg) to achieve gene silencing, doses of which are not approve for human delivery. The disclosed technology can achieve gene silencing using 0.5 mg/kg inhibitory nucleic acid in a lipid nanoparticle that does not include targeting ligands. </div>
    <div id="p0281" num="0281" class="description-paragraph"> [0139] In some embodiments, the nucleic acids, including but not limited to oligonucleotides, are modified or include one more modified nucleotides to increase stability, half- life, and nuclease sensitivity. To limit nuclease sensitivity, the native phosphodiester oligodeoxyribonucleotide, native phosphodiester oligoribonucleotide, ribonucleotide polymers, and deoxyribonucleotide polymers can include one more different modifications. Exemplary modifications, include but are not limited to phosphorothioate (PS) bonds, 2-O Methyl (2OMe), 2 Fluor bases, inverted dT and ddT, phosphorylation of the 3end of oligonucleotides, locked nucleic acids, and including a phosphoramidite C3 Spacer. </div>
    <div id="p0282" num="0282" class="description-paragraph"> [0140] The phosphorothioate bond substitutes a sulfur atom for a non-bridging oxygen in the phosphate backbone of an oligonucleotide. Approximately 50% of the time (due to the 2 resulting stereoisomers that can form), PS modification renders the internucleotide linkage more resistant to nuclease degradation. In some embodiments, the nucleic acids include one or more PS 

 bonds, for example at least 3 PS bonds at the 5 and 3 oligonucleotide ends to inhibit exonuclease degradation. Some nucleic acid include PS bonds throughout the entire oligonucleotide to help reduce attack by endonucleases as well. </div>
    <div id="p0283" num="0283" class="description-paragraph"> [0141] A naturally occurring post-transcriptional modification of RNA, 2OMe is found in tRNA and other small RNAs. In some embodiments, the nucleic acids or oligonucleotides are directly synthesized to contain 2OMe. This modification increases the Tm of RNA:RNA duplexes, but results in only small changes in RNA:DNA stability. It prevents attack by single- stranded endonucleases, but not exonuclease digestion. In some embodiment, these nucleic acids or oligonucleotides are also end blocked. DNA oligonucleotides that include this modification are typically 5- to 10-fold less susceptible to DNases than unmodified DNA. The 2OMe modification is commonly used in antisense oligonucleotides as a means to increase stability and binding affinity to target transcripts. </div>
    <div id="p0284" num="0284" class="description-paragraph"> [0142] 2-fluoro bases have a fluorine-modified ribose which increases binding affinity (Tm) and also confers some relative nuclease resistance compared to native RNA. In some embodiments, the nucleic acids or oligonucleotides include 2 fluoro bases in conjunction with PS-modified bonds. </div>
    <div id="p0285" num="0285" class="description-paragraph"> [0143] Inverted dT can be incorporated at the 3 end of an oligonucleotide, leading to a 3-3 linkage that will inhibit degradation by 3 exonucleases and extension by DNA polymerases. In addition, placing an inverted, 2,3 dideoxy-dT base (5 Inverted ddT) at the 5 end of an oligonucleotide prevents spurious ligations and may protect against some forms of enzymatic degradation. </div>
    <div id="p0286" num="0286" class="description-paragraph"> [0144] Some embodiments provide nucleic acids or oligonucleotides that include a phosphoramidite C3 Spacer. The phosphoramidite C3 Spacer can be incorporated internally, or at either end of an oligo to introduce a long hydrophilic spacer arm for the attachment of fluorophores or other pendent groups. The C3 spacer also can be used to inhibit degradation by 3 exonucleases. </div>
    <div id="p0287" num="0287" class="description-paragraph"> [0145] In some embodiments, the nucleic acids or oligonucleotides include locked nucleic acids. Locked nucleic acids include modified RNA nucleotides in which the 2-O and 4- C atoms of the ribose are joined through a methylene bridge. This additional bridge limits the flexibility normally associated with the ring, essentially locking the structure into a rigid conformation. </div>
    <div id="p0288" num="0288" class="description-paragraph"> [0146] LNAs can be inserted into both RNA and DNA oligonucleotides. 

 [0147] Other types of cargo that can be delivered via the disclosed nanoparticles include but are not limited to chemotherapeutic agents, cytotoxic agents, radioactive ions, small molecules, proteins, polynucleotides, and nucleic acids. </div>
    <div id="p0289" num="0289" class="description-paragraph"> [0148] Representative chemotherapeutic agents include, but are not limited to amsacrine, bleomycin, busulfan, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epirubicin, etoposide, fludarabine, fluorouracil, gemcitabine, hydroxycarbamide, idarubicin, ifosfamide, irinotecan, leucovorin, liposomal doxorubicin, liposomal daunorubicin, lomustine, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin, procarbazine, raltitrexed, satraplatin, streptozocin, tegafur-uracil, temozolomide, teniposide, thiotepa, tioguanine, topotecan, treosulfan, vinblastine, vincristine, vindesine, vinorelbine, or a combination thereof. Representative pro-apoptotic agents include, but are not limited to fludarabinetaurosporine, cycloheximide, actinomycin D, lactosylceramide, 15d-PGJ(2) and combinations thereof. F. Exemplary Lipid Nanoparticle Formulations </div>
    <div id="p0290" num="0290" class="description-paragraph"> [0149] In one embodiment, the lipid nanoparticle formulation includes about 30 mol % to about 70 mol % conformationally constrained ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 25 mol % to about 45 mol % cholesterol, and about 0 mol % to about 5 mol % PEG-lipid. In another embodiment, the lipid nanoparticle formulation include about 35 mol % conformationally constrained ionizable lipid, about 16 mol % phospholipid, about 46.5 mol % cholesterol, and about 2.5 mol % PEG-lipid. In another embodiment, the lipid nanoparticle formulation include about 50 mol % conformationally constrained ionizable lipid, about 10 mol % phospholipid, about 38.5 mol % cholesterol, and about 1.5 mol % PEG-lipid. </div>
    <div id="p0291" num="0291" class="description-paragraph"> [0150] One embodiment provides a lipid nanoparticle formulation including about 33 mol % to about 36 mol % conformationally constrained ionizable lipid with an adamantane tail, about 15 mol% to about 17 mol % 1-2-distearoyl-sn-glycero-3-phosphocholine, about 2 mol % to about 3 mol % C<sub>14</sub>PEG<sub>2000,</sub> and about 45 mol % to about 47 mol % cholesterol, based on the total moles of these four ingredients. </div>
    <div id="p0292" num="0292" class="description-paragraph"> [0151] Another embodiment provides a lipid nanoparticle formulation including 35 mol % conformationally constrained ionizable lipid with an adamantane tail, 16 mol % 1-2- 

 distearoyl-sn-glycero-3-phosphocholine, and 2.5 mol % C<sub>14</sub>PEG<sub>2000,</sub> 46 mol % cholesterol, based on the total moles of these four ingredients. </div>
    <div id="p0293" num="0293" class="description-paragraph"> [0152] Another embodiment provides a lipid nanoparticle formulation in which the mass ratio of (ionizable lipid, cholesterol, lipid-PEG, and phospholipid):siRNA is between about 2:1 and 20:1. </div>
    <div id="p0294" num="0294" class="description-paragraph"> [0153] In yet another embodiment the lipid nanoparticle formulation includes 3-[(1- Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12- octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and an inhibitory nucleic acid. </div>
    <div id="p0295" num="0295" class="description-paragraph"> [0154] One embodiment provides a lipid nanoparticles composition containing 3-[(1- Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12- octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for a gene. Another embodiment provides a lipid nanoparticle including 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA encoding an RNA guided DNA endonuclease. G. Pharmaceutical compositions </div>
    <div id="p0296" num="0296" class="description-paragraph"> [0155] Pharmaceutical compositions including the disclosed lipid nanoparticles are provided. The lipid nanoparticle compositions can be formulated in whole or in part as pharmaceutical compositions. Pharmaceutical compositions may include one or more nanoparticle compositions. For example, a pharmaceutical composition may include one or more nanoparticle compositions including one or more different therapeutic and/or prophylactics including but not limited to one or more nucleic acids of different types or encode different agents. In some embodiments the pharmaceutical compositions include one or more pharmaceutically acceptable excipients or accessory ingredients including but not limited to a pharmaceutically acceptable carrier. </div>
    <div id="p0297" num="0297" class="description-paragraph"> [0156] Pharmaceutical compositions containing the nanoparticles can be formulated for administration by parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), transdermal (either passively or using iontophoresis or electroporation), or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration or using bioerodible inserts and can be formulated in dosage forms appropriate for each route of administration. </div>
    <div id="p0298" num="0298" class="description-paragraph"> [0157] In some in vivo approaches, the nanoparticle compositions disclosed herein are administered to a subject in a therapeutically effective amount. As used herein the termeffective 

 amount ortherapeutically effective amount means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of the disorder being treated or to otherwise provide a desired pharmacologic and/or physiologic effect. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., age, immune system health, etc.), the disease, and the treatment being effected. </div>
    <div id="p0299" num="0299" class="description-paragraph"> [0158] For the disclosed nanoparticles, as further studies are conducted, information will emerge regarding appropriate dosage levels for treatment of various conditions in various patients, and the ordinary skilled worker, considering the therapeutic context, age, and general health of the recipient, will be able to ascertain proper dosing. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired. For the disclosed nanoparticles, generally dosage levels of 0.001 mg to 5 mg of nucleic acid per kg of body weight daily are administered to mammals. More specifically, a preferential dose for the disclosed nanoparticles is 0.01 mg / kg to 0.25 mg/kg. For the disclosed nanoparticles, generally dosage levels of 0.2 mg to 100 mg of the four components (ionizable lipid, cholesterol, PEG-lipid, and phospholipid) / kg of body weight are administered to mammals. More specifically, a preferential dose of the disclosed nanoparticles is 0.05 mg / kg to 0.5 mg / kg of the four components / kg of body weight. </div>
    <div id="p0300" num="0300" class="description-paragraph"> [0159] In certain embodiments, the lipid nanoparticle composition is administered locally, for example by injection directly into a site to be treated. Typically, the injection causes an increased localized concentration of the lipid nanoparticle composition which is greater than that which can be achieved by systemic administration. The lipid nanoparticle compositions can be combined with a matrix as described above to assist in creating an increased localized concentration of the polypeptide compositions by reducing the passive diffusion of the polypeptides out of the site to be treated. 1. Formulations for Parenteral Administration </div>
    <div id="p0301" num="0301" class="description-paragraph"> [0160] In some embodiments, the nanoparticle compositions disclosed herein, including those containing lipid nanoparticles, are administered in an aqueous solution, by parenteral injection. The formulation may also be in the form of a suspension or emulsion. In general, pharmaceutical compositions are provided including effective amounts of a lipid nanoparticle, and optionally include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions optionally include one or 

 more for the following: diluents, sterile water, buffered saline of various buffer content (e.g., Tris- HCl, acetate, phosphate), pH and ionic strength; and additives such as detergents and solubilizing agents (e.g., TWEEN 20 (polysorbate-20), TWEEN 80 (polysorbate-80)), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), and preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. The formulations may be lyophilized and redissolved/resuspended immediately before use. The formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. 2. Controlled Delivery Polymeric Matrices </div>
    <div id="p0302" num="0302" class="description-paragraph"> [0161] The lipid nanoparticles disclosed herein can also be administered in controlled release formulations. Controlled release polymeric devices can be made for long term release systemically following implantation of a polymeric device (rod, cylinder, film, disk) or injection (microparticles). The matrix can be in the form of microparticles such as microspheres, where the agent is dispersed within a solid polymeric matrix or microcapsules, where the core is of a different material than the polymeric shell, and the peptide is dispersed or suspended in the core, which may be liquid or solid in nature. Unless specifically defined herein, microparticles, microspheres, and microcapsules are used interchangeably. Alternatively, the polymer may be cast as a thin slab or film, ranging from nanometers to four centimeters, a powder produced by grinding or other standard techniques, or even a gel such as a hydrogel. </div>
    <div id="p0303" num="0303" class="description-paragraph"> [0162] Either non-biodegradable or biodegradable matrices can be used for delivery of lipid nanoparticles, although in some embodiments biodegradable matrices are preferred. These may be natural or synthetic polymers, although synthetic polymers are preferred in some embodiments due to the better characterization of degradation and release profiles. The polymer is selected based on the period over which release is desired. In some cases, linear release may be most useful, although in others a pulse release orbulk release may provide more effective results. The polymer may be in the form of a hydrogel (typically in absorbing up to about 90% by weight of water), and can optionally be crosslinked with multivalent ions or polymers. </div>
    <div id="p0304" num="0304" class="description-paragraph"> [0163] The matrices can be formed by solvent evaporation, spray drying, solvent extraction and other methods known to those skilled in the art. Bioerodible microspheres can be 

 prepared using any of the methods developed for making microspheres for drug delivery, for example, as described by Mathiowitz and Langer, J. Controlled Release, 5:13-22 (1987); Mathiowitz, et al., Reactive Polymers, 6:275-283 (1987); and Mathiowitz, et al., J. Appl. Polymer Sci., 35:755-774 (1988). </div>
    <div id="p0305" num="0305" class="description-paragraph"> [0164] The devices can be formulated for local release to treat the area of implantation or injection which will typically deliver a dosage that is much less than the dosage for treatment of an entire body or systemic delivery. These can be implanted or injected subcutaneously, into the muscle, fat, or swallowed. III. Methods of Manufacturing Lipid Nanoparticles </div>
    <div id="p0306" num="0306" class="description-paragraph"> [0165] Methods of manufacturing lipid nanoparticles are known in the art. In one embodiment, the disclosed lipid nanoparticles are manufactured using microfluidics. For exemplary methods of using microfluidics to form lipid nanoparticles, see Leung, A.K.K, et al., J Phys Chem, 116:18440-18450 (2012), Chen, D., et al., J Am Chem Soc, 134:6947-6951 (2012), and Belliveau, N.M., et al., Molecular Therapy-Nucleic Acids, 1: e37 (2012). Briefly, the cargo, such as an oligonucleotide or siRNA, is prepared in one buffer. The other lipid nanoparticle components (ionizable lipid, PEG-lipid, cholesterol, and DSPC) are prepared in another buffer. A syringe pump introduces the two solutions into a microfluidic device. The two solutions come into contact within the microfluidic device to form lipid nanoparticles encapsulating the cargo. </div>
    <div id="p0307" num="0307" class="description-paragraph"> [0166] Methods of screening the disclosed lipid nanoparticles are discussed in International Patent Application No. PCT/US/2018/058171, which is incorporated by reference in its entirety. The screening methods characterizes vehicle delivery formulations to identify formulations with a desired tropism and that deliver functional cargo to the cytoplasm of specific cells. The screening method uses a reporter that has a functionality that can be detected when delivered to the cell. Detecting the function of the reporter in the cell indicates that the formulation of the delivery vehicle will deliver functional cargo to the cell. A chemical composition identifier is included in each different delivery vehicle formulation to keep track of the chemical composition specific for each different delivery vehicle formulation. In one embodiment, the chemical composition identifier is a nucleic acid barcode. The sequence of the nucleic acid bar code is paired to the chemical components used to formulate the delivery vehicle in which it is loaded so that when the nucleic acid bar code is sequenced, the chemical composition of the delivery vehicle that delivered the barcode is identified. Representative reporters include, but are not limited to 

 siRNA, mRNA, nuclease protein, nuclease mRNA, small molecules, epigenetic modifiers, and phenotypic modifiers. IV. Methods of Use </div>
    <div id="p0308" num="0308" class="description-paragraph"> [0167] Methods of using the disclosed lipid nanoparticles to deliver cargo, for example nucleic acids, to specific cells or organs are disclosed herein. In some embodiments, the nanoparticles deliver therapeutic or prophylactic agents to specific cells or organs in a subject in need thereof in the absence of a targeting ligand. In another embodiment, the disclosed lipid nanoparticles are useful to treat or prevent diseases in a subject in need thereof. </div>
    <div id="p0309" num="0309" class="description-paragraph"> [0168] In some embodiments, the disclosed nanoparticles are delivered directly to the subject. In other embodiments, the lipid nanoparticles are contacted with cells ex vivo, and the treated cells are administered to the subject. The cells can be autologous cells, for example immune cells including but not limited to T cells or cells that differentiate into T cells. In some embodiments, the disclosed lipid nanoparticles may be used as vehicles for adoptive cell transfer. A. Methods of Delivering Cargo to Cells </div>
    <div id="p0310" num="0310" class="description-paragraph"> [0169] Methods of delivering a therapeutic and/or prophylactic nucleic acids to a subject in need thereof are provided herein. </div>
    <div id="p0311" num="0311" class="description-paragraph"> [0170] In some embodiments, the disclosed lipid nanoparticle composition targets a particular type or class of cells (e.g., cells of a particular organ or system thereof). For example, a nanoparticle composition including a therapeutic and/or prophylactic of interest may be specifically delivered to immune cells in the subject. Exemplary immune cells include but are not limited to CD8+, CD4+, or CD8+CD4+ cells. In other embodiments, the lipid nanoparticles can be formulated to be delivered in the absence of a targeting ligand to a mammalian liver immune cells, spleen T cells, or lung endothelial cells. Specific delivery to a particular class or type of cells indicates that a higher proportion of lipid nanoparticles are delivered to target type or class of cells. In some embodiments, specific delivery may result in a greater than 2 fold, 5 fold, 10 fold, 15 fold, or 20 fold increase in the amount of therapeutic and/or prophylactic per 1 g of tissue of the targeted destination. 

 B. Methods of Gene Regulation </div>
    <div id="p0312" num="0312" class="description-paragraph"> [0171] Methods of using the disclosed lipid nanoparticles for gene regulation are provided herein. In one embodiment, the lipid nanoparticles can be used for reducing gene expression in a target cell in a subject in need thereof. In such an embodiment, a subject is administered a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and an inhibitory nucleic acid. The lipid nanoparticle can deliver the inhibitory nucleic acid to the target cell in the subject without a targeting ligand. The inhibitory nucleic acid can be siRNA. </div>
    <div id="p0313" num="0313" class="description-paragraph"> [0172] Another embodiment provides methods of using the disclosed lipid nanoparticles for editing a gene in a cell in a subject in need thereof. In such an embodiment, the subject is administered two populations of lipid nanoparticles. The first population includes lipid nanoparticles having a formulation including Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for the gene that is being targeted. The second population of lipid nanoparticles includes lipid nanoparticles having a formulation including Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA encoding an RNA-guided DNA endonuclease. The RNA-guided DNA endonuclease can be Cas9, CasX, CasY, Cas13, or Cpf1. </div>
    <div id="p0314" num="0314" class="description-paragraph"> [0173] In one embodiment, the cell that is targeted for gene regulation is an immune cell. The immune cell can be a T cell, such as CD8+ T cell, CD4+ T cell, or T regulatory cell. Other exemplary immune cells for gene editing include but are not limited to macrophages, dendritic cells, or liver immune cells. </div>
    <div id="p0315" num="0315" class="description-paragraph"> [0174] Exemplary genes that can be targeted include but are not limited to T cell receptors, B cell receptors, CTLA4, PD1, FOXO1, FOXO3, AKTs, CCR5, CXCR4, LAG3, TIM3, Killer immunoglobulin-like receptors, GITR, BTLA, LFA-4, T4, LFA-1, Bp35, CD27L receptor, TNFRSF8, TNFRSF5, CD47, CD52, ICAM-1, LFA-3, L-selectin, Ki-24, MB1, B7, B70, M- CSFR, TNFR-II, IL-7R, OX-40, CD137, CD137L, CD30L, CD40L, FasL, TRAIL, CD257, LIGHT, TRAIL-R1, TRAILR2, TRAIL-R4, TWEAK-R, TNFR, BCMA, B7DC, BTLA, B7-H1, 

 B7-H2, B7-H3, ICOS, VEGFR2, NKG2D, JAG1, GITR, CD4, CCR5, GATA-3, MTORC1, MTORC2, RAPTOR, GATOR, FOXP3, NFAT, IL2R, and IL7. </div>
    <div id="p0316" num="0316" class="description-paragraph"> [0175] Exemplary tumor-associated antigens that can be recognized by T cells and are contemplated for targeting, include but are not limited to MAGE1, MAGE3, MAGE6, BAGE, GAGE, NYESO-1, MART1/Melan A, MC1R, GP100, tyrosinase, TRP-1, TRP-2, PSA, CEA, Cyp-B, Her2/Neu, hTERT, MUC1, PRAME, WT1, RAS, CDK-4, MUM-1, KRAS, MSLN and - catenin. C. Subjects to be Treated </div>
    <div id="p0317" num="0317" class="description-paragraph"> [0176] In some embodiments, the subjects treated are mammals experiencing cancer, autoimmune disease, infections disease, organ transplant, organ failure, or a combination thereof. In some embodiments, the methods described herein may cause T cells to present specific antigens for the treatment of cancer or autoimmune disease. In some embodiments, the methods described herein may be used for T cell priming. In some embodiments, the methods described herein may be used to deliver DNA or mRNA that cause T cells to present MHC-peptide complexes. In some embodiments, the methods described herein may be used to deliver one or more of DNA, siRNA, or mRNA to a T cell to avoid anergy. 

</div>
    <div id="p0318" num="0318" class="description-paragraph">EXAMPLES Example 1. Preparation of a Constrained Lipid </div>
    <div id="p0319" num="0319" class="description-paragraph">
      <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/14/b2/10/d7f7abacb9f1d1/imgf000052_0001.png"><img id="imgf000052_0001" he="152" wi="162" file="imgf000052_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="648" height="608" alt="Figure imgf000052_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/14/b2/10/d7f7abacb9f1d1/imgf000052_0001.png"/></a></div>
    </div>
    <div id="p0320" num="0320" class="description-paragraph"> [0177] To a solution of linoleic acid 1 (4.0 g, 14.2 mmol), 4-dimethylaminopyridine (DMAP) (0.4 g, 2.9 mmol), N,N-diisopropylethylamine (DIPEA) (3.7 mL, 20.5 mmol) and 2- (hydroxymethyl)propane-1,3-diol (1.5 g, 14.2 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (40mL) under nitrogen atmosphere was added N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDCI) (4.1g, 20.5 mmol) at 25 C. The reaction mixture was stirred at room temperature overnight and linoleic acid 1 was consumed completely as monitored by TLC. Then the reaction mixture was directly concentrated under reduced pressure. Purification of the crude residue via silica gel flash 

 column chromatography (gradient eluent: 1-30% of EtOAc/hexane) afforded compound 2 (2.3 g, 44% yield) and compound 3 (1.7 g, 30% yield) as colorless oil. </div>
    <div id="p0321" num="0321" class="description-paragraph"> [0178] To a solution of compound 2 (150 mg, 0.41 mmol), DMAP (10 mg, 0.1 mmol), DIPEA (0.1 mL, 0.6 mmol) and adamantane (79 mg, 0.41 mmol) in anhydrous CH2Cl2 (2 mL) under nitrogen atmosphere was added EDCI (114 mg, 0.6 mmol). The reaction mixture was stirred at room temperature overnight, and compound 2 was consumed completely as monitored by TLC. Then the reaction mixture was directly concentrated under reduced pressure. Purification of the crude residue via silica gel flash column chromatography (gradient eluent: 0-20% of EtOAc/hexane) afforded compound 4 (103 mg, 53% yield) as a colorless oil. </div>
    <div id="p0322" num="0322" class="description-paragraph"> [0179] To a solution of compound 4 (76 mg, 0.16 mmol) and DMAP (45 mg, 0.37 mmol) in anhydrous CH2Cl2 (2 mL). Under nitrogen atmosphere was added 4- nitrophenylchloroformate (65 mg, 0.32 mmol). After stirring at room temperature for 1 hour, 3- diethylamino-1-propanol (0.44 mL, 0.96 mmol) was added into the reaction mixture and then stirred at room temperature for 1 hour. The reaction mixture was directly concentrated under reduced pressure. Purification of the crude residue via silica gel flash column chromatography (gradient eluent: 0-4% of MeOH/DCM) afforded compound 1-1 (32 mg, 29% yield) as a colorless oil. HRMS (ESI, m/z) calculated for C<sub>42</sub>H<sub>72</sub>NO<sub>7</sub> [M + H]<sup>+</sup>: 702.5303, found 702.5277. </div>
    <div id="p0323" num="0323" class="description-paragraph"> [0180] Other lipids were prepared by methods similar to the steps described in this example. Example 2. Lipid nanoparticles containing a conformationally constrained lipid can form stable LNPs. Materials and Methods: </div>
    <div id="p0324" num="0324" class="description-paragraph"> [0181] Nanoparticle Formulation. Nanoparticles were formulated using a microfluidic device as previously described. Briefly, nucleic acids (siRNA and DNA barcodes) were diluted in citrate buffer while lipid-amine compounds, alkyl tailed PEG, cholesterol, and DSPC were diluted in ethanol. PEG, cholesterol, and DSPC was purchased from Avanti Lipids. Citrate and ethanol phases were combined in a microfluidic device by syringe pumps. </div>
    <div id="p0325" num="0325" class="description-paragraph"> [0182] Nanoparticle Characterization. LNP hydrodynamic diameter was measured using a plate reader formatted dynamic light scattering machine (Wyatt). LNPs were diluted in sterile 1X PBS to a concentration of ~0.06 mg/mL and analyzed. LNPs were only included if they 

 formed monodisperse populations with diameter between 20 and 200nm. Particles that met these criteria were dialyzed with 1X phosphate buffered saline (PBS, Invitrogen), and were sterile filtered with a 0.22 ^m filter. Results: </div>
    <div id="p0326" num="0326" class="description-paragraph"> [0183] 13 chemically diverse lipids containing amines were synthesized. The library was constructed to investigate whether the structure of the (i) amine and (ii) lipid tail affected delivery. Ascaffold lipid containing the unsaturated lipid linoleate and two ester bonds was purified (Fig. 1A). This scaffold did not have any amines. Amine variants were attached to the reactive sites, in order to create chemical diversity (Fig. 1A). At reactive site 1, 3 lipid tails with diverse structures (Fig.1B) were added via esterification. The control tail, L, was linoleate which created a construct with two identical lipid tails. Lipid S contained two lipid tails, bringing the total number of tails to 3. Finally, tail A contained adamantane, a constrained lipid with a defined armchair structure. At reactive site 2, 11 amine-containing head groups were added via esterification, resulting in head groups linked by ester or carbonate linkages, respectively. Head groups were chose based on previous reports that small molecules with similar structures have biological activity. After synthesis, the chemical structure of all 13 lipids was confirmed using high resolution mass spectroscopy or 1H-NMR. For clarity, each ionizable lipid was named with the nomenclature, head group number tail letter (e.g.1-L, 11-A). </div>
    <div id="p0327" num="0327" class="description-paragraph"> [0184] The ability of the 13 ionizable lipids (Fig. 1A-C) to form stable LNPs was investigated. The hydrodynamic diameter of LNPs carrying a chemically modified siRNA targeting GFP (siGFP) (Paunovska, et al., ACS Nano, 12:8341-8349 (2018)) as well as a DNA barcode (Sago et al., Nano Lett, (2018)) was measured. The LNPs were formulated using microfluidics (Chen, D., et al., J Am Chem Soc, 134:6948-6951 (2012)). Previously validated compounds were added to reduce the chance the results were affected by other constituents added to the LNP. The previously validated compounds were C14PEG2000, unmodified cholesterol, and either 1-2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1-2-dioleoyl-sn-glycero-3- phosphoethanolamine (DOPE) (Fig. 1D). As a control to ensure the results were not affected by the molar ratio of the 4 components, each lipid was formulated with 2 phospholipids and 4 molar ratios, for a total of 104 LNPs (Fig.1D). Notably, 100 of the LNPs formed small, monodisperse populations, as evidenced both by hydrodynamic diameter and polydispersity index. The diameter for individual LNPs varied between 30 and 170 nm, with an average of 76 nm (Fig. 1E) and an 

 average PDI of 0.15 (Fig.1F). The hydrodynamic diameter was analyzed as a function of ionizable lipid (Fig.1G), molar ratio of the four constituents (Fig.1H), and the type of phospholipid (DSPC / DOPE) added to the formulation (Fig.1I). In all cases, the average diameter varied between 50 and 100 nm. These data show that non-traditional lipids formed LNPs with hydrodynamic diameters similar to lipoproteins and natural viruses. Example 3. A high throughput siRNA screen for in vivo activity reveals LNPs with constrained lipids have biological activity in T cells. Materials and Methods: </div>
    <div id="p0328" num="0328" class="description-paragraph"> [0185] DNA Barcoding. Each chemically distinct LNP was formulated to carry its own unique DNA barcode and siRNA. For example, LNP1 carried DNA barcode 1 and siICAM2, while the chemically distinct LNP2 carried DNA barcode 2 and siGFP. Single stranded DNA sequences were purchased from Integrated DNA Technologies (IDT). To ensure equal amplification of each sequence, we included universal forward and reverse primer regions. Each barcode was distinguished using a unique 8 nucleotide sequence. An 8 nucleotide sequence can generate 65,536 distinct barcodes. 156 distinct sequences designed to prevent sequence bleaching on the Illumina MiniSeq sequencing machine were used. </div>
    <div id="p0329" num="0329" class="description-paragraph"> [0186] Animal Experiments. All animal experiments were performed in accordance with the Georgia Institute of Technologys IACUC. C57BL/6J (#000664), GFP (#003291), and constitutive SpCas9 (#026179) mice were purchased from The Jackson Laboratory and used between 5-12 weeks of age. In all experiments, N=3-5 mice/group were used. Mice were injected intravenously via the lateral tail vein. The nanoparticle concentration was determined using NanoDrop (Thermo Scientific). </div>
    <div id="p0330" num="0330" class="description-paragraph"> [0187] Cell Isolation &amp; Staining. Cells were isolated 72 hours (for screens) or 120 hours (for in vivo gene editing) hours after injection with LNPs unless otherwise noted. Mice were perfused with 20 mL of 1X PBS through the right atrium. As previously described (Dahlman, et al., Nat Nano, 9:648-655 (2014); Paunovska, K., et al., Nano Lett, 18:2148-2157 (2018)), tissues were cut and placed in a digestive enzyme solution with Collagenase Type I (Sigma Aldrich), Collagenase XI (Sigma Aldrich) and Hyaluronidase (Sigma Aldrich) at 37 C for 45 minutes. The digestive enzyme for heart included Collagenase IX. Cell suspension was filtered through 70mm mesh and red blood cells were lysed. Cells were stained to identify populations and sorted using 

 the BD FacsFusion in the Georgia Institute of Technology Cellular Analysis Core for in vivo experiments. The antibody clones used were: anti-CD31 (390, BioLegend), anti-CD45.2 (104, BioLegend), anti-CD19 (6D5, Biolegend), anti-CD3 (17A2, Biolegend), anti-CD8a (53-6.7, Biolegend), and anti-CD4 (GK1.5, Biolegend). </div>
    <div id="p0331" num="0331" class="description-paragraph"> [0188] PCR Amplification for Illumina Sequencing. All samples were amplified and prepared for sequencing using nested PCR.2 ^L of primers were added to 5 ^L of Kapa HiFi 2X master mix, and 3 ^L template DNA/water. The second PCR, added Nextera XT chemistry, indices and i5/i7 adapter regions. Dual-indexed samples were run on a 2% agarose gel to ensure that PCR reaction occurred before being pooled and gel purified. </div>
    <div id="p0332" num="0332" class="description-paragraph"> [0189] Deep Sequencing. Illumina sequencing was conducted in Georgia Institute of Technologys Molecular Evolution core. Runs were performed on an Illumina Miniseq. Primers were designed based on Nextera XT adapter sequences. </div>
    <div id="p0333" num="0333" class="description-paragraph"> [0190] Barcode Sequencing Normalization. Counts for each particle, per cell type, were normalized to the barcoded LNP mixture applied to cells or injected into the mouse. </div>
    <div id="p0334" num="0334" class="description-paragraph"> [0191] TNS Assay. The pKa of 7C1 and BM1 was measured as previously described (Dahlman, J.E., et al., Nat Nano, 9:648-655 (2014)). Briefly, a stock solution of 10mM HEPES (Sigma), 10mM MES (Sigma), 10mM sodium acetate (Sigma), and 140nM sodium chloride (Sigma) was prepared and pH adjusted with hydrogen chloride and sodium hydroxide to a range of pH between 4 and 10. Using 4 replicates for each nanoparticle at each pH, 140 mL pH-adjusted buffer was added to a 96-well plate, followed by the addition 5 mL of 2-(p-toluidino)-6-napthalene sulfonic acid (60 mg / mL). 5uL of each nanoparticle was added to each well. After 5 minutes of incubation under gentle shaking, fluorescence absorbance was measured using excitation wavelengths of 325 nm and emission wavelength of 435nm. </div>
    <div id="p0335" num="0335" class="description-paragraph"> [0192] RNA interference. siRNAs were chemically modified at the 2 position to increase stability and negate immunostimulation. 72 hours after injection, tissues were isolated and protein expression was determined via flow cytometry. GFP mean fluorescent intensity in PBS-treated mice was normalized to 100 percent. </div>
    <div id="p0336" num="0336" class="description-paragraph"> [0193] In vivo Cas9 Editing. Mice constitutively expressing SpCas9 were injected with cLNP carrying 2 mg / kg of sgGFP. 5 days after injection, cells were isolated via FACS. Indels were measured by TIDES. 

 Results: </div>
    <div id="p0337" num="0337" class="description-paragraph"> [0194] LNP delivery of siRNA to target cells (in this case, T lymphocytes) as well as 8 off-target cell types in vivo was evaluated. siGFP chemically modified to reduce immunostimulation and enhance on-target silencing via preferential antisense RISC loading (Fig. S2A) was used. Studying 1 LNP per group, and using 5 mice / group, this screen would require &gt;500 mice and significant time / flow cytometry resources. Therefore a DNA barcode-based screen was developed to evaluate how over 100 LNPs functionally delivered siGFP, in any combination of target cells, in a single mouse (Fig. 2A). LNP-1, with chemical structure 1, was formulated to carry siGFP and DNA barcode 1. LNP-N, with chemical structure N, was separately formulated to carry siGFP and DNA barcode N. Naked barcodes were also included as an experimental control (Paunovska, K., et al., Nano Lett, 18:2148-2157 (2018)), since DNA does not readily cross the cell bilayer. The LNPs were pooled together, and intravenously injected into mice that constitutively express GFP under a CAG promoter (Fig. 2B). The GFP acted as the functional delivery readout. It was hypothesized that LNPs which functionally delivered siGFP into the cytoplasm would have lower GFP protein expression. Thus, 3 days after injecting mice, GFP<sup>Low</sup> cells were isolated using fluorescence activated cell sorting (FACS), and deep sequenced to quantify the efficiency with which all N LNPs delivered barcodes into the cells. Normalized delivery, i.e., the number of barcodes for each individual barcode, normalized by the total number of barcode counts within that sample, was used. Normalized delivery can be used to analyze barcoded LNP datasets and is analogous to counts per million in RNAseq experiments (Lokugamage, M.P., et al., Current Opinion in Biomedical Engineering, 7:1-8 (2018)). Since GFP is expressed in all cell types, this assay can (i) compare GFP knockdown in any combination of on- / off-target cells and (ii) quickly identify LNPs that co-localized in GFPLow cells, all in a single animal. </div>
    <div id="p0338" num="0338" class="description-paragraph"> [0195] Three days after injecting a total dose of 1.5 mg / kg into mice (100 distinct LNPs, 0.015 mg / kg / particle on average), GFP silencing was quantified in 9 cell types. Compared to PBS treated mice, there was an increased number of GFP<sup>Low</sup> splenic B cells and splenic T cells (Fig. 2C). The average GFP protein silencing, quantified by mean fluorescent intensity, was highest in splenic T cells, followed by liver immune cells, splenic B cells, and lung endothelial cells (Fig.2D). Surprisingly, no evidence of silencing was found in hepatocytes, a cell type that is preferentially targeted12-15 by most LNPs (Fig.2C,D). To check the quality of this dataset, the 

 GFP<sup>Low</sup> lung splenic T cells were sequenced, and as a further check, lung endothelial cells, splenic B cells, and liver immune cells were also sequenced. In all 4 cell types, the normalized delivery of both negative controls (naked barcodes) was lower than barcodes delivered by LNPs, as expected (Fig.2E). </div>
    <div id="p0339" num="0339" class="description-paragraph"> [0196] A large-scale in vivo structure function analysis using the DNA sequencing data was then performed to evaluate whether any nanoparticle material properties promoted delivery to splenic T cells. The enrichment for different nanoparticle properties was calculated. Enrichment is the odds a nanoparticle with a particular property would show up by chance in particles that (i) performed in the top 10%, and separately, (ii) particles that performed in the bottom 10% was calculated. Nanoparticles formulated with DSPC were enriched in effective particles, whereas nanoparticles formulated with DOPE were enriched in particles that performed poorly (Fig. 2F). To confirm these results, the normalized delivery for all LNPs formulated with DSPC and DOPE, respectively, was compared. DSPC-containing LNPs outperformed DOPE-containing LNPs (Fig. 2G). Finally, the normalized delivery ofpaired LNPs was calculated, i.e., LNPs that had the same molar ratios and ionizable lipids (but different phospholipids). The specific DSPC LNPs that significantly outperformed their paired DOPE containing LNP were identified (Fig. 2H). Based on these data, it was concluded that the phospholipid contained within the LNP affected splenic T cell delivery. Having observed the impact of phospholipid, future chemical analysis was limited to DSPC containing formulations. </div>
    <div id="p0340" num="0340" class="description-paragraph"> [0197] The same enrichment analyses were performed for the 13 ionizable lipids, for both the lipid tail and head group. 3 ionizable lipids were enriched (Fig.2I). To elucidate if the headgroup of the ionizable lipid impacted enrichment, enrichment of each headgroup versus headgroup molecular weight, hydrophobicity (LogP), and polar surface area were plotted (Figures. 4A-4C, Table 1). No correlations were observed between these chemical traits and enrichment. The lipid that was most enriched, 11-A, contained a conformationally constrained adamantane tail. The enrichment of 11-A was compared with 11-L and 11-S, two lipids with the same headgroup (11), but different second lipid tails. To determine if the difference in enrichment was due to the structural transformation of the second lipid tail, the normalized DNA delivery of each lipid was analyzed. 11-A resulted in significantly more delivery than 11-L and 11-S (Fig. 2J). A paired analysis was performed using compounds with the same molar ratio. Adamantane containing tails outperformed other tail structure (Figure 4D). Normalized T cell delivery was plotted against LNP 

 size, and no relationship was found (Figure 4E). Taken together, these data suggest that for monodisperse LNPs with hydrodynamic diameters between 30 and 170 nm, LNP chemical structure affects delivery more than size. Table 1: Enrichment of LNPs with Various Headgroups </div>
    <div id="p0341" num="0341" class="description-paragraph"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/76/db/464a56e90a5e3d/imgf000059_0002.png"><img id="imgf000059_0002" he="84" wi="158" file="imgf000059_0002.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes" width="632" height="336" alt="Figure imgf000059_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d1/76/db/464a56e90a5e3d/imgf000059_0002.png"/></a></div> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1b/07/9f/6fd2a0a8090cab/imgf000059_0001.png"><img id="imgf000059_0001" he="84" wi="157" file="imgf000059_0001.tif" img-format="tif" img-content="table" orientation="portrait" inline="yes" width="628" height="336" alt="Figure imgf000059_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1b/07/9f/6fd2a0a8090cab/imgf000059_0001.png"/></a></div>
 Example 4. cLNPs deliver small RNAs that change gene expression in CD8<sup>+</sup> T cells. Materials and Methods: </div>
    <div id="p0342" num="0342" class="description-paragraph">See materials and methods sections above. Results: </div>
    <div id="p0343" num="0343" class="description-paragraph"> [0198] Like all high throughput screening systems, the value of the siGFP / DNA barcode assay is related to its ability to make predictions. Based on the sequencing data, a nanoparticle was selected for further investigation (Figures. 3A-3B). Based on enrichment analysis, this cLNP contained a constrained lipid as well as DSPC. Over the course of several experiments, the LNP was formulated with a control siRNA targeting Luciferase (siLuc) or siGFP, and intravenously injected into mice at doses between 0.5 mg / kg and 2.0 mg / kg (Fig. 3C,D). Compared to T cells isolated from mice treated with PBS or siLuc, T cells isolated from mice treated with siGFP had reduced GFP expression. Notably, robust protein silencing was observed 

 at doses as low as 0.5 mg / kg (Fig.3C,D). GFP protein expression was measured in subsets of T cells, namely CD4+ and CD8+, observing more potent protein silencing in CD8+ T cells (Fig.3E). Additionally, GFP silencing was quantified in 6 off-target cell types in the liver and the spleen. No significant silencing was observed at doses of 0.5 mg / kg and 1.5 mg / kg (Fig. S4A-F), suggesting that these cLNPs preferentially silence genes in splenic CD8+ T cells. </div>
    <div id="p0344" num="0344" class="description-paragraph"> [0199] To confirm the efficacy of the novel cLNP with a gene editing payload, the lead cLNP carrying sgRNA targeting GFP was injected into mice (Platt, R.J., et al., Cell, 159:440-445 (2014)) constitutively expressing Cas9 and GFP at a dose of 2.0 mg / kg. After five days, GFP expression was measured in CD3+ T cells as well as in CD4+ and CD8+ T cells. Similar to the observed CD8+ tropism with siRNA, more potent protein silencing was observed in CD8+ than in CD4+ T cells (Fig. 3F). Additionally, this decrease in GFP expression was coupled with an increase in % GFP<sup>Low</sup> CD8+ T cells (Fig. 3G). Taken together, these data led to the conclusion that cLNPs without targeting ligands can deliver siRNA to splenic T cells at doses below 1 mg / kg. cLNPs were well tolerated at doses of siRNA and sgRNA in all experiments as indicated by no observed weight loss 24hrs after administration </div>
    <div id="p0345" num="0345" class="description-paragraph"> [0200] Nanoparticles targeting non-hepatocytes are notoriously difficult to design (Lorenzer, C., et al., J Control Release, 203:1-15 (2015)), in large part because there is no high throughput method to study nanoparticle siRNA delivery in vivo. This universal problem in nanomedicine slows the development of all RNA therapies, since scientists are forced to perform high throughput nanoparticle assays in vitro, even though cell culture does not recapitulate all the factors (heterogenous vasculature (Augustin, H.G., et al., Science, 357 (2017), complex microenvironment (MacParland, S.A., et al., ACS Nano, 11:2428-2443 (2017), off-target cells (Tavares, A.J., et al., PNAS, 114:E10871-e10880 (2017), differential blood flow rates (Tsoi, K.M. et al., Nat Mater, 15:1212-1221 (2016)) that affect delivery in vivo. Notably, the results from the screen predicted that preferential T cell delivery would occur; these data were confirmed with a LNP selected from the library. These data provide compelling evidence that high throughput in vivo siRNA screens can rapidly identify nanoparticles with novel tropism. </div>
    <div id="p0346" num="0346" class="description-paragraph"> [0201] While in the foregoing specification this invention has been described in relation to certain embodiments thereof, and many details have been put forth for the purpose of illustration, it will be apparent to those skilled in the art that the invention is susceptible to 

 additional embodiments and that certain of the details described herein can be varied considerably without departing from the basic principles of the invention. </div>
    <div id="p0347" num="0347" class="description-paragraph"> [0202] All references cited herein are incorporated by reference in their entirety. The subject matter described herein may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the subject matter described herein. 
</div>
  </div>
  </div>
  </section>

  <section itemprop="claims" itemscope>
    <h2>Claims</h2>
    
    <div itemprop="content" html><div mxw-id="PCLM280916577" lang="EN" load-source="WIPO-OCR" class="claims ocr">
    <claim-statement>We claim: </claim-statement>
    <claim id="clm-0001" num="1">
      <div class="claim-text"> 1. A compound of Formula (I): </div>
      <div class="claim-text"> , 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/fa/d1/2be83d028831d7/imgf000062_0001.png"><img id="imgf000062_0001" he="130" wi="149" file="imgf000062_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="596" height="520" alt="Figure imgf000062_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a5/fa/d1/2be83d028831d7/imgf000062_0001.png"/></a></div>
 , 

</div>
      <div class="claim-text">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/38/71/ef/3b0bda984bcf29/imgf000063_0001.png"><img id="imgf000063_0001" he="105" wi="149" file="imgf000063_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="596" height="420" alt="Figure imgf000063_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/38/71/ef/3b0bda984bcf29/imgf000063_0001.png"/></a></div>
      </div>
      <div class="claim-text"> R3 and R4 are each independently 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/32/47/30/6fb418646384d4/imgf000063_0002.png"><img id="imgf000063_0002" he="19" wi="149" file="imgf000063_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="596" height="76" alt="Figure imgf000063_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/32/47/30/6fb418646384d4/imgf000063_0002.png"/></a></div>
 2. A compound of Formula (III): </div>
      <div class="claim-text">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/0a/a4/bb855eed23a482/imgf000063_0003.png"><img id="imgf000063_0003" he="45" wi="80" file="imgf000063_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="320" height="180" alt="Figure imgf000063_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/0a/a4/bb855eed23a482/imgf000063_0003.png"/></a></div>
      </div>
      <div class="claim-text"> R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, and R<sub>9</sub> are each independently: -C<sub>8</sub>H<sub>17</sub>, -C<sub>10</sub>H<sub>21</sub>, -C<sub>12</sub>H<sub>25</sub>, -C<sub>13</sub>H<sub>27</sub>, - C<sub>14</sub>H<sub>29</sub>, C<sub>16</sub>H<sub>33</sub>, or adamantanyl, </div>
      <div class="claim-text"> m and n are each independently 0, 1, </div>
    </claim>
    <claim id="clm-0002" num="2">
      <div class="claim-text">2, 3, or 4; 

</div>
      <div class="claim-text"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/fd/e6/fc5766637a4164/imgf000064_0004.png"><img id="imgf000064_0004" he="66" wi="150" file="imgf000064_0004.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="yes" width="600" height="264" alt="Figure imgf000064_0004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/fd/e6/fc5766637a4164/imgf000064_0004.png"/></a></div>
 R10 and R11 are each independentlyH or
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4a/7c/6c/d23ef652bb7a21/imgf000064_0001.png"><img id="imgf000064_0001" he="11" wi="21" file="imgf000064_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="84" height="44" alt="Figure imgf000064_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4a/7c/6c/d23ef652bb7a21/imgf000064_0001.png"/></a></div>
 and </div>
      <div class="claim-text"> R12 is -C10H21. </div>
    </claim>
    <claim id="clm-0003" num="3">
      <div class="claim-text">3. The compound of claim 1, wherein R2 is 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3c/f2/2e/b72774a13f4525/imgf000064_0002.png"><img id="imgf000064_0002" he="11" wi="34" file="imgf000064_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="136" height="44" alt="Figure imgf000064_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3c/f2/2e/b72774a13f4525/imgf000064_0002.png"/></a></div>
 or 
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/05/7f/38/c245cc95445f2f/imgf000064_0003.png"><img id="imgf000064_0003" he="13" wi="35" file="imgf000064_0003.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="140" height="52" alt="Figure imgf000064_0003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/05/7f/38/c245cc95445f2f/imgf000064_0003.png"/></a></div>
 . </div>
    </claim>
    <claim id="clm-0004" num="4">
      <div class="claim-text">4. A lipid nanoparticle composition comprising: </div>
      <div class="claim-text"> a conformationally constrained ionizable lipid; </div>
      <div class="claim-text"> a phospholipid; </div>
      <div class="claim-text"> a polyethylene glycol-lipid; </div>
      <div class="claim-text"> a cholesterol; and optionally </div>
      <div class="claim-text"> a nucleic acid. </div>
    </claim>
    <claim id="clm-0005" num="5">
      <div class="claim-text">5. The lipid nanoparticle composition of claim 4, wherein the conformationally constrained ionizable lipid comprises a structure according to claim 1 or 2. </div>
    </claim>
    <claim id="clm-0006" num="6">
      <div class="claim-text">6. The lipid nanoparticle composition of claim 4 or 5, wherein the amount of conformationally constrained ionizable lipid present is in the range of about 35 to about 65 mole percent, based on total moles. 

</div>
    </claim>
    <claim id="clm-0007" num="7">
      <div class="claim-text">7. The lipid nanoparticle composition of any one of claims 4-6, wherein the conformationally constrained ionizable lipid has a structure according to </div>
      <div class="claim-text"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fc/9e/59/af0c0b9e8aef48/imgf000065_0001.png"><img id="imgf000065_0001" he="40" wi="129" file="imgf000065_0001.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="516" height="160" alt="Figure imgf000065_0001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fc/9e/59/af0c0b9e8aef48/imgf000065_0001.png"/></a></div>
 . </div>
    </claim>
    <claim id="clm-0008" num="8">
      <div class="claim-text">8. The lipid nanoparticle composition of any one of claims 4-6, wherein the conformationally constrained ionizable lipid has a structure according to </div>
      <div class="claim-text"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dd/cc/1d/85606d918d1f7d/imgf000065_0002.png"><img id="imgf000065_0002" he="40" wi="128" file="imgf000065_0002.tif" img-format="tif" img-content="drawing" orientation="portrait" inline="no" width="512" height="160" alt="Figure imgf000065_0002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dd/cc/1d/85606d918d1f7d/imgf000065_0002.png"/></a></div>
 . </div>
    </claim>
    <claim id="clm-0009" num="9">
      <div class="claim-text">9. The lipid nanoparticle composition of any one of claims 4-8, wherein the phospholipid is 1-2-distearoyl-sn-glycero-3-phosphocholine (DSPC). </div>
    </claim>
    <claim id="clm-0010" num="10">
      <div class="claim-text">10. The lipid nanoparticle composition of any one of claims 4-9, wherein the polyethylene glycol-lipid is C14PEG2000 or C18PEG2000. </div>
    </claim>
    <claim id="clm-0011" num="11">
      <div class="claim-text">11. The lipid nanoparticle composition of any one of claims 4, 5 or 7-10, wherein the composition comprises about 30 mol % to about 70 mol % conformationally constrained ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 25 mol % to about 45 mol % cholesterol, and about 0.1 mol % to about 5 mol % polyethylene glycol-lipid. </div>
    </claim>
    <claim id="clm-0012" num="12">
      <div class="claim-text">12. The lipid nanoparticle composition of any one of claims 4-11, wherein the nucleic acid comprises RNA, DNA, single-stranded RNA, single-stranded DNA, double-stranded RNA, 

 double stranded DNA, triple-stranded DNA, siRNA, shRNA, sgRNA, mRNA, miRNA, antisense DNA, or a combination thereof. </div>
    </claim>
    <claim id="clm-0013" num="13">
      <div class="claim-text">13. The lipid nanoparticle composition of any one of claims 4-12, wherein the nucleic acid encodes a protein. </div>
    </claim>
    <claim id="clm-0014" num="14">
      <div class="claim-text">14. The lipid nanoparticle composition of any one of claims 4-13,wherein the nucleic acid encodes an RNA-guided DNA endonuclease. </div>
    </claim>
    <claim id="clm-0015" num="15">
      <div class="claim-text">15. The lipid nanoparticle composition of claim 14, wherein the RNA-guided DNA endonuclease is Cas9, CasX, CasY, Cas13, or Cpf1. </div>
    </claim>
    <claim id="clm-0016" num="16">
      <div class="claim-text">16. The nanoparticle composition of any one of claims 4-12, wherein the lipid nanoparticle has a hydrodynamic diameter in the range of from about 30 nm to about 170 nm. </div>
    </claim>
    <claim id="clm-0017" num="17">
      <div class="claim-text">17. A lipid nanoparticle composition comprising: </div>
      <div class="claim-text"> a conformationally constrained ionizable lipid comprising an adamantane tail; 1-2-distearoyl-sn-glycero-3-phosphocholine (DSPC); </div>
      <div class="claim-text"> C<sub>14</sub>PEG<sub>2000</sub>; </div>
      <div class="claim-text"> cholesterol; and </div>
      <div class="claim-text"> siRNA. </div>
    </claim>
    <claim id="clm-0018" num="18">
      <div class="claim-text">18. The lipid nanoparticle of claim 17, wherein the conformationally constrained ionizable lipid is 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate. </div>
    </claim>
    <claim id="clm-0019" num="19">
      <div class="claim-text">19. The lipid nanoparticle of claim 17 or 18, wherein C<sub>14</sub>PEG<sub>2000</sub> is present at about 2.0 to about 3.0 mole percent, DSPC is present at about 15 to about 17 mole percent, cholesterol is present at about 45 to about 47 mole percent, the conformationally constrained ionizable lipid is present at about 33 to about 36 mole percent, and the siRNA is present at 5 to 20 mass ratio of total lipid to siRNA. 

</div>
    </claim>
    <claim id="clm-0020" num="20">
      <div class="claim-text">20. The lipid nanoparticle of any one of claims 17-19, wherein C<sub>14</sub>PEG<sub>2000</sub> is present at about 2.5 mole percent, DSPC is present at about 16 mole percent, cholesterol is present at about 46.5 mole percent, and the conformationally constrained ionizable lipid is present at about 35 mole percent. </div>
    </claim>
    <claim id="clm-0021" num="21">
      <div class="claim-text">21. A pharmaceutical composition comprising the lipid nanoparticle composition of any one of claims 4-20, and a pharmaceutically acceptable excipient. </div>
    </claim>
    <claim id="clm-0022" num="22">
      <div class="claim-text">22. A method of delivering a nucleic acid to a subject in need thereof, comprising, administering to the subject the lipid nanoparticle composition of any one of claims 4-20 or the pharmaceutical composition of claim 21. </div>
    </claim>
    <claim id="clm-0023" num="23">
      <div class="claim-text">23. The method of claim 22, further comprising administering a second therapeutic agent to the subject. </div>
    </claim>
    <claim id="clm-0024" num="24">
      <div class="claim-text">24. A method of delivering a nucleic acid to an immune cell in a subject in need thereof, comprising: </div>
      <div class="claim-text"> administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate; </div>
      <div class="claim-text"> DSPC; </div>
      <div class="claim-text"> a polyethylene glycol-lipid; </div>
      <div class="claim-text"> a cholesterol; and </div>
      <div class="claim-text"> a nucleic acid, </div>
      <div class="claim-text"> wherein the lipid nanoparticle composition delivers the nucleic acid to the immune cell in the subject. </div>
    </claim>
    <claim id="clm-0025" num="25">
      <div class="claim-text">25. The method of claim 24, wherein the lipid nanoparticle composition does not contain a targeting ligand that targets the lipid nanoparticle composition to the immune cell. </div>
    </claim>
    <claim id="clm-0026" num="26">
      <div class="claim-text">26. The method of claim 24 or 25, wherein the immune cell is a T cell. 

</div>
    </claim>
    <claim id="clm-0027" num="27">
      <div class="claim-text">27. The method of claim 26, wherein the T cell is a CD8+ T cell. </div>
    </claim>
    <claim id="clm-0028" num="28">
      <div class="claim-text">28. The method of claim 26, wherein the T cell is a T regulatory cell. </div>
    </claim>
    <claim id="clm-0029" num="29">
      <div class="claim-text">29. The method of claim 26, wherein the T cell is CD4+. </div>
    </claim>
    <claim id="clm-0030" num="30">
      <div class="claim-text">30. The method of claim 24 or 25, wherein the immune cell is a macrophage, dendritic cell, or liver immune cell. </div>
    </claim>
    <claim id="clm-0031" num="31">
      <div class="claim-text">31. A method for reducing splenic or hepatic clearance of a nanoparticle composition comprising formulating the nanoparticle composition with an amount of a conformationally constrained ionizable lipid that is effective to reduce or inhibit splenic or hepatic clearance of the nanoparticle composition when administered to a subject. </div>
    </claim>
    <claim id="clm-0032" num="32">
      <div class="claim-text">32. The method of claim 31, wherein the conformationally constrained ionizable lipid comprises a structure according to claim 1 or 2. </div>
    </claim>
    <claim id="clm-0033" num="33">
      <div class="claim-text">33. A method for increasing delivery of a nanoparticle composition to non-hepatocyte cells in a subject comprising formulating the nanoparticle composition to comprise an amount of a conformationally constrained ionizable lipid that is effective to increase delivery of the nanoparticle composition to non-hepatocyte cells when administered to the subject. </div>
    </claim>
    <claim id="clm-0034" num="34">
      <div class="claim-text">34. The method of claim 33, wherein the conformationally constrained ionizable lipid comprises a structure according to claim 1 or 2. </div>
    </claim>
    <claim id="clm-0035" num="35">
      <div class="claim-text">35. The method of claim 33 or 34, wherein the nanoparticle composition is a lipid nanoparticle pharmaceutical composition. </div>
    </claim>
    <claim id="clm-0036" num="36">
      <div class="claim-text">36. The method of claim 35, wherein the lipid nanoparticle pharmaceutical composition comprises a phospholipid, a polyethylene glycol-lipid, a cholesterol, and optionally a first nucleic acid. 

</div>
    </claim>
    <claim id="clm-0037" num="37">
      <div class="claim-text">37. The method of any one of claims 33-36, wherein the non-hepatocyte cells are at least one of splenic B cells, splenic T cells, lung endothelial cells, and liver immune cells. </div>
    </claim>
    <claim id="clm-0038" num="38">
      <div class="claim-text">38. The method of any one of claims 33-37, wherein the nanoparticle composition further comprises a second nucleic acid that is delivered to the subject in an amount in the range of about 0.5 mg/kg to about 2.0 mg/kg. </div>
    </claim>
    <claim id="clm-0039" num="39">
      <div class="claim-text">39. The method of claim 38, wherein the amount of the second nucleic acid delivered to the subject is less than about 1.0 mg/kg. </div>
    </claim>
    <claim id="clm-0040" num="40">
      <div class="claim-text">40. A method for reducing gene expression in an immune cell in a subject in need thereof, comprising: </div>
      <div class="claim-text"> administering to the subject a lipid nanoparticle composition consisting of 3-[(1-Adamantanyl)acetoxy]-2-{[3- (diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate; </div>
      <div class="claim-text"> DSPC; </div>
      <div class="claim-text"> a polyethylene glycol-lipid; </div>
      <div class="claim-text"> cholesterol; and </div>
      <div class="claim-text"> an inhibitory nucleic acid, </div>
      <div class="claim-text"> wherein the lipid nanoparticle composition delivers the inhibitory nucleic acid to the immune cell in the subject. </div>
    </claim>
    <claim id="clm-0041" num="41">
      <div class="claim-text">41. The method of claim 40, wherein the inhibitory nucleic acid is siRNA. </div>
    </claim>
    <claim id="clm-0042" num="42">
      <div class="claim-text">42. The method of claim 40 or 41, wherein the amount of the inhibitory nucleic acid administered to the subject is less than about 1.0 mg/kg. </div>
    </claim>
    <claim id="clm-0043" num="43">
      <div class="claim-text">43. The method of claim 42, wherein the amount of inhibitory nucleic acid administered to the subject is about 0.5 mg/kg. </div>
    </claim>
    <claim id="clm-0044" num="44">
      <div class="claim-text">44. A method for editing a gene in an immune cell in a subject in need thereof, comprising: 

 administering to the subject a lipid nanoparticle composition comprising a first and second population of lipid nanoparticles, </div>
      <div class="claim-text"> wherein the first population of lipid nanoparticles consists of 3-[(1- Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and sgRNA specific for the gene, and </div>
      <div class="claim-text"> wherein the second population of lipid nanoparticles consists of 3-[(1- Adamantanyl)acetoxy]-2-{[3-(diethylamino)propoxycarbonyloxy]methyl}propyl (9Z,12Z)-9,12-octadecadienoate, DSPC, a polyethylene glycol-lipid, cholesterol, and mRNA encoding an RNA guided DNA endonuclease. </div>
    </claim>
    <claim id="clm-0045" num="45">
      <div class="claim-text">45. The method of claim 44, wherein the RNA guided DNA endonuclease is selected from the group consisting of Cas9, CasX, CasY, Cas13, and Cpf1. </div>
    </claim>
    <claim id="clm-0046" num="46">
      <div class="claim-text">46. The method of claim 44 or 45, wherein the amount of one or both of the sgRNA and mRNA administered to the subject is less than about 1.0 mg/kg. </div>
    </claim>
    <claim id="clm-0047" num="47">
      <div class="claim-text">47. The method of claim 46, wherein the amount of one or both of the sgRNA and mRNA administered to the subject is about 0.5 mg/kg. 
</div>
    </claim>
  </div>
  </div>
  </section>

  <section itemprop="application" itemscope>

    <section itemprop="metadata" itemscope>
      <span itemprop="applicationNumber">PCT/US2020/043512</span>
      <span itemprop="priorityDate">2019-07-29</span>
      <span itemprop="filingDate">2020-07-24</span>
      <span itemprop="title">Nanomaterials containing constrained lipids and uses thereof 
       </span>
      <span itemprop="ifiStatus">Ceased</span>
      
      <a href="/patent/WO2021021634A1/en">
        <span itemprop="representativePublication">WO2021021634A1</span>
        (<span itemprop="primaryLanguage">en</span>)
      </a>
    </section>

    <h2>Priority Applications (7)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">CA3145913A</span>
            
            <a href="/patent/CA3145913A1/en">
              <span itemprop="representativePublication">CA3145913A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">Nanomaterials containing constrained lipids and uses thereof 
     </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">KR1020227006660A</span>
            
            <a href="/patent/KR20220040484A/en">
              <span itemprop="representativePublication">KR20220040484A</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">
        Nanomaterials containing constrained lipids and uses thereof
       
     </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US17/630,861</span>
            
            <a href="/patent/US20220273566A1/en">
              <span itemprop="representativePublication">US20220273566A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">Nanomaterials containing constrained lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">CN202080068505.5A</span>
            
            <a href="/patent/CN114502542A/en">
              <span itemprop="representativePublication">CN114502542A</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">Nanomaterials comprising restricted lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">AU2020323897A</span>
            
            <a href="/patent/AU2020323897A1/en">
              <span itemprop="representativePublication">AU2020323897A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">Nanomaterials containing constrained lipids and uses thereof 
     </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">EP20846355.4A</span>
            
            <a href="/patent/EP4003967A4/en">
              <span itemprop="representativePublication">EP4003967A4</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">
        CONSTRAINED LIPID-CONTAINING NANOMATERIALS AND CORRESPONDING USES
       
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">JP2022506087A</span>
            
            <a href="/patent/JP7600208B2/en">
              <span itemprop="representativePublication">JP7600208B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">
        Nanomaterials containing constrained lipids and uses thereof - Patents.com
       
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Applications Claiming Priority (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201962879731P</span>
            
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2019-07-29</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US62/879,731</span>
            
          </td>
          <td itemprop="priorityDate"></td>
          <td itemprop="filingDate">2019-07-29</td>
          <td itemprop="title"></td>
        </tr>
      </tbody>
    </table>

    

    

    <h2>Publications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Publication Number</th>
          <th>Publication Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">WO2021021634A1</span>
            
            <span itemprop="thisPatent">true</span>
            <a href="/patent/WO2021021634A1/en">
              WO2021021634A1
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-02-04</td>
        </tr>
      </tbody>
    </table>

  </section>

  <section itemprop="family" itemscope>
    <h1>Family</h1>
    <h2>ID=74228270</h2>

    <h2>Family Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/US2020/043512</span>
            <span itemprop="ifiStatus">Ceased</span>
            
            <a href="/patent/WO2021021634A1/en">
              <span itemprop="representativePublication">WO2021021634A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2019-07-29</td>
          <td itemprop="filingDate">2020-07-24</td>
          <td itemprop="title">Nanomaterials containing constrained lipids and uses thereof 
       </td>
        </tr>
      </tbody>
    </table>

    

    

    <h2>Country Status (8)</h2>
    <table>
      <thead>
        <tr>
          <th>Country</th>
          <th>Link</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">US</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/US20220273566A1/en">
              <span itemprop="representativePublication">US20220273566A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">EP</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/EP4003967A4/en">
              <span itemprop="representativePublication">EP4003967A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">JP</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/JP7600208B2/en">
              <span itemprop="representativePublication">JP7600208B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">KR</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/KR20220040484A/en">
              <span itemprop="representativePublication">KR20220040484A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CN</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CN114502542A/en">
              <span itemprop="representativePublication">CN114502542A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">AU</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/AU2020323897A1/en">
              <span itemprop="representativePublication">AU2020323897A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CA</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CA3145913A1/en">
              <span itemprop="representativePublication">CA3145913A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">WO</span>
            (<span itemprop="num">1</span>)
            <meta itemprop="thisCountry" content="true">
          </td>
          <td>
            <a href="/patent/WO2021021634A1/en">
              <span itemprop="representativePublication">WO2021021634A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
      </tbody>
    </table>

    <h2>Cited By (24)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US20210169804A1/en">
              <span itemprop="publicationNumber">US20210169804A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-12-06</td>
          <td itemprop="publicationDate">2021-06-10</td>
          <td><span itemprop="assigneeOriginal">Guide Therapeutics, Inc.</span></td>
          <td itemprop="title">Nanomaterials 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/CN113637708A/en">
              <span itemprop="publicationNumber">CN113637708A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-08-09</td>
          <td itemprop="publicationDate">2021-11-12</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">CRISPR-cas9 gene editing system delivery vector and preparation method and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/CN114436994A/en">
              <span itemprop="publicationNumber">CN114436994A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-26</td>
          <td itemprop="publicationDate">2022-05-06</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Adamantane tailed lipids and their application in cell transfection
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2022221697A1/en">
              <span itemprop="publicationNumber">WO2022221697A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-04-17</td>
          <td itemprop="publicationDate">2022-10-20</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023044343A1/en">
              <span itemprop="publicationNumber">WO2023044343A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-14</td>
          <td itemprop="publicationDate">2023-03-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Acyclic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023044333A1/en">
              <span itemprop="publicationNumber">WO2023044333A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-14</td>
          <td itemprop="publicationDate">2023-03-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023122611A1/en">
              <span itemprop="publicationNumber">WO2023122611A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-12-23</td>
          <td itemprop="publicationDate">2023-06-29</td>
          <td><span itemprop="assigneeOriginal">Georgia Tech Research Corporation</span></td>
          <td itemprop="title">Ionizable lipids with bioactive motifs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023133089A1/en">
              <span itemprop="publicationNumber">WO2023133089A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-04</td>
          <td itemprop="publicationDate">2023-07-13</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Ionizable lipids for multiple organ targeting 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023230601A1/en">
              <span itemprop="publicationNumber">WO2023230601A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-27</td>
          <td itemprop="publicationDate">2023-11-30</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Identification of nanoparticles for preferential tissue or cell targeting 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024006960A1/en">
              <span itemprop="publicationNumber">WO2024006960A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-06-29</td>
          <td itemprop="publicationDate">2024-01-04</td>
          <td><span itemprop="assigneeOriginal">Juno Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11865190B2/en">
              <span itemprop="publicationNumber">US11865190B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-10-09</td>
          <td itemprop="publicationDate">2024-01-09</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024102677A1/en">
              <span itemprop="publicationNumber">WO2024102677A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-08</td>
          <td itemprop="publicationDate">2024-05-16</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12059477B2/en">
              <span itemprop="publicationNumber">US12059477B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-01-20</td>
          <td itemprop="publicationDate">2024-08-13</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Nanomaterials 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024233308A2/en">
              <span itemprop="publicationNumber">WO2024233308A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-05</td>
          <td itemprop="publicationDate">2024-11-14</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025007148A1/en">
              <span itemprop="publicationNumber">WO2025007148A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-30</td>
          <td itemprop="publicationDate">2025-01-02</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Polymer lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025049690A1/en">
              <span itemprop="publicationNumber">WO2025049690A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-29</td>
          <td itemprop="publicationDate">2025-03-06</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular polyethylene glycol lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12268753B2/en">
              <span itemprop="publicationNumber">US12268753B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-01-20</td>
          <td itemprop="publicationDate">2025-04-08</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Nanomaterials comprising a biodegradable feature 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12296053B2/en">
              <span itemprop="publicationNumber">US12296053B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-07-20</td>
          <td itemprop="publicationDate">2025-05-13</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Nanomaterials comprising triols 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025101501A1/en">
              <span itemprop="publicationNumber">WO2025101501A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-07</td>
          <td itemprop="publicationDate">2025-05-15</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025117969A1/en">
              <span itemprop="publicationNumber">WO2025117969A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-01</td>
          <td itemprop="publicationDate">2025-06-05</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Process for manufacturing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025128871A2/en">
              <span itemprop="publicationNumber">WO2025128871A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-13</td>
          <td itemprop="publicationDate">2025-06-19</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025166238A1/en">
              <span itemprop="publicationNumber">WO2025166238A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-31</td>
          <td itemprop="publicationDate">2025-08-07</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Fast-shedding polyethylene glycol lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12435035B2/en">
              <span itemprop="publicationNumber">US12435035B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-01-09</td>
          <td itemprop="publicationDate">2025-10-07</td>
          <td><span itemprop="assigneeOriginal">Guide Therapeutics, Llc</span></td>
          <td itemprop="title">Nanomaterials 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025250751A1/en">
              <span itemprop="publicationNumber">WO2025250751A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-05-31</td>
          <td itemprop="publicationDate">2025-12-04</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Families Citing this family (15)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014093701A1/en">
              <span itemprop="publicationNumber">WO2014093701A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-12-12</td>
          <td itemprop="publicationDate">2014-06-19</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2016501531A/en">
              <span itemprop="publicationNumber">JP2016501531A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-12-12</td>
          <td itemprop="publicationDate">2016-01-21</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3011033B1/en">
              <span itemprop="publicationNumber">EP3011033B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-06-17</td>
          <td itemprop="publicationDate">2020-02-19</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BR112016013213A2/en">
              <span itemprop="publicationNumber">BR112016013213A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2013-12-12</td>
          <td itemprop="publicationDate">2017-12-05</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Inst Technology</span></td>
          <td itemprop="title">
  administration, use and therapeutic applications of crisper systems and compositions for targeting disorders and diseases using particle delivery components
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3653703A1/en">
              <span itemprop="publicationNumber">EP3653703A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-12</td>
          <td itemprop="publicationDate">2020-05-20</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4219699A1/en">
              <span itemprop="publicationNumber">EP4219699A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-12</td>
          <td itemprop="publicationDate">2023-08-02</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BR112016013207A2/en">
              <span itemprop="publicationNumber">BR112016013207A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-12</td>
          <td itemprop="publicationDate">2017-09-26</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Inst Technology</span></td>
          <td itemprop="title">
        administration, use and therapeutic applications of crisp systems and compositions for hbv and viral disorders and diseases
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2015369725A1/en">
              <span itemprop="publicationNumber">AU2015369725A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-12-24</td>
          <td itemprop="publicationDate">2017-06-29</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">CRISPR having or associated with destabilization domains 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG10201912329YA/en">
              <span itemprop="publicationNumber">SG10201912329YA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-06-18</td>
          <td itemprop="publicationDate">2020-02-27</td>
          <td><span itemprop="assigneeOriginal">Broad Inst Inc</span></td>
          <td itemprop="title">Crispr Enzyme Mutations Reducing Off-Target Effects 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2016205759A1/en">
              <span itemprop="publicationNumber">WO2016205759A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-06-18</td>
          <td itemprop="publicationDate">2016-12-22</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute Inc.</span></td>
          <td itemprop="title">Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024081639A1/en">
              <span itemprop="publicationNumber">WO2024081639A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-10-11</td>
          <td itemprop="publicationDate">2024-04-18</td>
          <td><span itemprop="assigneeOriginal">Seawolf Therapeutics, Inc.</span></td>
          <td itemprop="title">Novel lipid nanoparticle compositions for the delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115925563B/en">
              <span itemprop="publicationNumber">CN115925563B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-02-28</td>
          <td itemprop="publicationDate">2023-05-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid molecule for targeted pulmonary delivery of nucleic acid, and preparation method and application thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN116199646B/en">
              <span itemprop="publicationNumber">CN116199646B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-03-07</td>
          <td itemprop="publicationDate">2024-01-26</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A Tris-based ionizable lipid and its preparation method and application
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025053636A1/en">
              <span itemprop="publicationNumber">WO2025053636A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-09-05</td>
          <td itemprop="publicationDate">2025-03-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Nucleic acid delivery system using lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025147545A1/en">
              <span itemprop="publicationNumber">WO2025147545A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2024-01-03</td>
          <td itemprop="publicationDate">2025-07-10</td>
          <td><span itemprop="assigneeOriginal">Juno Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles for delivery of nucleic acids and related methods and uses 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Citations (2)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2015095340A1/en">
              <span itemprop="publicationNumber">WO2015095340A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2013-12-19</td>
          <td itemprop="publicationDate">2015-06-25</td>
          <td>
            <span itemprop="assigneeOriginal">Novartis Ag</span>
          </td>
          <td itemprop="title">Lipids and lipid compositions for the delivery of active agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2017173054A1/en">
              <span itemprop="publicationNumber">WO2017173054A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-03-30</td>
          <td itemprop="publicationDate">2017-10-05</td>
          <td>
            <span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span>
          </td>
          <td itemprop="title">Lipid nanoparticle formulations for crispr/cas components 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Family Cites Families (2)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL315314A/en">
              <span itemprop="publicationNumber">IL315314A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-07-11</td>
          <td itemprop="publicationDate">2024-10-01</td>
          <td><span itemprop="assigneeOriginal">Opko Biologics Ltd</span></td>
          <td itemprop="title">
        Long-term coagulation factors and methods for their preparation
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2021012934A/en">
              <span itemprop="publicationNumber">MX2021012934A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-04-25</td>
          <td itemprop="publicationDate">2022-04-06</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics Inc</span></td>
          <td itemprop="title">
        IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES.
       
       </td>
        </tr>
      </tbody>
    </table>

    <ul>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2020</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">AU</span>
            <span itemprop="applicationNumber">AU2020323897A</span>
            <a href="/patent/AU2020323897A1/en"><span itemprop="documentId">patent/AU2020323897A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">CN</span>
            <span itemprop="applicationNumber">CN202080068505.5A</span>
            <a href="/patent/CN114502542A/en"><span itemprop="documentId">patent/CN114502542A/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">KR</span>
            <span itemprop="applicationNumber">KR1020227006660A</span>
            <a href="/patent/KR20220040484A/en"><span itemprop="documentId">patent/KR20220040484A/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Ceased</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US17/630,861</span>
            <a href="/patent/US20220273566A1/en"><span itemprop="documentId">patent/US20220273566A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">CA</span>
            <span itemprop="applicationNumber">CA3145913A</span>
            <a href="/patent/CA3145913A1/en"><span itemprop="documentId">patent/CA3145913A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">EP</span>
            <span itemprop="applicationNumber">EP20846355.4A</span>
            <a href="/patent/EP4003967A4/en"><span itemprop="documentId">patent/EP4003967A4/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">WO</span>
            <span itemprop="applicationNumber">PCT/US2020/043512</span>
            <a href="/patent/WO2021021634A1/en"><span itemprop="documentId">patent/WO2021021634A1/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Ceased</span>
            <span itemprop="thisApp" content="true" bool></span>
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2020-07-24</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2022506087A</span>
            <a href="/patent/JP7600208B2/en"><span itemprop="documentId">patent/JP7600208B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
    </ul>

    </section>

  <section>
    <h2>Patent Citations (2)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferences" itemscope repeat>
          <td>
            <a href="/patent/WO2015095340A1/en">
              <span itemprop="publicationNumber">WO2015095340A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2013-12-19</td>
          <td itemprop="publicationDate">2015-06-25</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">Lipids and lipid compositions for the delivery of active agents 
       </td>
        </tr>
        <tr itemprop="backwardReferences" itemscope repeat>
          <td>
            <a href="/patent/WO2017173054A1/en">
              <span itemprop="publicationNumber">WO2017173054A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-03-30</td>
          <td itemprop="publicationDate">2017-10-05</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulations for crispr/cas components 
       </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Non-Patent Citations (1)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="detailedNonPatentLiterature" itemscope repeat>
          <td>
            <span itemprop="title">See also references of <a href="/patent/EP4003967A4#nplCitations">EP4003967A4</a></span>
            <span itemprop="examinerCited">*</span>
            
          </td>
        </tr>
      </tbody>
    </table>
  </section>

  <h2>Cited By (27)</h2>
  <table>
    <caption>* Cited by examiner,  Cited by third party</caption>
    <thead>
      <tr>
        <th>Publication number</th>
        <th>Priority date</th>
        <th>Publication date</th>
        <th>Assignee</th>
        <th>Title</th>
      </tr>
    </thead>
    <tbody>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11980673B2/en">
            <span itemprop="publicationNumber">US11980673B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-10-09</td>
        <td itemprop="publicationDate">2024-05-14</td>
        <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
        <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11865190B2/en">
            <span itemprop="publicationNumber">US11865190B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-10-09</td>
        <td itemprop="publicationDate">2024-01-09</td>
        <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
        <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US20210169804A1/en">
            <span itemprop="publicationNumber">US20210169804A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2019-12-06</td>
        <td itemprop="publicationDate">2021-06-10</td>
        <td><span itemprop="assigneeOriginal">Guide Therapeutics, Inc.</span></td>
        <td itemprop="title">Nanomaterials 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12435035B2/en">
            <span itemprop="publicationNumber">US12435035B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-01-09</td>
        <td itemprop="publicationDate">2025-10-07</td>
        <td><span itemprop="assigneeOriginal">Guide Therapeutics, Llc</span></td>
        <td itemprop="title">Nanomaterials 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12268753B2/en">
            <span itemprop="publicationNumber">US12268753B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-01-20</td>
        <td itemprop="publicationDate">2025-04-08</td>
        <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
        <td itemprop="title">Nanomaterials comprising a biodegradable feature 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12059477B2/en">
            <span itemprop="publicationNumber">US12059477B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-01-20</td>
        <td itemprop="publicationDate">2024-08-13</td>
        <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
        <td itemprop="title">Nanomaterials 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2022221697A1/en">
            <span itemprop="publicationNumber">WO2022221697A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-04-17</td>
        <td itemprop="publicationDate">2022-10-20</td>
        <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipid nanoparticle compositions 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN113637708B/en">
            <span itemprop="publicationNumber">CN113637708B</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-08-09</td>
        <td itemprop="publicationDate">2023-07-25</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">
        A CRISPR-cas9 gene editing system delivery vector and its preparation method and application
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN113637708A/en">
            <span itemprop="publicationNumber">CN113637708A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-08-09</td>
        <td itemprop="publicationDate">2021-11-12</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">CRISPR-cas9 gene editing system delivery vector and preparation method and application thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023044333A1/en">
            <span itemprop="publicationNumber">WO2023044333A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-14</td>
        <td itemprop="publicationDate">2023-03-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023044343A1/en">
            <span itemprop="publicationNumber">WO2023044343A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-14</td>
        <td itemprop="publicationDate">2023-03-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Acyclic lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023122611A1/en">
            <span itemprop="publicationNumber">WO2023122611A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-12-23</td>
        <td itemprop="publicationDate">2023-06-29</td>
        <td><span itemprop="assigneeOriginal">Georgia Tech Research Corporation</span></td>
        <td itemprop="title">Ionizable lipids with bioactive motifs 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023133089A1/en">
            <span itemprop="publicationNumber">WO2023133089A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-01-04</td>
        <td itemprop="publicationDate">2023-07-13</td>
        <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
        <td itemprop="title">Ionizable lipids for multiple organ targeting 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN114436994B/en">
            <span itemprop="publicationNumber">CN114436994B</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-01-26</td>
        <td itemprop="publicationDate">2024-02-27</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">Adamantane tail chain lipid and application thereof in cell transfection 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN114436994A/en">
            <span itemprop="publicationNumber">CN114436994A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-01-26</td>
        <td itemprop="publicationDate">2022-05-06</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">
        Adamantane tailed lipids and their application in cell transfection
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023230601A1/en">
            <span itemprop="publicationNumber">WO2023230601A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-05-27</td>
        <td itemprop="publicationDate">2023-11-30</td>
        <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
        <td itemprop="title">Identification of nanoparticles for preferential tissue or cell targeting 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024006960A1/en">
            <span itemprop="publicationNumber">WO2024006960A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-06-29</td>
        <td itemprop="publicationDate">2024-01-04</td>
        <td><span itemprop="assigneeOriginal">Juno Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles for delivery of nucleic acids 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12296053B2/en">
            <span itemprop="publicationNumber">US12296053B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-07-20</td>
        <td itemprop="publicationDate">2025-05-13</td>
        <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
        <td itemprop="title">Nanomaterials comprising triols 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024102677A1/en">
            <span itemprop="publicationNumber">WO2024102677A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-11-08</td>
        <td itemprop="publicationDate">2024-05-16</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024233308A2/en">
            <span itemprop="publicationNumber">WO2024233308A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-05-05</td>
        <td itemprop="publicationDate">2024-11-14</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025007148A1/en">
            <span itemprop="publicationNumber">WO2025007148A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-06-30</td>
        <td itemprop="publicationDate">2025-01-02</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Polymer lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025049690A1/en">
            <span itemprop="publicationNumber">WO2025049690A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-08-29</td>
        <td itemprop="publicationDate">2025-03-06</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular polyethylene glycol lipids 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025101501A1/en">
            <span itemprop="publicationNumber">WO2025101501A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-11-07</td>
        <td itemprop="publicationDate">2025-05-15</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025117969A1/en">
            <span itemprop="publicationNumber">WO2025117969A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-12-01</td>
        <td itemprop="publicationDate">2025-06-05</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Process for manufacturing lipid nanoparticles 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025128871A2/en">
            <span itemprop="publicationNumber">WO2025128871A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-12-13</td>
        <td itemprop="publicationDate">2025-06-19</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025166238A1/en">
            <span itemprop="publicationNumber">WO2025166238A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-01-31</td>
        <td itemprop="publicationDate">2025-08-07</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Fast-shedding polyethylene glycol lipids 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025250751A1/en">
            <span itemprop="publicationNumber">WO2025250751A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-05-31</td>
        <td itemprop="publicationDate">2025-12-04</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
    </tbody>
  </table>

  <section>
    <h2>Also Published As</h2>
    <table>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Publication date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7600208B2/en">
              <span itemprop="publicationNumber">JP7600208B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-12-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220273566A1/en">
              <span itemprop="publicationNumber">US20220273566A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-09-01</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114502542A/en">
              <span itemprop="publicationNumber">CN114502542A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-05-13</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4003967A4/en">
              <span itemprop="publicationNumber">EP4003967A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-01-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2022542389A/en">
              <span itemprop="publicationNumber">JP2022542389A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-10-03</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2020323897A1/en">
              <span itemprop="publicationNumber">AU2020323897A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-02-24</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3145913A1/en">
              <span itemprop="publicationNumber">CA3145913A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-02-04</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4003967A1/en">
              <span itemprop="publicationNumber">EP4003967A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-06-01</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20220040484A/en">
              <span itemprop="publicationNumber">KR20220040484A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-03-30</td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Similar Documents</h2>
    <table>
      <thead>
        <tr>
          <th>Publication</th>
          <th>Publication Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/JP7600208B2/en">
                <span itemprop="publicationNumber">JP7600208B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-12-16">2024-12-16</time>
            
            
          </td>
          <td itemprop="title">
        Nanomaterials containing constrained lipids and uses thereof - Patents.com
       
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/JP7636330B2/en">
                <span itemprop="publicationNumber">JP7636330B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-02-26">2025-02-26</time>
            
            
          </td>
          <td itemprop="title">
        Drug delivery system containing oxidized cholesterol - Patents.com
       
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP2377517B1/en">
                <span itemprop="publicationNumber">EP2377517B1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2020-01-22">2020-01-22</time>
            
            
          </td>
          <td itemprop="title">Pharmaceutical composition containing an anionic drug, and a production method therefor 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/JP2017500865A/en">
                <span itemprop="publicationNumber">JP2017500865A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2017-01-12">2017-01-12</time>
            
            
          </td>
          <td itemprop="title">
  Compositions and formulations of leptin mRNA
 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2018067302A2/en">
                <span itemprop="publicationNumber">WO2018067302A2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-04-12">2018-04-12</time>
            
            
          </td>
          <td itemprop="title">Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20220054633A1/en">
                <span itemprop="publicationNumber">US20220054633A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2022-02-24">2022-02-24</time>
            
            
          </td>
          <td itemprop="title">Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP2319519A1/en">
                <span itemprop="publicationNumber">EP2319519A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2011-05-11">2011-05-11</time>
            
            
          </td>
          <td itemprop="title">Composition for inhibiting expression of target gene 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            
            <meta itemprop="isScholar" content="true">
              <meta itemprop="scholarID" content="7605928583119946277">
              <a href="/scholar/7605928583119946277"><span itemprop="scholarAuthors">Molla et al.</span></a>
            
          </td>
          <td>
            
            <time itemprop="publicationDate" datetime="2020">2020</time>
            
          </td>
          <td itemprop="title">Combinatorial synthesis of a lipidoid library by thiolactone chemistry: in vitro screening and in vivo validation for siRNA delivery</td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            
            <meta itemprop="isScholar" content="true">
              <meta itemprop="scholarID" content="1573955480014021864">
              <a href="/scholar/1573955480014021864"><span itemprop="scholarAuthors">Dreaden et al.</span></a>
            
          </td>
          <td>
            
            <time itemprop="publicationDate" datetime="2018">2018</time>
            
          </td>
          <td itemprop="title">RNApeptide nanoplexes drug DNA damage pathways in highgrade serous ovarian tumors</td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20230092306A1/en">
                <span itemprop="publicationNumber">US20230092306A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2023-03-23">2023-03-23</time>
            
            
          </td>
          <td itemprop="title">Substance delivery carrier and composition 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20120244210A1/en">
                <span itemprop="publicationNumber">US20120244210A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2012-09-27">2012-09-27</time>
            
            
          </td>
          <td itemprop="title">Composition for suppressing expression of target gene 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/CN113491774A/en">
                <span itemprop="publicationNumber">CN113491774A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2021-10-12">2021-10-12</time>
            
            
          </td>
          <td itemprop="title">Liver targeting conjugate for treating hepatitis B, lipid-based pharmaceutical composition, preparation method and application thereof 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20250339539A1/en">
                <span itemprop="publicationNumber">US20250339539A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-11-06">2025-11-06</time>
            
            
          </td>
          <td itemprop="title">Phosphate Membrane Nanodiscs Conjugated to Therapeutic Agents and Medical Uses Thereof 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/EP2666856A1/en">
                <span itemprop="publicationNumber">EP2666856A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2013-11-27">2013-11-27</time>
            
            
          </td>
          <td itemprop="title">Composition for inhibiting target gene expression 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            
            <meta itemprop="isScholar" content="true">
              <meta itemprop="scholarID" content="7030753081327636542">
              <a href="/scholar/7030753081327636542"><span itemprop="scholarAuthors">Gl et al.</span></a>
            
          </td>
          <td>
            
            <time itemprop="publicationDate" datetime="2025">2025</time>
            
          </td>
          <td itemprop="title">Precision engineering of macrophage reprogramming with RNA interference-loaded lipid nanoparticles: a game-changer in cancer immunotherapy</td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2025063214A1/en">
                <span itemprop="publicationNumber">WO2025063214A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-03-27">2025-03-27</time>
            
            
          </td>
          <td itemprop="title">Method for producing ligand-modified lipid nanoparticles encapsulating nucleic acid 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20120207818A1/en">
                <span itemprop="publicationNumber">US20120207818A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2012-08-16">2012-08-16</time>
            
            
          </td>
          <td itemprop="title">Composition for suppressing expression of target gene 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2024210160A1/en">
                <span itemprop="publicationNumber">WO2024210160A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-10-10">2024-10-10</time>
            
            
          </td>
          <td itemprop="title">Conjugation complex 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/CN113384706A/en">
                <span itemprop="publicationNumber">CN113384706A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2021-09-14">2021-09-14</time>
            
            
          </td>
          <td itemprop="title">Conjugate for treating hepatitis B, lipid-based pharmaceutical composition, preparation method and application thereof 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/KR20200143416A/en">
                <span itemprop="publicationNumber">KR20200143416A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2020-12-23">2020-12-23</time>
            
            
          </td>
          <td itemprop="title">
        Therapeutic targeting of oncogenes using exosomes
       
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/HK1260123A1/en">
                <span itemprop="publicationNumber">HK1260123A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2019-12-13">2019-12-13</time>
            
            
          </td>
          <td itemprop="title">Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology 
       </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Legal Events</h2>
    <table>
      <thead>
        <tr>
          <th>Date</th>
          <th>Code</th>
          <th>Title</th>
          <th>Description</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-03-17">2021-03-17</time></td>
          <td itemprop="code">121</td>
          <td itemprop="title">Ep: the epo has been informed by wipo that ep was designated in this application</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">20846355</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">EP</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Kind code of ref document</strong>:
              <span itemprop="value">A1</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-01-26">2022-01-26</time></td>
          <td itemprop="code">ENP</td>
          <td itemprop="title">Entry into the national phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">3145913</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">CA</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-01-28">2022-01-28</time></td>
          <td itemprop="code">ENP</td>
          <td itemprop="title">Entry into the national phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">2022506087</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">JP</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Kind code of ref document</strong>:
              <span itemprop="value">A</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-02-01">2022-02-01</time></td>
          <td itemprop="code">NENP</td>
          <td itemprop="title">Non-entry into the national phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref country code</strong>:
              <span itemprop="value">DE</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-02-24">2022-02-24</time></td>
          <td itemprop="code">ENP</td>
          <td itemprop="title">Entry into the national phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">2020323897</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">AU</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Date of ref document</strong>:
              <span itemprop="value">20200724</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Kind code of ref document</strong>:
              <span itemprop="value">A</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-02-25">2022-02-25</time></td>
          <td itemprop="code">ENP</td>
          <td itemprop="title">Entry into the national phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">20227006660</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">KR</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Kind code of ref document</strong>:
              <span itemprop="value">A</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-03-04">2022-03-04</time></td>
          <td itemprop="code">ENP</td>
          <td itemprop="title">Entry into the national phase</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Ref document number</strong>:
              <span itemprop="value">2020846355</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Country of ref document</strong>:
              <span itemprop="value">EP</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Effective date</strong>:
              <span itemprop="value">20220228</span>
            </p>
          </td>
        </tr>
      </tbody>
    </table>
  </section>

</article>

    </search-app>
    
    <script></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  </body>
</html>
